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ABSTRACT 
 
The aim of this PhD was to identify the influence of factors that affect 
anticoagulation response to warfarin and NOACs on clinical response with the aim to 
further optimise treatment safety and patient management. 
In a randomised controlled trial, 181 patients with INR >6.0 were randomly 
allocated to receive orally either a tailored dose based upon index INR and BSA, or a 
fixed-dose (1 or 2mg) of vitamin K. The tailored dose resulted in a greater proportion 
of patients returning to within target INR range (68.9% v 52.8%; p=0.026), whilst a 
smaller proportion of patients remained above target INR range (p<0.001). 
Studies have confirmed that variant CYP2C9 and VKORC1 allele carriers require 
more time to achieve stable dosing and have a higher risk of supra-therapeutic INR 
and serious bleeding risk during initiation. In a retrospective cohort study, neither 
VKORC1, CYP2C9 genotype, nor their total variant allele count was associated with 
TTR% during warfarin maintenance or induction phase (p>0.05). 
A study in children on chronic warfarin therapy showed low levels of plasma 
vitamin K which are associated with CYP4F2 genotype with the patients with low 
plasma vitamin K being more likely to carry one or two variant alleles (76.2% vs 
45.4%; p=0.011). Chronic low levels of vitamin K, influenced by CYP4F2 genotype, 
might affect bone development and vascular health in children on warfarin. 
The link between warfarin treatment and vascular calcification was further 
explored in the same cohort of children, by assessing plasma uc-MGP concentration, 
a sensitive biological marker of vascular calcification. No association was found 
between plasma uc-MGP concentration and either anticoagulation intensity, duration 
of warfarin therapy, or warfarin daily dose. 
Patients on warfarin scheduled for surgery have to withdraw treatment for 5 days 
to avoid peri-operative bleeding. A previously developed algorithm that included 
genetic, demographic and clinical data was validated using an independent cohort of 
patients (n=117) who completed a short course of warfarin. There was a strong and 
highly significant correlation between the observed and predicted INR values by the 
algorithm (r=0.949, p<0.001).  
In an ex-vivo study, rivaroxaban in elderly subjects produced a greater 
prolongation of PT (p<0.05) and modified PT (p<0.001) and a greater suppression in 
the rate and amount of thrombin generation compared to young subjects, suggesting 
an age-related increase in sensitivity to the drug.  
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 Blood coagulation 
Haemostasis, the arrest of bleeding after vascular insult, is a vital function of 
human organism and comprises platelets, the vasculature, coagulation factors and 
the fibrinolytic system (Figure 1.1) (Thornton and Douglas, 2010, Chee, 2014). Back 
in the 1960’s, the term coagulation ‘cascade’ was introduced to describe the 
activation of downstream serine proteases from their inactive precursor (zymogen), 
while their glycoprotein co-factor catalyses the next reaction of the cascade (Davie 
and Ratnoff, 1964, Macfarlane, 1964). Blood coagulation depends on two distinct 
pathways, the intrinsic and the extrinsic. They converge on a common pathway which 
leads to the production of fibrin. This protein along with platelets form blood clots 
over a wound site to stop haemorrhage (Pallister and Watson, 2010). 
 
 
Figure 1.1: The coagulation mechanism in humans  
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Blood clotting is normally inhibited by endothelial cells in the wall of blood vessels. 
Although coagulation proteins circulate in the bloodstream, it is their inactive form 
that is present and therefore clotting does not occur. Tissue injury initiates the blood-
clotting cascade. 
Physiological haemostasis is achieved through the balance between the two 
activation pathways. Extrinsic pathway is the initially activated pathway of plasma-
mediated haemostasis. As a result of trauma, tissue factor (TF) is exposed to plasma 
procoagulants, a process that is normally prevented by the normal vascular 
endothelium. TF then binds with activated coagulation factor VIII (VIIIa) and calcium 
cations (Ca2+), forming the extrinsic tenase complex that leads to the conversion of 
factor X to its activated form Xa (Palta et al., 2014). 
The contact activation intrinsic pathway begins with the formation of a primary 
complex consisting of high molecular weight kininogen, pre-kallikrein and coagulation 
factor XII on the surface of collagen. Pre-kallikrein is converted to kallikrein and factor 
XII to XIIa, which activates factor XI. Activated factor XI further activates factor IX. 
IXa along with the cofactor VIIIa form the intrinsic tenase complex on a phospholipid 
surface which catalyses the conversion to Xa (Palta et al., 2014, Pallister and 
Watson, 2010). 
Factor X acts at the crossroad of the two haemostatic pathways. Both pathways 
combine to a common route in which factor Xa with its cofactor Va, platelets, tissue 
phospholipids and Ca2+ convert prothrombin (factor II) to thrombin (IIa). Thrombin 
has numerous functions, with the most important being the conversion of fibrinogen 
to fibrin, the building block of a haemostatic plug. Factor XIII is also activated by 
thrombin. Factor XIIIa and activated fibrin monomers form covalent bonds that 
crosslink the fibrin polymers to create a stabilised clot (thrombus) (Palta et al., 2014). 
Factors VIII and V, their inhibitor protein C in the presence of thrombomodulin as 
well as platelets are all activated by thrombin during the initiation of the extrinsic 
pathway (Pallister and Watson, 2010). This shows the importance of thrombin for the 
haemostatic mechanism. 
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 Thrombosis 
 Causes and epidemiology 
Blood clotting (thrombosis) is the most common cause of morbidity and mortality 
worldwide (Weitz, 2014). It is a disease relevant to ageing and is triggered by three 
different mechanisms, comprising vessel wall damage, blood composition 
abnormalities and blood flow disturbances. These mechanisms are known as 
‘Virchow’s triad’ (Wolberg et al., 2012). 
The predisposition to form a clot (thrombus) inappropriately is called thrombophilia 
and can arise from either genetic factors, acquired changes in the clotting 
mechanism such as increased levels of procoagulants, decreased levels of natural 
anticoagulants and defects in the fibrinolytic system (Heit, 2008) or, more commonly, 
from the interaction between hereditary and acquired factors. 
The most common inherited form of thrombophilia is Factor V Leiden, a mutation 
in the F5 gene which expresses the coagulation factor V. Among European 
populations, 3-8% of people are heterozygous and 1 in 5,000 people are 
homozygous for this mutation. It is less common in other populations (US National 
Library of Medicine). Due to their increased inherent tendency to form blood clots, 
these individuals may form a clot without a cause before the age of 45 years. Other 
inherited causes of blood clots are shown in Table 1.1 (Indiana Hemophilia and 
Thrombosis Center). 
 
Decreased level 
of natural 
anticoagulants 
Increased levels of 
natural procoagulants 
Abnormal 
fibrinolysis 
Other inherited 
causes 
Antithrombin Factor V Leiden or 
activated protein C 
resistance 
Decreased levels of 
tissue plasminogen 
activator 
Paroxysmal 
nocturnal 
haemoglobinuria Protein C 
Protein S Prothrombin 20210 
mutation 
Increased levels of 
plasminogen activator 
inhibitor  Thrombomodulin 
Heparin Cofactor II Hyperhomocysteinemia Elevated thrombin-
activated fibrinolysis 
inhibitor  Tissue Factor Pathway Inhibitor 
FVII, FIX, FXI, FVII, 
VWF 
Table 1.1: Inherited causes of blood clots 
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The most prevalent acquired thrombophilia is antiphospholipid syndrome. It is 
associated with both venous and arterial thromboses. The risks are even greater 
during pregnancy, due to the underlying physiological changes (Khare and Nelson-
Piercy, 2003, Armstrong et al., 2014). 
Arterial thromboembolism is caused when a blood clot blocks the flow of blood to 
a specific organ. This state normally affects people with atherosclerosis; fatty 
deposits attach to the arterial wall which narrows, increasing the risk for a blood clot. 
Embolisation is the process of a blood clot breaking off and travelling to another part 
of the body. The symptoms of thrombosis are dependent on the part of the body in 
which the clot is formed. Atherosclerosis and thrombosis in the coronary vessels 
leads to oxygen starvation to the myocardium leading to cardiac events, while 
embolization of thrombus in a vein can lead to pulmonary embolism (PE). 
The manifestation of venous thrombosis can be either deep vein thrombosis 
(DVT) or PE. DVT occurs in approximately two thirds of total thromboembolic 
episodes (Cushman, 2007, Heit, 2008). Recent epidemiological studies estimate that 
venous thromboembolism affects 133 per 100,000 of the population annually in the 
USA. Recurrent venous thromboembolism appears in about 30% of individuals within 
the next 10 years, with serious outcomes for the survival and quality of life of the 
patient (Heit, 2008, Martinez et al., 2014). 
Blood clotting disorders can also arise as a result of surgery, pregnancy, long-
term immobilisation, autoimmune diseases, cancer, heart disease and many more 
situations (Cushman, 2007). 
 Atrial fibrillation and risk of stroke 
Atrial fibrillation (AF) is a common cardiac arrhythmia that affects over 33.5 million 
people globally (GBD 2013 Mortality and Causes of Death Collaborators, 2015). By 
2050, it is predicted to affect 6–12 million people in the USA and 72 million in Asia, 
while by 2060 it will affect 17.9 million in Europe (Morillo et al., 2017, Chiang et al., 
2015). Between 2000 and 2010, AF-related hospitalisations increased by 23% in the 
US (Tamayo et al., 2015). AF is an abnormality of the heart rhythm, which involves 
the atria beating irregularly, which causes the blood to pool and eventually may 
cause the formation of a blood clot ((IQWiG), 2006) (Figure 1.2). 
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Figure 1.2: Change of normal heart rhythm as a result of atrial fibrillation 
 
AF is the strongest known risk factor (5-fold) for stroke (Singer, 1998) with the 
association between AF and stroke of cardioembolic origin being widely recognised 
(Wolf et al., 1991). Stroke in patients with AF accounts for significant morbidity, 
mortality and economic burden in the developed world. In the presence of AF, 
strokes are more often lethal or result in more disability than in its absence (McGrath 
et al., 2013). The percentage of AF-attributed strokes increases with age, with a 16-
fold increase between patients aged 50-59 and 80-89 years (1.5% v 23.5% 
respectively) (Kannel and Benjamin, 2008). The total annual cost for stroke treatment 
in the USA between 2011 and 2012 was estimated to be $33 billion (Mozaffarian et 
al., 2015). Stroke is estimated to cost the economy in England around £7 billion per 
year, which includes direct costs to the NHS, informal care and costs because of lost 
productivity and disability (Mant et al., 2004). In England, Wales and Northern Ireland 
between 2015 and 2016 the mean per patient cost of health and social care was 
£46,039, ranging between £19,101 to £107,336 for patients with acute stroke each 
year (Xu et al., 2018). In addition, stroke impacts on productivity and employment as 
25% of all strokes in the UK happen among people of working age (Patel et al., 
2017). 
In the UK, scoring systems have been developed and are recommended by the 
National Institute for Health and Care Excellence (NICE) to calculate the risk of AF-
related complications (NICE a). Among many other scores, assessment of the risk of 
stroke can be performed using CHADS2, which was later refined to create CHA2DS2-
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VASc (Figure 1.3) (Kane a). A CHA2DS2-VASc score of 2 or higher denotes that full 
oral anticoagulation should be considered, while every increase in the score predicts 
ischemic stroke rate per year linearly (National Clinical Guideline Centre UK, 2014, 
O'Neal and Alonso, 2016).  
 Mechanical heart valves 
Valvular heart disease is currently well-managed by implanting an artificial 
metallic or tissue heart valve to either repair or replace the malfunctioning one, based 
on patient age, type of the valve disease and other medical conditions.  
Tissue or bioprosthetic valves are composed of animal or human tissue from 
donor heart. Despite their limited risk of thrombosis and the short course of treatment 
to prevent thrombosis, many patients require a second operation within 10 to 20 
years from the first valve replacement (Harris et al., 2015). 
 
 
Figure 1.3: Atrial fibrillation ischemic stroke CHA₂DS₂-VASc calculator (Kane a) 
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Mechanical heart valves are made from titanium and carbon. Several models are 
available for aortic and mitral replacement. Their main advantage over tissue valves 
is their durability and their greatest disadvantage is that they dramatically increase 
the risk of blood clots forming. Preventing the development of blood clots that cause 
heart attack or stroke is therefore of vital importance. Life-long treatment to prevent 
blood clots is recommended for mechanical valve replacement patients (Harris et al., 
2015, Baumgartner et al., 2017). 
 Prevention strategies 
Blood clots and their devastating effects can be prevented with two main 
strategies. The first includes lifestyle interventions. Wearing compression stockings, 
regular exercise, maintaining a normal weight, avoiding alcohol abuse and smoking 
can all reduce the risk of thrombosis (NICE b). 
However, in cases where these changes are not adequate to reduce the risk, 
medical treatment is required. Prevention of blood clots is routinely achieved by 
taking oral anticoagulant therapy. The success of anticoagulation is demonstrated by 
a reduction in the incidence of stroke, systemic embolism, myocardial infarction (MI) 
and death from any cause as well as by an increase in survival. 
 Oral anticoagulant therapy 
 Introduction 
Anticoagulation can be achieved by targeting different parts of the blood 
coagulation system and inhibiting clotting factors. Vitamin K antagonism was the first 
mechanism discovered to promote anticoagulation. In recent years, targeting the 
coagulation factors directly have resulted in new treatments that have recently 
become available in clinical practice.  
Coumarins, such as warfarin, phenprocoumon and acenocoumarol, also known 
as vitamin K antagonists (VKAs), have been the mainstay of oral anticoagulation 
therapy for the treatment of thromboembolic disease for almost 65 years. 
Randomised controlled studies have demonstrated that anticoagulation therapy with 
warfarin significantly reduces the overall risk of stroke, its severity and the associated 
risk of death in patients with AF (van Walraven et al., 2002, Hart et al., 2007). 
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Consequently, treatment guidelines advocate the use of warfarin prophylaxis in 
patients with AF at moderate-to-high risk of stroke (Monagle, 2004). 
Since 2010, the novel or otherwise known as non-vitamin K oral anticoagulants 
(NOACs) emerged in the market after receiving approval from the major drug 
regulatory agencies. The term NOAC is adopted by the European Society of 
Cardiology (ESC) AF guidelines (Kirchhof et al., 2016), and will be used throughout 
this thesis, instead of the term DOAC (direct oral anticoagulants) which is preferred in 
the USA. Drugs with two distinct mechanisms of action have been approved; direct 
thrombin (factor IIa) inhibitors and factor Xa inhibitors.  
 Vitamin K antagonists 
Three VKAs (warfarin, acenocoumarol, phenprocoumon) are currently used in 
clinical practice with profound structural similarities due to their common structural 
ancestor, dicoumarol (Figure 1.4) (NCBI a). VKAs are still among the most frequently 
drugs used worldwide. Warfarin is the VKA of choice in North America, the UK and 
Scandinavian countries, while acenocoumarol and phenprocoumon are mainly used 
in European countries (Ufer, 2005). 
 
 
Figure 1.4: Chemical structures of vitamin K antagonists (Adapted from 
PubChem database) 
 
9 
 History of warfarin use 
With over 65 years of clinical use, warfarin is the first oral anticoagulant drug and 
one of the most commonly prescribed drugs (Mega and Simon, 2015). Along with 
other coumarin anticoagulants, warfarin is prescribed for the prophylaxis and 
treatment of thromboembolic events in patients with AF, PE, MI, artificial heart valves 
and DVT (Wahl et al., 2015, Kamali and Wynne, 2010). 
The discovery of warfarin’s action dates back to the 1920s, when veterinarians in 
Canada noticed the causal relationship between spoiled sweet clover hay and animal 
deaths that local farmers had observed. Link, an American Biochemist, described the 
process in detail and reached the conclusion that factors within the spoiled hay 
reduced the clotting ability of the blood, a process that could be reversed by vitamin 
K. As a consequence, internal haemorrhage was fatal for cattle and sheep. About a 
decade later, the active compound called 3,3-methylene bis(4-hydroxycoumarin), 
was discovered. After the synthesis of multiple derivatives of dicoumarol, one of them 
was proposed for rodenticidal use. It was named warfarin sodium in 1941 by Link, 
who combined the first letters of the Wisconsin Alumni Research Foundation with the 
ending of coumarin, ‘arin’ (Link, 1959).  
 Mechanism of action 
The mechanism of anticoagulant action of warfarin was elucidated in 1978 by 
Whitlon and colleagues (Whitlon et al., 1978). The hypothesis that vitamin K reverses 
the action of dicoumarol derivatives and therefore of warfarin, was proven right. 
Vitamin K (as vitamin K hydroquinone) is an essential cofactor needed for the γ-
carboxylation of glutamic acid residues located at the amino-terminals of the vitamin 
K-dependent clotting proteins II, VII, IX and X, leading to their activation (Kirchhof et 
al., 2016). Coumarins block the vitamin K epoxide reductase (VKOR) enzyme 
causing anticoagulation by interfering with the cyclic interconversion of vitamin K 
hydroquinone (hence also referred to as ‘vitamin K antagonists’) thus inhibiting the 
activation of vitamin K-dependent clotting proteins (Whitlon et al., 1978) (Figure 1.5). 
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Figure 1.5: Inhibition of cyclic interconversion of vitamin K by warfarin 
 
 Pharmacokinetics and pharmacodynamics 
Warfarin is prescribed as a 50:50 racemic mixture of two stereoisomeric forms, S-
warfarin and R-warfarin, as a result of an asymmetric carbon in its structure. Warfarin 
is metabolised by the liver. S-warfarin is mainly metabolised by the microsomal liver 
enzyme CYP2C9 (cytochrome P450 isoform 2C9) that belongs to the cytochrome 
P450 enzyme system. As a result of this metabolic pathway, two inactive metabolites 
are produced. R-warfarin is metabolised by three different microsomal enzymes; 
CYP1A2, CYP3A4 and CYP2C19, producing inactive metabolites. S-warfarin is 5 
times more potent as inhibitor of VKOR enzyme and is metabolically deactivated 3 
times faster than the R enantiomer (Moyer et al., 2009) (Figure 1.6).  
R-warfarin’s clearance is half that of S-warfarin due to the half-life of R-warfarin 
being longer (37-89 hrs) compared to that of S-warfarin (21-43 hrs), but volume of 
distribution for both enantiomers is similar (U.S. Food and Drug Association, 2011). 
The dose of warfarin normally ranges between 5–10mg daily (Harter et al., 2015 ), 
however it can vary from 0.5mg/day to more than 10mg/day (Wadelius et al., 2007). 
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The mean half-life of warfarin in plasma is approximately 40 hours and after oral 
administration the anticoagulant action lasts 2-3 days (Mega and Simon, 2015).  
Warfarin’s concentration in blood reaches its peak within one hour after oral 
administration. However, the pharmacological effect of warfarin can be observed 
after about 48 hours. As a result, plasma warfarin concentration is not helpful in 
monitoring coagulation. For this reason, a standardised measurement of prothrombin 
time (PT) prolongation is used to monitor anticoagulation response (Monagle et al., 
2006).  
 
 
Figure 1.6: Warfarin racemic mixture metabolism by liver enzymes 
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 Clinical indications 
Warfarin is indicated for the prophylaxis and treatment of venous 
thromboembolism (VTE), PE, thromboembolic complications such as stroke 
associated with AF and/or cardiac valve replacement. It is also used for the reduction 
in the risk of systemic embolisation, recurrent MI or death after MI (2018, Keeling et 
al., 2011). 
Although most indications requiring anticoagulation therapy can also be managed 
by non-vitamin K oral anticoagulants, currently warfarin is the only treatment 
available for the prevention of thrombosis in patients with mechanical heart valve 
replacement (Otto, 2017). However, one in vivo preclinical study used a swine 
surgical model to demonstrate that apixaban had comparable efficacy to warfarin in 
reducing mechanical valve thrombosis (Lester et al., 2017). 
Contraindications for oral anticoagulation therapy in general include haemorrhagic 
stroke, recent major surgery or postpartum, pregnancy, bleeding disorders and 
potential bleeding lesions.  
 Warfarin therapy monitoring 
 PT/INR 
The prothrombin time or prothrombin ratio was previously used to monitor warfarin 
therapy. The prolongation of PT depends on reductions in three of the vitamin K 
dependent clotting factors. The PT was replaced in 1982 by the International 
Normalized Ratio (INR); the big advantage of using INR is that unlike PT the INR 
value is not affected by variability between reagents used by different laboratories for 
the measurement of anticoagulation response (Horton and Bushwick, 1999). 
The normal range of INR in healthy people is 0.8-1.3 (Horlocker et al., 2001). In 
patients starting coumarin derivatives, INR measurement is carried out frequently 
until it reaches the therapeutic range (usually 2.0-3.0 for most indications) for two 
consecutive days. Then, INR is measured two to three times per week for two weeks 
and if it remains stable and within the range, the measurement can take place less 
often but not less than monthly. However, some patients take longer to achieve 
therapeutic INR and as such require a greater number of INR determinations (Horton 
and Bushwick, 1999). 
13 
Anticoagulation response to warfarin, reflected in the INR value, can fluctuate 
from time to time in patients on stable maintenance therapy, with consequences in 
terms of thrombosis or bleeding risk (Figure 1.7). This can be caused by 
environmental factors, such as changes in diet and most importantly in vitamin K 
intake, poor patient compliance to treatment, alcohol consumption, concurrent illness 
and medications that interact with warfarin (Kuruvilla and Gurk-Turner, 2001). The 
quality of anticoagulation control in individual patients can be calculated using the 
time in therapeutic INR range (TTR).  
 
 
Figure 1.7: INR range and risk of thromboembolic and bleeding events 
 
 Time in therapeutic range 
Warfarin is effective and safe for thromboprophylaxis in AF patients when therapy 
is well managed and frequently monitored. Time in therapeutic range assesses the 
quality of warfarin treatment management. The higher the TTR, the lower the risk of 
bleeding or stroke (Connolly et al., 2008). 
The time in therapeutic range has typically been assessed by the Rosendaal 
method (Rosendaal et al., 1993). This linear interpolation method due to its 
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complexity requires a computerized system for calculation (shown in Appendix A). 
INR values are assigned to days without measured INRs via the drawing of a linear 
plot from the last measured INR to the next measured INR. Using values that are 
represented by this line, a value is assigned to each day. Then, all days with 
measured or assigned values are used to calculate the time in therapeutic range by 
dividing each patient’s time within the therapeutic range by the total time of 
observation. This assumes that between-test INR varies linearly (2011, Rosendaal et 
al., 1993) (Figure 1.8). 
 
 
Figure 1.8: Graphical presentation of linear interpolation method of Rosendaal 
et al, 1993 
 
TTR indicates the days which INR values are within the therapeutic range for the 
individual patient over a specific period of time. For instance, if a patient has a 
therapeutic range of 2.0 - 3.0, and on May 1st was tested at 2.5, then tested at 3.5 on 
May 31st, the number of days the patients was in range can be determined. Since 
there were 30 days between tests, it is assumed that the patient slowly moved from 
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2.5 to 3.5 over those 30 days, so around May 15th, the patient was probably over 
3.0, and therefore was out of range. Therefore, it is estimated that 15 days the 
patient was in range, and 15 days was out of range (within the 30 day time period), 
which means the patient’s TTR was 50% within that period of time. 
A stable schedule of INR checks is necessary in order to reduce the chance of 
errors in the calculation of TTR. For example, in the case of having few INR checks 
over a period of time and one INR measurement out of range, the TTR will be low 
and will not accurately reflect the quality of warfarin treatment during this time 
(Reiffel, 2017). According to the results of a multicentre study, overall survival is 
improved where TTR is >40% and below the TTR threshold of 58% and 65% there is 
little benefit of oral anticoagulant over antiplatelet therapy (Van Spall et al., 2012, 
Connolly et al., 2008). A TTR of >58% can provide confidence that patients will 
benefit from the treatment (Baker et al., 2009). 
Variability in the quality of healthcare system leads to great differences in the 
mean TTR between different geographical regions. Mean TTR was 36% in India and 
75% in Sweden in a recent major trial (Daniel et al., 2013). 
 Adverse effects of warfarin 
An uncommon adverse event with sudden onset within the first 8 days of 
treatment is skin necrosis (death of skin tissue), which is not a result of over-
anticoagulation. Women are more likely to present with skin necrosis and on average 
patients are in their 50s (Chan et al., 2000). Treatment includes immediate warfarin 
discontinuation, warfarin reversal with vitamin K and surgical debridement in over 
50% of cases. The suggested mechanism behind this event is underlying protein C, 
S or antithrombin III deficiencies (Fant and Fant, 2016). 
 Bleeding 
Bleeding problems are the most common and potentially life threatening 
complications of warfarin therapy. Risk factors that predispose to bleeding include 
age over 75, concomitant use of other blood-thinning medications, patients with a 
previous stroke, cancer, uncontrolled blood pressure, kidney or liver disease, 
gastrointestinal problems such as stomach ulcers, alcohol excess, and people at 
increased risk of falls, e.g. elderly.  
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Bleeding is associated with higher than desired intensity of anticoagulation (over-
anticoagulation). Warfarin-associated intracranial haemorrhage is the most feared 
and devastating, although less likely to occur. Red or brown urine, black or bloody 
stool, severe bleeding, including heavier menstrual bleeding than normal, coughing 
up or vomiting of blood and spontaneous bruising are all manifestations of bleeding 
complications and medical attention is required immediately. Bleeding from the gums 
or between menstrual periods is less serious but should still be reported (Shoeb and 
Fang, 2013). 
Assessment of the risk of major bleeding can be performed using HAS-BLED 
(Figure 1.9) (Pisters et al., 2010, Kane b). The HAS-BLED scoring system estimates 
the risk of major bleeding (intracranial bleeding, bleeding requiring hospitalization, a 
haemoglobin decrease of more than 2 g/dL, or the need for transfusion secondary to 
bleeding) for patients on anticoagulation for risk assessment in AF care (Kane b). 
Bleeding risk scores, such as HAS-BLED, should not be used to exclude patients 
from the use of oral anticoagulation, but rather to identify modifiable bleeding risk 
factors that can be managed to reduce a patient’s risk of bleeding from 
anticoagulation (Friberg et al., 2012). 
 
 
Figure 1.9: Bleeding risk HAS-BLED calculator  
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 Other complications 
In addition to bleeding, severe headache, joint pain, swelling especially after an 
injury, stomach pain, weakness or dizziness and vision changes have been reported 
as warfarin ADRs (Adverse drug reaction) that require immediate attention. 
Diarrhoea, inability to eat for more than 24 hours, nausea, vomiting, fever, jaundice, 
hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, and rash are less 
serious adverse events (FDA, 2011). (FDA, 2011) 
 Vascular calcification risk 
Warfarin has been suspected to cause vascular and arterial calcifications in 
patients on long term use. Based on the mechanism of action, warfarin inhibits the 
cyclic interconversion of vitamin K, blocking its action as a cofactor for the γ-
carboxylation of gamma-carboxyglutamic acid (Gla) residues by vitamin-K-dependent 
gamma-carboxylase and inhibiting calcium binding and normal function. As a result, 
all vitamin K dependent proteins, ranging from clotting factors II, VII, IX, X, protein C, 
S and Z to osteocalcin and matrix-Gla protein (MGP), remain inactive.  
MGP is mainly secreted by vascular smooth muscle cells and chondrocytes in the 
arterial tunica media. Its activation requires two posttranslational modifications; γ-
glutamate carboxylation and serine phosphorylation. Based on carboxylation and 
phosphorylation state, different species of MGP have been identified and ELISAs 
(Enzyme-linked immunosorbent assay) have been made available for the 
quantification of such species in human plasma (Schurgers et al., 2008). Studies on 
MGP showed that knockout mouse exhibited extensive and lethal calcification and 
cartilaginous metaplasia of the media of all elastic arteries. The function of MGP has 
been considered protective against calcification in human vasculature and is involved 
in modulating vascular calcium metabolism, although the mechanism is still to be fully 
understood (Wei et al., 2016, Bjorklund et al., 2018). 
Vitamin K antagonism during warfarin therapy has been associated with higher 
risk of calciphylaxis and arterial calcification in independent patient cohorts (Nigwekar 
et al., 2017). A systematic review has been published earlier in 2018 which reports 
conflicting results in terms of specific MGP species associated with local calcification 
development. Existing studies have looked at different calcification locations and 
have measured different circulating MGP species. It has become clear that there is a 
complex relationship between calcification risk and MGP. Further well-designed large 
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studies will help elucidate the underlying molecular mechanisms that can accelerate 
local disease progression within the vasculature and the predictive value of the 
currently defined MGP species (Barrett et al., 2018). 
 Reversal of anticoagulation due to warfarin therapy 
Warfarin anticoagulation reversal is required in cases whereby a patient presents 
in clinic with elevated INR and/or bleeding symptoms. The method of reversal is 
selected based upon the clinical severity of bleeding, if any, and the balance between 
bleeding and thrombosis risks (Makris and Watson, 2001). 
Immediate warfarin discontinuation is required in most cases. Current guidelines 
suggest the use of Prothrombin Complex Concentrate (PCC), based on patient 
weight and INR (Di Fusco et al., 2018) or Fresh Frozen Plasma (FFP) with additional 
IV administration of vitamin K when rapid reversal of anticoagulation is urgently 
required, as a result of life-threatening bleeding. Less severe or minor bleeding can 
be reversed using a lower dose of vitamin K IV, or oral administration (Holbrook et 
al., 2012, Hanley, 2004). 
When no bleeding has occurred and the management of over-anticoagulation is 
limited on the INR correction, simple omission of warfarin or low dose oral vitamin K 
in patients with high risk of bleeding is recommended. If INR exceeds a certain value 
(generally around 8-10), then oral administration of vitamin K is the chosen method 
for reversal (Holbrook et al., 2012, Hanley, 2004) 
 Variability in anticoagulation response  
Achieving effective and safe anticoagulation with warfarin is a major challenge in 
routine medical care because many factors can influence the pharmacodynamic 
effect of this drug. Whilst several factors including concurrent disease, drugs and 
patient compliance have been identified as affecting warfarin requirements in a 
predictable way, the observed intra-individual variability in anticoagulation response 
to warfarin cannot be fully explained at present. There is evidence that age and 
dietary factors can make a significant contribution to unstable control of 
anticoagulation. 
19 
 Ageing 
Although the use of warfarin has been steadily declining after the marketing of 
NOACs, the use of warfarin particularly in elderly patients is still widespread, because 
of its proven benefits in AF and the increasing prevalence of this condition (Morillo et 
al., 2017) Vitamin-K antagonists are associated with reduced mortality, even in 
vulnerable patients with AF over 65 (Bo et al., 2016). 
Nevertheless, it has been estimated that a third of patient hospitalizations in the 
elderly on warfarin are caused by haemorrhages and other adverse drug reactions of 
warfarin (Budnitz et al., 2011), while another study found that 1.5% of hospital 
admissions were due to warfarin complications (Hirri and Green, 2002). In the UK, 
ADRs were responsible for 6.5% of hospital admissions and warfarin alone was 
responsible for 10.5% of cases (Pirmohamed et al., 2004). 
When warfarin is prescribed, elderly people need to be carefully selected based 
on the ratio of benefit over risks (bleeding and thrombosis). Therapy is initiated in a 
low dose (1mg daily for 1 week then INR check, followed by 2mg daily for 1 week 
then INR check) compared to younger adults (usually 5mg daily for first 2 days, then 
INR check, especially if they have new DVT/PE) and the treatment requires close 
monitoring of the INR, especially after changes to regular medications or diet, in 
which case dose adjustments may be necessary (Bereznicki et al., 2006). Studies 
suggest that the return of the INR to within the individual target range after an over-
anticoagulation event is delayed with advanced age (Hylek et al., 2001). 
Cognitive decline with age has been associated with frequent haemorrhages and 
suboptimal therapy (Greg et al., 2010). Additionally, 50% of older patients requiring 
systemic anticoagulation do not receive it due to the higher risk of falls, which is 
responsible for discontinuation of warfarin treatment by GPs, however this needs to 
be properly assessed, and the ongoing review of the appropriateness of therapy as 
circumstances change is essential (Hagerty and Rich, 2017). 
Educating patients and carers can be of paramount importance both for the 
appropriate management of any ADRs and also the facilitation of self-monitoring, in 
particular for people who do not have easy access to anticoagulation clinics.  
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 Diet 
The significant impact of diet on adult anticoagulation control has long been 
reported in the literature (Lurie et al., 2010). Vitamin K intake is a major determinant 
of warfarin’s effect according to its mechanism of action. Prospective observational 
studies have reported a greater sensitivity of patients with low vitamin K stores to the 
pharmacodynamic effects of warfarin (Kim et al., 2010, Sconce et al., 2005b). 
Changes in vitamin K intake can be caused by various syndromes that affect 
nutrition, such as gastrointestinal ulcers, cancers poor fat absorption caused by 
celiac disease, cystic fibrosis, an intestinal or biliary tract disorder or part of their 
intestine removed (Krasinski et al., 1985, Lin et al., 1992). Dietary supplements are 
another source of vitamin K intake. Warfarin dose adjustments, especially during 
initiation of therapy, are necessary to balance these changes (Kurnik et al., 2003). 
Other food sources interfere with enzymes that metabolise warfarin, as in the 
example of grapefruit and herbs which can subsequently alter anticoagulation 
response (Veronese et al., 2003). 
The implementation of strategies such as educating patients on anticoagulant 
therapy to adopt a balanced dietary intake, to report any supplements to their GP or 
Pharmacist as well as monitoring the INR, intra-patient variability in anticoagulation 
response can be reduced (White, 2010). 
1.3.2.8.2.1 Vitamin K 
The discovery of vitamin K dates back to 1929. Henrik Dam, a Danish biochemist, 
initially named it the “antihaemorrhagic vitamin of the chick” after the observation that 
muscular and subcutaneous bleeding was common in chicks with lipid-free diet. In 
1935, soon after this discovery and because of Dam’s work on diets, he proved that 
vitamin K (from the German and Scandinavian “Koagulation”) was a fat soluble 
vitamin, distinct from other vitamins known at that time (A, C, D and E). Dam’s 
research also paved the way to the discovery of two different forms of vitamin K. The 
first one, vitamin K1 or phylloquinone was found to be present in hog liver, vegetable 
oils and green leafy vegetables, while bacterial activity could lead to the synthesis of 
vitamin K2 or menaquinone. Later, in 1939, the group of Edward Doisy synthesised 
and characterised both forms of vitamin K. Therefore, the 1943 Nobel Prize in 
Physiology and Medicine was shared between Dan and Doisy for their contributions 
(O'Reilly, 1976, Azuma et al., 2014). 
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Due to the antihaemorrhagic effect of vitamin K, it was introduced in clinical 
practice as treatment or prophylaxis of bleeding conditions. The actual mechanism of 
action of vitamin K was revealed several years later, in 1974 (Ferland, 2012). 
Vitamins K1 and K2 share most of their basic chemical structure, which mainly 
comprises of a naphthoquinone ring and long side chains (Figure 1.10). Vitamin K2, 
after conversion from vitamin K1, is the active form in the human body (Okano et al., 
2008). Seven major menaquinones (MK-4 to MK-10) have been identified, which 
contain 4–10 repeating isoprenoid units (Booth, 2012). A third form of vitamin K, 
called vitamin K3 or menadione was later synthesised. This form lacks a side chain 
(Figure 1.10) (NCBI b, Booth and Suttie, 1998). Menadione has previously been 
used as a dietary supplement, however later was prohibited by the Food and Drug 
Administration of the USA due to its toxicity (Azuma et al., 2014). 
 
 
Figure 1.10: Vitamin K forms and structures (Adapted from PubChem database) 
As mentioned earlier, blood clotting factors dependent on vitamin K (factors II, VII, 
IX, X and proteins C, Z and S) are activated following post-translational carboxylation 
(Kamali and Wynne, 2010). The modification occurs in the N-terminus of the newly 
formed protein chain of coagulation factors. It consists of carboxylation of glutamic 
acid residues in the zymogen precursors of coagulation proteins. In 1974, both 
Stenflo and Nelsestuen with their colleagues, independently showed that the 
previously unrecognised amino acid, γ-carboxyglutamic acid, was present in 
functional prothrombin with the property of binding calcium (Suttie, 1993, Stenflo et 
al., 1974, Nelsestuen et al., 1974). Further investigation of prothrombin’s chemical 
structure revealed that in its amino terminal region between residues 7-33, the 10 
previously considered to be glutamic acid residues were modified into Gla. Gla 
residues are highly conserved among coagulation factors and other vitamin K 
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dependent proteins. All coagulation factors are homologous to prothrombin in 
residues 1-40 (Dowd et al., 1995). 
The presence of Gla residues enables the proteins to bind calcium, which forms 
ion bridges between the coagulation enzymes and negatively charged phospholipids 
on the membrane surfaces of endothelial, vascular cells and blood platelets. This 
calcium-mediated interaction of these proteins is essential in controlling coagulation 
protein conformation by enabling internal Gla-Gla binding (Suttie, 1993). 
The enzyme that accomplishes the carboxylation, called γ-glutamyl carboxylase 
(GGCX) was initially discovered by Suttie and colleagues (Suttie, 1993). This enzyme 
requires certain substrates; CO2, O2 and the reduced form of vitamin K (KH2), 
hydroquinone for its activity. The levels of KH2 control the rate of clotting protein 
carboxylation, which results in the conversion of vitamin K to vitamin K epoxide. The 
proposed mechanism is the reaction of vitamin K hydroquinone with oxygen resulting 
in the formation of a strong base which abstracts a proton from the γ-carbon of the 
glutamic acid residue. An intermediate carbanion is then formed and undergoes 
carboxylation into Gla. Finally, vitamin K 2,3-epoxide is formed (Suttie, 1993). 
Vitamin K epoxide is recycled to vitamin KH2 via a two-step reaction. VKOR is the 
enzyme that converts vitamin K epoxide into the quinone form and reduces the 
quinone into the hydroquinone form of the vitamin. The latter reduction process has 
an alternative pathway mediated by a NAD(P)H-dependent quinone reductase. The 
described enzymatic recycling of vitamin K hydroquinone is called “the vitamin K 
cycle” (Whitlon et al., 1978, Stafford, 2005). Vitamin is rapidly catabolized and from 
the liver it is excreted mainly in bile. A smaller amount appears in urine (Shearer et 
al., 1974). 
Antagonism or deficiency of vitamin K leads to inadequate γ-carboxylation. 
Proteins induced by vitamin K absence or antagonism (PIVKA) are released into the 
blood (Shapiro et al., 1986). Protein Induced By Vitamin K Absence Factor II (PIVKA-
II) relates to the under-carboxylated prothrombin due to the absence of vitamin K. 
Apart from the coagulation proteins, vitamin K is essential for the synthesis of 
numerous proteins with different physiological functions, all characterised by the 
presence of Gla residues. To date, 19 human proteins have been acknowledged as 
being γ-carboxylated. These include notably the matrix-Gla protein, GAS6, 
nephrocalcin, osteocalcin, periostin and others. These proteins control a number of 
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physiological functions as well as being involved in the endothelial function, kidney 
stone generation and bone formation. The role of vitamin K in osteoporosis has been 
greatly debated; there are conflicting reports linking vitamin K insufficiency to 
osteoporosis (Shah et al., 2014). 
Nonetheless, it has been shown that certain biochemical mechanisms protect the 
synthesis of vitamin K dependent coagulation proteins at the expense of other Gla 
proteins. Based on the triage hypothesis, coagulation factors are essential for short-
term survival and therefore acute deficiency of vitamin K can result in life threatening 
bleeding (Holmes et al., 2012). 
1.3.2.8.2.2 Dietary intake 
The main source of vitamin K in humans is through the diet. Numerous lists 
mainly consisting of green leafy vegetables and vegetable oils have been published, 
along with the vitamin K content of each food (Table 1.2) (Suttie, 1992, Booth and 
Suttie, 1998). The USDA National Nutrient Database for Standard Reference 
includes a very detailed phylloquinone content in foods (U.S. Department of 
Agriculture, 2015). Elder et al also published a report of vitamin K content of various 
foods, with the distinction between vitamin K1 and K2 (Elder et al., 2006). 
The dietary vitamin K intake varies among different age groups, such as newborn, 
children and adults. In a U.S. study, the median vitamin K intake from food and 
supplements was between 82 to 119 μg/day for adult Americans (Institute of 
Medicine US Panel on Micronutrients, 2001). There is currently no established 
recommended dietary allowance for phylloquinone due to lack of sufficient data. The 
current “dietary reference value” of 1 μg/kg (∼65-80 µg of phylloquinone/day in an 
average sized individual) is based on coagulation factor function; substantially higher 
recommended daily doses have been suggested because of findings that the 
requirement for vitamin K is greater for the extra-hepatic vitamin K-dependent 
proteins, including those found in bone (e.g. osteocalcin) (Sokoll et al., 1997). In 
2001, the adequate intake level for vitamin K based on consumption levels in healthy 
individuals was established as shown in Table 1.3 (Food and Nutrition Board, 2001).  
Neither pregnancy nor lactation necessitate additional vitamin K uptake in women 
(Food and Nutrition Board, 2001). A previous study of dietary intake of vitamin K in a 
national sample of British elderly people demonstrated that 59% had an intake below 
1 μg/kg/day (Thane et al., 2002b). 
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Food item Phylloquinone 
content 
(µg/100g) 
Food item Phylloquinone 
content 
(µg/100g) 
Vegetables  Protein sources  
Collard greens 440 Dry soybeans 47 
Spinach 380 Dry lentils 22 
Salad greens 315 Liver 5 
Broccoli 180 Eggs 2 
Brussels sprouts 177 Fresh meats <1 
Cabbage 145 Fresh fish <1 
Bibb lettuce 122 Whole milk <1 
Asparagus 60 Tuna in oil 24 
Okra 40   
Iceberg lettuce 35 Prepared foodsa  
Green beans 33 Salad dressings 100 
Green peas 24 Coleslaw 80 
Cucumber 20 Mayonnaise 41 
Cauliflower 20 Beef chow mein 31 
Carrots 10 Muffins 25 
Tomatoes 6 Doughnuts 10 
Potatoes 1 Apple pie 11 
  Potato chips 15 
Fats and oils  French fries 5 
Soybean oil 193 Macaroni cheese 5 
Canola oil 127 Lasagne 5 
Cottonseed oil 60 Pizza 4 
Olive oil 55 Hamburger/bun 4 
Corn oil 3 Hot dog/bun 3 
Margarinea 42 Baked beans 3 
Butter 7 Bread 3 
a Phylloquinone content may vary widely according to the source of oil used 
Table 1.2: Phylloquinone (vitamin K1) content of foods (Adapted from (Booth 
and Suttie, 1998)) 
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Life Stage Age Vitamin K (μg/day) 
Infants 
0-6 months 2.0 
7-12 months 2.5 
Children 
1-3 years 3.0 
4-8 years 5.5 
9-13 years 6.0 
Adolescents 14-18 years 7.5 
Adults > 19 years 
12.0 (males) 
9.0 (females) 
Table 1.3: Adequate Intake of vitamin K (Adapted from (Food and Nutrition 
Board, 2001)) 
 
Phylloquinone is used in daily clinical practice for several purposes, for instance 
as a supplement, antidote and medication for the prevention and treatment of the 
haemorrhagic disease of the newborn (vitamin K deficiency bleeding; VKDB). Vitamin 
K deficiency is rare in adults. Malnutrition, malabsorption, medications that can 
interfere with vitamin K absorption or metabolism, or significant alcohol intake are the 
common causes of vitamin K deficiency. In cases of vitamin K deficiency, vitamin K is 
administered orally, intravenously or intramuscularly. In cases of overdose with 
coumarin, reversal of excessive anticoagulation is achieved through vitamin K, given 
either orally or intravenously depending on clinical circumstances (Tran and 
Alderman, 2013, Biss et al., 2012, Hanley, 2004). 
Of all the fat-soluble vitamins, vitamin K has the highest individual daily variation 
in both dietary intake and corresponding plasma concentrations. This is because 
dark green vegetables, which are the main source of vitamin K, are not consistently 
consumed on a daily basis. For example, in a study of post-menopausal women in 
New England, USA, intake ranged from 3-2761µg of phylloquinone per day (Booth et 
al., 1995). In a UK population, the mean intake was 103 (95% CI 94, 112) µg per day 
(Yan et al., 2004). 
There has been a long-term interest amongst researchers in the detection and 
quantification of vitamin K in plasma. Detection of vitamin K1 by fluorimetry was first 
reported in 1986 and has since been optimised further to achieve better selectivity 
and sensitivity. Further work resulted in the detection and quantification of vitamin K 
in plasma  using reverse-phase high performance liquid chromatography (HPLC) 
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technique with fluorescence detection after post-column reduction with zinc (Lambert 
et al., 1986, Haroon et al., 1986, Wang et al., 2004). 
1.3.2.8.2.3  Influence on anticoagulation control  
Anticoagulation control during warfarin therapy is highly sensitive to fluctuating 
levels of vitamin K in the diet because the activation of the main clotting factors (II, 
VII, IX and X) is dependent on vitamin K availability (Lubetsky et al., 1999, Franco et 
al., 2004, Booth, 2010). Diet with low vitamin K content is associated with greater 
susceptibility to INR fluctuations caused by small changes in vitamin K intake (Kurnik 
et al., 2004).  
Sudden changes in dietary vitamin K intake resulting in poor anticoagulation 
control may put patients at increased risk of potential life-threatening bleeding and 
thromboembolic complications. Indeed, prosthetic valve thrombosis (Chow et al., 
1990) and MI (Walker, 1984) have been reported in patients who increased their 
vitamin K intake during anticoagulation therapy, and in the case report by Walker 
(Walker, 1984) this was linked to the patient embarking on a vegetable-rich, weight-
reduction diet. Conversely, diffuse bruising (presumably due to enhanced 
anticoagulation) in one case report was linked to the patient stopping their 
consumption of large amounts of porcine liver, thereby reducing his vitamin K intake 
(Chow et al., 1990). Thus, it has been suggested that patients should maintain a 
consistent dietary vitamin K intake during anticoagulation therapy, generally no more 
than 250 to 500 µg/day (Pedersen et al., 1991). 
An earlier crossover study in anticoagulated patients demonstrated an inverse 
relationship between vitamin K intake and anticoagulation response, as measured by 
the International Normalised Ratio (INR) (Franco et al., 2004). Another study in 
patients on chronic therapy with warfarin and with stable control of anticoagulation 
demonstrated that for every 100 µg increase in vitamin K intake over the previous 4 
days, INR value fell by 0.2 units (Khan et al., 2004), further clarifying the extent of the 
inter-relationship between dietary vitamin K and the INR. Consistent with these 
observations, Lubetsky et al. found that, INR values decreased in 32% (16/50) of 
anticoagulated patients following a vitamin K intake of ≥250 µg/day. The patients had 
significantly lower median INR values (1.9 and 3.0, respectively; p<0.001) and 
required a higher maintenance steady state warfarin dose (5.7 and 3.5 mg/day, 
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respectively; p<0.001), compared to those receiving <250 µg/day of vitamin K 
(Lubetsky et al., 1999). 
In order to reduce intra-patient variability in anticoagulation response, patients are 
advised to maintain an adequate and consistent intake of dietary vitamin K that at 
least meets the current dietary reference value of 65-80 µg/day. Self-monitoring of 
vitamin K intake aids, such as the ‘K-Card’ (Couris et al., 2000), which was designed 
as a checklist of common foods and beverages providing ≥5 µg vitamin K per 
serving, may be helpful in this regard (Couris et al., 2000). 
1.3.2.8.2.4 Vitamin K supplementation 
Low vitamin K levels can cause a patient’s warfarin dose requirement to vary with 
even minor changes in vitamin K intake. Several studies have shown that daily oral 
supplementation with vitamin K could improve stability of anticoagulation control in 
patients who are more susceptible to dietary changes, because of their poor and 
erratic dietary vitamin K intake, such as the elderly (Ford et al., 2007, Sconce E, 
2007, Rombouts et al., 2007, Khan et al., 2004). A small study in 2005 demonstrated 
that vitamin K supplementation improved anticoagulation control, possibly due to the 
more steady activation of vitamin K–dependent clotting factors (Reese et al., 2005). 
At the same time, our group demonstrated that patients with variably low dietary 
intake of vitamin K were more likely to have unstable control of anticoagulation 
compared to their matched stable counterparts (Sconce et al., 2005b). Kim and 
colleagues in 2010 confirmed that patients with low vitamin K intake are more 
sensitive to minor changes in vitamin K intake and thus more likely to have unstable 
anticoagulation control (Kim et al., 2010). Another prospective study proposed that a 
vitamin K-guided management strategy is clinically feasible for the maintenance of 
oral anticoagulation intensity (De Assis et al., 2009). 
Schurgers and colleagues investigated the safe initiation of vitamin K 
supplementation on anticoagulation response in healthy subjects. They studied the 
dose-response relationship of vitamin K supplementation on anticoagulation control 
and concluded that the administration of 100 µg of vitamin K daily did not significantly 
influence INR value (Schurgers et al., 2004). Despite a study showing that 25 µg 
significantly reduced the INR in patients with low vitamin K status (Kurnik et al., 
2004), it was later recommended that supplementation with a 100 µg vitamin K daily 
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dose is preferable to negate any influence of variability in dietary vitamin K intake 
(Oldenburg, 2005). 
In 2007, three separate studies on the effect of vitamin K supplementation on 
anticoagulation stability reported similar findings. In a double-blinded placebo 
controlled study, seventy patients with unstable control of anticoagulation were 
randomised to receive either 150μg oral vitamin K, or placebo daily for 6 months. The 
study confirmed that vitamin K supplementation results in significant improvement in 
anticoagulation stability attributed to a reduction in inter-day variability in dietary 
vitamin K intake (Sconce E, 2007). A second open label crossover study of 9 patients 
with unstable anticoagulation control showed a reduction in INR variability after 
500μg of oral vitamin K supplementation daily (Ford et al., 2007). Rombouts and 
colleagues also demonstrated the positive effect on anticoagulation control of 100μg 
vitamin K supplementation once daily for 24 weeks in an unselected group of 200 
patients on chronic therapy with phenprocoumon (Rombouts et al., 2007). 
A recent meta-analysis reported no beneficial effect of low-dose vitamin K 
supplementation on the reduction of clinically relevant adverse events in patients 
taking VKAs (Lam et al., 2013). However, the meta-analysis lacked sufficient data to 
show that daily vitamin K supplementation has an impact on the incidence of adverse 
events in anticoagulated patients. Although the 2008 American College of Chest 
Physicians (ACCP) guidelines (Ansell J, 2008) recommended the use of low dose 
vitamin K supplementation in patients with chronically unstable anticoagulation, this 
was recommended against in the updated 2012 guidelines (Holbrook et al., 2012). 
1.3.2.8.2.5 Enteral feeds 
Enteral feeds may be an unsuspected source of additional dietary vitamin K in 
patients receiving warfarin. Although a decrease in the vitamin K content of enteral 
feedings has been observed over the years (Dickerson, 2008), some feeds may 
contain for example up to 20 µg vitamin K per 8 fl oz (237ml) serving (Table 1.4). 
This may explain why certain enteral feeds have been reported to lower the 
anticoagulant effect of warfarin (Penrod et al., 2001, Shearer, 2009a, Klang et al., 
2010). Thus, it is important to consider the significant impact of enteral nutrition on 
anticoagulation response in patients on warfarin therapy. 
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Product Kcal Per 100mL serving Vitamin K content (μg) 
Fresubin® original a 100 6.7 
Fresubin® original fibre a 100 6.7 
Fresubin® 1000 complete a 418 10 
Fresubin® 1200 complete a 500 10 
Fresubin® 1500 complete a 420 6.7 
Fresubin® 1800 complete a 500 10 
Fresubin® 2250 complete a 
Fresubin® energy a 
Fresubin® energy fibre a 
Fresubin® HP energy a 
630 6.67 
Ensure TwoCal b 200 8.5 
Nutrison® c 
Nutrison® MCT c 100 5.3 
Nutrison® Multi Fibre c 103 5.3 
Nutrison® Energy c 150 8 
Nutrison® Energy Multi Fibre c 153 8 
Nutrison® Protein Plus c 125 6.6 
Nutrison® Protein Plus Multi Fibre c 128 6.6 
Nutrison® 800 Complete Multi Fibre c 83 8 
Nutrison® 1000 Complete Multi Fibre c 104 8 
Resource Energy d 151 14 
Peptamen® HN d 133 9 
Vital 1.5kcal b 150 7 
Novasource® GI Control d 106 6 
Novasource® GI Control d 155 11 
 Per 8 fl oz serving ^  
Jevity® 1 Cal b 250 15 
Jevity 1.2 Cal (formerly Jevity Plus) b 285 20 
Jevity® 1.5 Cal b 355 19 
Osmolite® 1 Cal b 250 15 
Osmolite® 1.2 Cal b 285 20 
Osmolite® 1.5 Cal b 355 19 
Ensure® b 220 20 
Ensure® High Protein b 160 20 
Ensure® Plus b 350 20 
Ensure® Plus HN b 250 20 
Ensure® Enlive® Advanced Nutrition 
Shake b 350 20 
Two cal® b 475 20 
Perative® b 308 17 
a Information retrieved from Fresenius Kabi (http://www.fresenius-kabi.co.uk/4727.htm; accessed 
14/02/2017) 
b Information retrieved from Abbott (https://abbottnutrition.com/; accessed 14/02/2017) 
c Information retrieved from Nutricia Clinical (http://www.nutricia.co.uk/; accessed 15/02/2017) 
d Information retrieved from Nestlé HealthCare Nutrition (https://www.nestlehealthscience.co.uk; 
accessed 15/02/2017) 
^ 8 fl oz (US) = 237 ml 
* Information retrieved from https://www.evidence.nhs.uk/formulary/bnf/current/; accessed 14/02/2017) 
Table 1.4: Vitamin K content of various enteral feeds ready-to-drink according 
to the British National Formulary, 2017* 
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Vitamin K also plays a key role in anticoagulation control in children. The main 
sources of phylloquinone in neonates, especially preterm infants, are the prophylactic 
dose of phylloquinone given at birth, along with the vitamin K intake derived from 
either parenteral and/or enteral feeding. Breast-fed infants, due to low quantity of 
vitamin K in human milk, are more sensitive to the anticoagulant effect of warfarin 
compared to formula-fed infants. Infant formula preparations with high vitamin K 
content frequently administered to pre-term neonates, lead to higher warfarin dose 
requirements (Bonduel, 2006, Clarke P., 2015). 
1.3.2.8.2.6 Dietary supplements 
Vitamin K is a constituent of many multivitamin preparations. The anticoagulant 
effect of vitamin K antagonists is lessened even by multivitamin formulations 
containing small amounts of vitamin K. In relation to this, Kurnik et al. reported three 
cases of patients treated with warfarin who had presented with sub-therapeutic INR 
after taking multivitamin supplements containing vitamin K, which necessitated an 
increase in warfarin dose with one patient experiencing major thrombosis (Kurnik et 
al., 2003). One of the patients, whose warfarin requirements had increased from 45 
to 60 mg per week, discontinued the multivitamin preparation without notifying her 
physician and subsequently experienced haematoma accompanied by an INR of 
13.2 (Kurnik et al., 2003). Consequent to these observations, patients are best 
advised to avoid multivitamin preparations containing vitamin K.  
There is evidence that vitamin E interferes with vitamin K metabolism, as 
demonstrated by an increase in PIVKA-II plasma concentrations (Booth et al., 2004, 
Heck et al., 2000). Both vitamin K and vitamin E are metabolised by CYP4F2 
(cytochrome P450 isoform 4F2) enzyme, which may explain the basis for their 
interaction (Sontag and Parker, 2002). However, in a randomised double-blind study, 
vitamin E at relatively high doses (800 or 1200 IU/day) was shown to have no effect 
on warfarin anticoagulation (Kim and White, 1996). 
Vitamin C has been reported to interact with warfarin in vitro (Stenton et al., 2001., 
Harris, 1995). The suggested mechanisms of this interaction include enzyme 
induction leading to enhanced warfarin metabolism, potentiation of vitamin K activity, 
influence in either the synthesis or the rate of catabolism of the vitamin K-dependent 
clotting factors, and capillary fragility (Deckert, 1973). A more recent study in rats in 
vivo demonstrated that the co-administration of vitamin C with warfarin leads to an 
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increase in the activity of coagulation factors II, VII, IX and X and a decrease in PT 
and activated partial thromboplastin time (APTT) (Khoshvaghti et al., 2011). Contrary 
to these findings however, it has been reported that vitamin C does not alter the 
anticoagulant effect of warfarin in either dogs or guinea pigs (Deckert, 1973, 
Weintraub and Griner, 1974). In patients on chronic warfarin therapy, we found no 
association between dietary vitamin C levels (2.2–95.9 μM) and warfarin dose 
requirement (Wynne et al., 2006). 
Low dietary vitamin D intake is shown to be a risk factor for cardiovascular and 
thrombotic events (Khademvatani et al., 2014, Kojima et al., 2012). Vitamin D also 
plays an important role in the regulation of bone metabolism and in the prevention of 
osteomalacia and osteoporosis. There is a suggestion that vitamin D interacts with 
the mode of action of vitamin K. However, this remains unclear; whilst there are data 
indicating that vitamin D influences the vitamin K-dependent activation of osteocalcin. 
(Tsugawa, 2015), there are data showing that vitamin D does not affect levels of 
serum undercarboxylated osteocalcin, a sensitive measure of vitamin K status 
(Wynne et al., 2006, O'Connor et al., 2010). 
The provitamin coenzyme Q10 (ubidecarenone) is a dietary supplement taken for 
a range of cardiovascular disorders (Pepping, 1999) and has been linked to 
decreased anticoagulation when taken with warfarin (Spigset, 1994). Coenzyme Q10 
is structurally related to vitamin K and thus may have procoagulant effects in 
anticoagulated patients (Morton, 1971). There are four case reports of falls in INR 
values following the co-administration of coenzyme Q10 with warfarin and 
subsequent restoration of initial INR values after discontinuation of coenzyme Q10 
(Combs et al., 1976, Landbo and Almdal, 1998, Spigset, 1994). A study in patients 
receiving long-term anticoagulation therapy however found that concomitant 
coenzyme Q10 intake (100 mg/day) had no significant effect on warfarin dose 
requirements (Engelsen et al., 2003). As, at the present, there are conflicting reports 
about the effect of coenzyme Q10 on anticoagulation response to warfarin, patients 
should be advised to, either avoid the concomitant use of coenzyme Q10, or for 
healthcare providers to perform additional INR tests when patients start or stop 
taking coenzyme Q10. 
Fish oils contain eicosapentanoic and docosahexanoic acids, which may inhibit 
vitamin K-dependent coagulation factors. One case report described elevated INR 
values when the patient concerned had taken fish oil supplement with warfarin 
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(Buckley et al., 2004). However, this contrasts with the findings of an earlier placebo-
controlled, randomised, double-blinded study in 16 patients receiving chronic warfarin 
therapy, in whom fish oil supplementation (3–6 grams/day) was shown to have no 
significant effect on anticoagulation control (Bender et al., 1998). In the absence of 
further information, patients are advised to discuss the possible interaction between 
fish oil supplements and warfarin with their healthcare provider. 
Cambria-Kiely reported the case of a 70-year-old man with hypertriglyceridaemia 
who was stable on long-term warfarin (INR 2.3–2.5) before he started drinking soya 
milk. Shortly thereafter, his INR dropped below the therapeutic range (1.6); when he 
stopped taking soya milk, his INR returned to the therapeutic range (Cambria-Kiely, 
2002). Interestingly, while soybeans and soybean oil contain high amounts of vitamin 
K (Table 1.2, section 1.3.2.8.2.2), soya milk contains only trace amounts of the 
vitamin (Cambria-Kiely, 2002). Further confirmation of the existence of an interaction 
between warfarin and soya milk and the possible mechanism for such interaction is 
needed. In the absence of further information, patients on warfarin therapy should 
avoid introducing soya milk into their diet. 
Supplements containing L-carnitine have been found to enhance the 
anticoagulant effect of the vitamin K antagonist, acenocoumarol. The mechanism for 
such interaction is unclear. Whether L-carnitine also interacts with warfarin or 
phenprocoumon is unknown at this stage. Therefore, patients on vitamin K 
antagonists are advised to discuss with their healthcare provider the possible risks 
before taking L-carnitine (Martinez et al., 1993, Bachmann and Hoffmann, 2004).   
1.3.2.8.2.7 Plant materials 
Interactions between herbs and other plant material and warfarin are commonly 
reported, sometimes with serious consequences of major bleeding (Izzo and Ernst, 
2009). Theoretically, any herb or plant material that may contain compounds related 
to coumarin or salicylate can augment the anticoagulant effect of vitamin K 
antagonists, through inhibition of either blood clotting or platelet aggregation (Hu et 
al., 2005). 
Up until 2014, thirty eight different herbs had been reported in the literature with 
the potential to interact with warfarin. Evidence suggests that the likelihood of an 
interaction with warfarin is high (level I) for four of these herbs, probable (level II) for 
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three, possible (level III) for ten and doubtful (level IV) for twenty one (Ge et al., 
2014). 
Garlic, ginkgo, St. John's wort, cranberry, grapefruit, cannabis, chamomile and red 
clover have been identified as having major interaction with warfarin (Ge et al., 
2014). Few reports have linked the use of garlic and gingko biloba with bleeding; 
however, there is no evidence that they directly affect coagulation. Ginger has been 
shown to inhibit platelet aggregation (Hu et al., 2005), which may potentiate the 
anticoagulant effect of warfarin. There have been case reports of an interaction 
between St John’s wort (Hypericum perforatum) and vitamin K antagonists (warfarin, 
phenprocoumon), where the use of St John’s wort resulted in the lowering of INR and 
unstable control of anticoagulation (Henderson et al., 2002). A single case of raised 
INR after concomitant use of Angelica sinensis (Dong quai) and warfarin has been 
reported (Haller, 2006). Enhanced anticoagulation and bleeding events have been 
reported after patients on warfarin therapy took the traditional Chinese medicine, 
Salvia miltiorrhiza (danshen) (Izzat et al., 1998, Hu et al., 2005). 
There have been several reports of interaction between warfarin and cranberry 
juice (Hamann et al., 2011, Paeng et al., 2007, Mergenhagen and Sherman, 2008). 
For instance, an elderly patient on warfarin who had a poor appetite following a chest 
infection consumed very little except cranberry juice and was admitted to hospital 
6 weeks later with an INR of >50. He died of gastrointestinal and pericardial 
haemorrhage (Suvarna et al., 2003). The advice of the UK Committee on Safety of 
Medicines is to limit the intake of cranberry juice in patients taking warfarin (Suvarna 
et al., 2003). The mechanism of the interaction between warfarin and cranberry juice 
is at present unclear. However, it has been suggested that the flavonoids present in 
cranberry juice, which can inhibit CYP2C9 enzyme responsible for (S)-warfarin 
metabolism, can explain the interaction between cranberry juice and warfarin 
(Beckmann-Knopp et al., 2000). It is plausible that vitamin C, also a constituent of 
cranberry juice, contributes to alteration in anticoagulation response to warfarin, 
possibly by a number of mechanisms, including alterations in warfarin metabolism, 
competition with vitamin K in binding to vitamin K epoxide reductase which is the 
target enzyme for warfarin, and the rate of loss or catabolism of the vitamin K-
dependent clotting factors. 
It may also be pertinent to avoid the consumption of grapefruit juice given reports 
of enhanced warfarin anticoagulation after consuming grapefruit juice (Bartle, 1999). 
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Although an earlier controlled study failed to demonstrate an interaction between 
warfarin and grapefruit juice (Sullivan et al., 1998), other studies have reported that 
grapefruit juice enhances the anticoagulant effect of warfarin by inhibiting mainly 
CYP3A4 and CYP2C9 enzymes involved in warfarin metabolism (Veronese et al., 
2003, Guo and Yamazoe, 2004). 
Green tea, which is often taken as a dietary supplement because of its reputed 
health benefits (including antioxidant and antibacterial properties), contains 
substantial amounts of vitamin K and therefore drinking large amounts may 
antagonise the anticoagulant effects of warfarin (Booth et al., 1993). Indeed, one 
report describes a warfarin-treated patient who experienced a marked decrease in 
INR after daily consumption of large amounts of green tea, with a subsequent INR 
increase when the beverage was discontinued (without a change in warfarin dosage) 
(Taylor and Wilt, 1999). In the absence of further information, patients receiving 
anticoagulation therapy are advised to discuss the consumption of green tea and its 
possible impact on warfarin anticoagulation response with their healthcare provider.  
 Alcohol consumption 
Alcohol intake is another important factor in patients receiving warfarin, as this 
may increase or decrease the anticoagulant effect of coumarins. Acute alcohol intake 
(e.g. ingestion of a few alcoholic drinks at a single sitting) may increase 
anticoagulation, via decreased hepatic metabolism of warfarin (Weathermon and 
Crabb, 1999) or displacement of the drug from albumin with subsequent increase in 
unbound drug (Ha et al., 2000). Conversely, chronic consumption of alcohol may 
decrease the anticoagulant effect by activating cytochrome P450, thereby increasing 
the metabolism of warfarin (Weathermon and Crabb, 1999). However, in an earlier 
literature review, Wells et al. concluded that alcohol potentiated warfarin 
anticoagulation only if the patient had concomitant liver disease (Wells et al., 1994). 
A Dutch study found that although habitual alcohol consumption or heavy drinking 
(≥6 drinks/day) did not affect anticoagulation control, a recent decrease in alcohol 
intake increased the risk of having an INR value ≥6.0 and thus increasing the risk of 
bleeding in the patient (Penning-van Beest et al., 2002). A case report of a patient on 
warfarin with a low-dose beer consumption was found to be the cause of elevated 
INR. The authors recommended close monitoring of INR when alcohol is taken in 
combination with warfarin and other concomitant medication (Havrda et al., 2005). In 
the absence of consistent data, it is clear that patients should either avoid alcohol or 
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at least avoid erratic consumption of alcohol while receiving warfarin with close INR 
monitoring. 
 Drug interactions  
Interactions with other medications are very common for warfarin and evidence 
shows that NOACs also interact with some drug categories (Hankey and Eikelboom, 
2011). Pharmacodynamic as well as pharmacokinetic mechanisms are responsible 
for these interactions, which either potentiate or inhibit the anticoagulant response. 
A distinct example of common interaction of warfarin is antibiotics. Antibiotics 
generally displace warfarin from albumin, its carrier protein. Hence, there is greater 
availability of warfarin and increased anticoagulation. Antibiotics that alter 
gastrointestinal flora also reduce the population of bacteria producing menaquinones. 
In both instances, a lower warfarin dose is required (White, 2010). 
Other medications inhibit or induce cytochrome P450 enzymes, such as CYP2C9. 
Drugs that interfere with platelet aggregation and increase the risk of bleeding or 
others that increase the risk of thrombosis interact with anticoagulant therapy. In their 
review, Holbrook et al summarise the great number of drug interactions with warfarin 
(Holbrook et al., 2005). 
 Warfarin pharmacogenetics 
Warfarin dose requirements are mainly determined by the genetic predisposition 
in adults. Two genes, CYP2C9 and VKORC1, have been identified and well 
described in terms of their impact on warfarin treatment in adult populations (Nowak-
Gottl et al., 2010). CYP2C9 and VKORC1 combined with other clinical factors (age, 
body size, sex etc.) explain more than 50% of interindividual variability in dose 
requirement in a number of different patient cohorts (Sconce et al., 2005a, Caldwell 
et al., 2007, Wadelius et al., 2009, Carlquist et al., 2006, Gage et al., 2008 , 
Pirmohamed et al., 2013). 
 CYP2C9 polymorphisms 
Initially observed in 1995, single nucleotide polymorphisms (SNPs) in the coding 
region of the CYP2C9 gene impact on the enzymatic activity of CYP2C9. This is 
clinically important because it is the main cause for variations in the metabolism of 
warfarin (Furuya et al., 1995, Aithal et al., 1999). CYP2C9 gene is located on 
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chromosome 10, cytogenetic band q24 (NCBI a). A mutation in a region of the gene 
that is important for the formation of the three-dimensional structure of the protein 
can severely influence the activity and selectivity of the enzyme (Figure 1.11). 
Decreased capacity to metabolise S-warfarin has been demonstrated to lead to 
increased sensitivity to warfarin and therefore increased risk for bleeding (Kamali and 
Wynne, 2010). 
 
 
Figure 1.11: 3D structure of CYP2C9 enzyme and S-warfarin (Adapted from 
https://www.ncbi.nlm.nih.gov/Structure) 
 
The wild type allele is termed as CYP2C9 *1. Among the most widely studied 
SNPs are c.430C>T rs1799853 (*2 allele), c.1075A>C rs1057910 (*3 allele) and 
818delA rs9332131 (*6 allele) (Moyer et al., 2009). The CYP2C9*2 variant protein is 
only 12% as potent as the wild-type enzyme in hydroxylating S-warfarin (Rettie et al., 
1994), while the CYP2C9*3 variant enzyme demonstrates only 5% activity compared 
to CYP2C9*1 (Linder, 2001). 
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However, one third of patients carrying wild type CYP2C9 alleles need a lower 
daily dose of warfarin. Kamali et al suggested that there are several other factors 
affecting each patient’s warfarin dose requirements (Kamali and Wynne, 2010).  
In European Caucasians, frequencies of CYP2C9*2 and CYP2C9*3 alleles are 
10% and 6%, respectively. Differences in CYP2C9 genotype distributions among 
European populations are small (Sánchez-Diz et al., 2009, Cavallari and Perera, 
2012). In the Ethiopian population the frequencies are much lower (94, 4 and 2% 
respectively) and frequencies of *2 and *3 are even lower in African Americans (2% 
and 1%, respectively). Other SNPs found only in African Americans are *8 and *11 
(frequency of 6% and 4%, respectively) (Scordo et al., 2001, Cavallari and Perera, 
2012). Interestingly, as we move from East to West Asia, the carrier rate increases 
for CYP2C9 *2 and *3 alleles (Gaikwad et al., 2014). In Japanese, warfarin clearance 
was found to be reduced by up to 90% in CYP2C9*3 homozygotes (Takahashi and 
Echizen, 2001). 
 VKOR polymorphisms 
Polymorphisms in the VKOR enzyme (Figure 1.12), the target of warfarin, have a 
significant effect on warfarin dose requirement. The VKORC1 gene was located after 
positional cloning on chromosome 16, cytogenetic band p11.2 (NCBI a). Two SNPs 
encoding complex subunit 1 of VKOR enzyme (VKORC1) have been found to affect 
the dose requirement for warfarin. The first variant includes the -1639G>A 
substitution in the promoter region and results in a reduction of the normal 
transcription of VKORC1 gene to a half of it (Carlquist and Anderson, 2011), 
increasing the sensitivity to warfarin (Yuan et al., 2005). Interestingly, the 1173C>T 
variant in the intron 1 of VKORC1 gene is in linkage disequilibrium with the -
1639G>A (Kamali and Wynne, 2010). The second SNP is the 3730G>A transition on 
the 3′ untranslated region. The study of D'Andrea et al showed a significantly lower 
requirement for warfarin dose in patients being homozygotes for the variant allele in 
either of these two polymorphisms (D'Andrea et al., 2005). 
Large variability has been observed in the prevalence of the different VKORC1 
alleles among different ethnic populations. Associated with low dose warfarin (Yuan 
et al., 2005), the VKORC1 -1639 variant allele (A) is found in 90% of East Asians and 
as we move from East to West Asia, the carrier rate decreases (Gaikwad et al., 
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2014). The frequency of the VKORC1-1639A allele is 40% in European Caucasians 
and 11% in African Americans (Cavallari and Perera, 2012). 
 
 
Figure 1.12: 3D structure of VKORC1 enzyme (Adapted from 
https://www.ncbi.nlm.nih.gov/Structure) 
 
 Polymorphisms in other genes 
Other SNPs have also been identified by recent meta-analyses to have an impact 
on warfarin dose requirements. A novel CYP2C9 polymorphism (rs7089580) has 
been associated with higher gene expression and faster S-warfarin clearance, thus 
resulting in higher dose requirements in African Americans (Hernandez et al., 2015). 
Additionally, warfarin daily dose requirement is altered in the presence of certain 
alleles in CYP4F2 gene (p.V433M, rs2108622). A meta-analysis of thirty studies 
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showed that T-allele carriers required an 8.3% higher mean daily warfarin dose than 
CC homozygotes to achieve a stable international normalized ratio (INR). The 
authors concluded that, although CYP2C9 and VKORC1 polymorphisms remain the 
main genetic causes of inter-individual variability in response to warfarin, this novel 
CYP4F2 polymorphism also has a low effect (Danese et al., 2012). Other studies 
have focused on the mechanism through which CYP4F2 rs2108622 polymorphism 
affects warfarin dose (Hirai et al., 2013). CYP4F2 gene codes for a vitamin K1 mono-
oxidase that catabolises vitamin K as shown by McDonald et al. Thus, a defective 
oxidase leads to elevated hepatic vitamin K levels and higher warfarin dose 
requirements (McDonald et al., 2009). 
More recent studies have demonstrated the contribution of very rare variants in 
the observed inter-individual variability in warfarin response. One part of the currently 
unexplained variability should be attributed to rare variants that have not appeared in 
previous GWAS, but have been demonstrated as a result of studies with different 
design (exome array and two-stage extreme phenotype strategies) by Liu and 
colleagues (Liu et al., 2017) and Luo and colleagues (Luo et al., 2017).  
 Combined genotypes effect 
Previous research has shed light to the combined effect of CYP2C9 and VKORC1 
genotypes for calculation of the appropriate warfarin dose (Jorgensen et al., 2012). In 
2007, the U.S. Food and Drug Administration (FDA) proposed that CYP2C9 and 
VKORC1 genotypes should be taken into account for dose adjustments (FDA, 2007) 
and in 2010 specific dosing recommendations for genotype-based dosing ranges 
(0.5-7mg/day) were published and have been included in warfarin’s product label 
(Table 1.5) (FDA, 2010, Johnson et al., 2011).  
 
VKORC1 CYP2C9 
 *1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3 
GG 5-7 mg 5-7 mg 3-4 mg 3-4 mg 3-4 mg 0.5-2 mg 
GA 5-7 mg 3-4 mg 3-4 mg 3-4 mg 0.5-2 mg 0.5-2 mg 
AA 3-4 mg 3-4 mg 0.5-2 mg 0.5-2 mg 0.5-2 mg 0.5-2 mg 
Table 1.5: Ranges of expected maintenance warfarin daily dose based on 
CYP2C9 and VKORC1 genotypes (Taken from (FDA, 2010)) 
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At least four FDA-approved analytical platforms have been available since 2010 
for CYP2C9 and VKORC1 genotyping. While comparing them, all proved to be 
accurate for the common alleles with their own strengths and weaknesses (Maurice 
et al., 2010). 
Several small studies on warfarin and acenocoumarol have concluded that 
carriers of a combination of CYP2C9 and VKORC1 polymorphisms have an 
increased risk for over anticoagulation compared to wild type or single variant carriers 
(Schalekamp et al., 2006, Tomek et al., 2013). Small pilot studies evaluating the use 
of pharmacogenomic information to guide initiation of warfarin therapy demonstrated 
benefits such as decreased frequency of warfarin dose adjustments, less time to 
stabilise within the target INR therapeutic range and increased time spent within the 
therapeutic range during initiation (Abohelaika et al., 2016). 
In a meta-analysis of nine randomised controlled trials (RCTs) involving in total 
2812 patients, a genotype-guided dosing strategy did not demonstrate improvement 
in TTR, reduction in the number of patients with an INR > 4 or a reduction in major 
bleeding or thromboembolic events compared with clinical dosing algorithms 
(Stergiopoulos and Brown, 2014). This finding was replicated in other RCTs, too 
(Kimmel et al., 2013, Witt et al., 2016). 
More recently, the clinical response to warfarin using genetic information was 
compared with edoxaban as part of Effective Anticoagulation with Factor Xa Next 
Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 (ENGAGE 
AF-TIMI 48), an RCT in patients with AF. A subgroup of the warfarin-treated group, 
involving 4833 patients (33.7% of sample size included in the RCT), was genotyped 
for the common CYP2C9 and VKORC1 alleles and patients were categorised in bins 
according to the FDA guidance, thus validating the genetic binning provided in 
warfarin label. During the first 90 days, the risk of bleeding with warfarin was 1.3 
times higher in the sensitive responders (3-4mg dose, Table 1.5) and 2.7 times 
higher in the highly sensitive (0.5-2mg dose, Table 1.5) compared with normal 
responders. Treatment with edoxaban versus warfarin reduced bleeding risk in all 
patients, especially so in sensitive and highly sensitive responders (Mega et al., 
2015). 
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 Pharmacogenetics-based dosing algorithms 
The extent to which pharmacogenetics-guided dosing can improve the safety of 
oral anticoagulation therapy has been investigated in two large prospective multi-
centre randomized clinical trials; the European trial Pharmacogenomic Approach to 
Coumarin Therapy (EU-PACT) and the US trial Clarification of Optimal 
Anticoagulation through Genetics (COAG) (Pirmohamed et al., 2013, Kimmel et al., 
2013). Both studies involved patients with an indication for oral anticoagulation 
therapy with the primary outcome measure being the percentage TTR following the 
initiation of warfarin therapy.  
The double-blinded COAG trial focused on warfarin and evaluated the value of a 
pharmacogenetics-based dosing as opposed to the single-blinded EU-PACT that 
studied three vitamin K antagonists in parallel in three arms (warfarin, 
acenocoumarol and phenprocoumon) (Pirmohamed et al., 2013). COAG study 
compared genotype-guided dosing versus a clinical dosing algorithm and failed to 
show a significant difference in the TTR (45.2% vs 45.4%, P=0.91, mean difference 
of 0.2%). More ethnic variation was observed in COAG (67% White, 27% Black, and 
6% Hispanic) compared to EU-PACT (>98% White). 
Although the EU-PACT trial found the pharmacogenetic algorithm (which also 
included clinical data) to be superior over a fixed loading dose regimen in significantly 
improving TTR (67.4% vs 60.3%, P<0.001, mean difference of 7%), the absence of 
blinding of clinicians and patients is questioned (Kimmel, 2015).  
GM-CSF for Immunomodulation Following Trauma (GIFT) study in 2017 showed 
that genotype-guided warfarin dosing reduced the combined risk of major bleeding, 
INR of 4 or greater, venous thromboembolism or death, compared with clinically 
guided dosing in patients undergoing elective hip or knee arthroplasty and treated 
with warfarin (Gage et al., 2017). 
 Non-vitamin K antagonist oral anticoagulants (NOACs) 
The term NOAC is widely recognized and is recommended by the ESC AF 
guidelines to describe the newer class of oral anticoagulants. The term DOACs is 
adopted in the US and both terms refer to the direct factor Xa inhibitors, rivaroxaban, 
apixaban and edoxaban and the direct thrombin inhibitor (DTI), dabigatran. Solely for 
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the purpose of consistency with the European guidelines, the term NOAC will be 
used throughout this thesis. 
 Factor Xa inhibitors 
Rivaroxaban, apixaban and edoxaban are new generation oral anticoagulants, 
which directly target the Xa factor of the coagulation pathway (Figure 1.13) (NCBI b). 
Factor Xa is generated by both the extrinsic and intrinsic coagulation pathways. 
Factor Xa inhibitors are generally used as prophylaxis in patients having knee and 
hip replacement surgery, due to their high risk of DVT and PE (Samama, 2011). In 
2011, rivaroxaban was also approved for stroke prevention in people with non-
valvular atrial fibrillation (NVAF) (U.S. Food and Drug Association, 2011). 
 
 
Figure 1.13: Chemical structures of factor Xa inhibitors (Adapted from PubChem 
database) 
 
Three major trials that proved the non-inferiority of NOACs against warfarin led to 
the authorisation of factor Xa inhibitors. The Rivaroxaban Once Daily Oral Direct 
Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke 
and Embolism Trial in Atrial Fibrillation (ROCKET AF) was a multicentre, randomized, 
double-blind, double-dummy, event-driven trial that was conducted at 1178 
participating sites in 45 countries involving 14,264 patients. The trial compared once-
daily oral rivaroxaban with dose-adjusted warfarin for the prevention of stroke and 
systemic embolism in patients with NVAF who were at moderate-to-high risk for 
stroke (Patel et al., 2011). Rivaroxaban was also examined for the treatment of DVT 
in the Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic 
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pulmonary embolism (EINSTEIN-PE) and the Oral, direct Factor Xa inhibitor 
rivaroxaban in patients with acute symptomatic deep vein thrombosis (EINSTEIN-
DVT) trials which demonstrated non-inferior efficacy over subcutaneous enoxaparin 
followed by a vitamin K antagonist (either warfarin or acenocoumarol) (EINSTEIN 
Investigators et al., 2010, EINSTEIN–PE Investigators, 2012). 
The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation (ARISTOTLE) trial compared apixaban with warfarin for the prevention of 
stroke or systemic embolism in patients with AF and at least one additional risk factor 
for stroke. It was a double-blind study which randomly assigned 18,206 patients with 
AF from about 40 countries in a 1:1 ratio to receive either apixaban or warfarin 
titrated to a target INR range (2.0-3.0) (Lopes et al., 2010, Granger et al., 2011). 
Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein 
Thrombosis as First-Line Therapy (AMPLIFY) trial showed that apixaban is non-
inferior to conventional therapy with subcutaneous enoxaparin and concomitant 
warfarin for the acute management of patients with symptomatic VTE (Agnelli et al., 
2013). 
The ENGAGE AF-TIMI 48 trial was a three-group, randomized, double-blind, 
double-dummy trial comparing two dose regimens of edoxaban with warfarin for the 
prevention of stroke and systemic embolism. Patients were randomly assigned, in a 
1:1:1 ratio, to receive warfarin titrated to achieve an INR of 2.0 to 3.0, or to receive 
high-dose (60mg) or low-dose (30mg) edoxaban. It was conducted at 1393 centres in 
46 countries, involving a total of 21,026 patients (Ruff et al., 2010, Giugliano et al., 
2013). Edoxaban administered once daily after initial treatment with heparin in 
Hokusai-VTE (Comparative Investigation of Low Molecular Weight Heparin/ 
Edoxaban Tosylate Versus Low Molecular Weight Heparin/ Warfarin in the Treatment 
of Symptomatic Deep-Vein Blood Clots) was non-inferior to warfarin for the treatment 
of VTE (The Hokusai-VTE Investigators, 2013). 
The advantage of direct factor Xa inhibitors over the VKAs is the lack of the need 
for monitoring and dose adjustment. Their oral administration, their possible use at 
fixed dosage in the vast majority of patients, as well as their largely predictable 
pharmacokinetics have rapidly increased their use worldwide. They have a rapid 
onset and offset of action, and unlike VKAs have less interactions with food and other 
medications. Their main disadvantage is currently the absence of a specific reversal 
agent in the market, unlike dabigatran but this is going to change in early 2020, when 
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NICE is expected to authorise a new reversal agent for factor Xa inhibitors (NICE d, 
2019). Andexanet-alfa is currently being studied and has been shown to decrease 
factor Xa-activity by 89% for rivaroxaban treated patients and by 95% for apixaban 
treated patients after a bolus dose (Sartori and Cosmi, 2018). 
 Pharmacokinetics of factor Xa inhibitors 
Rivaroxaban has greater bioavailability with concomitant food consumption 
(almost 100%) than without food (66%). Apixaban is not influenced by food but has a 
lower bioavailability (50%), while edoxaban is only mildly influenced (6-22% 
increased absorption) with 62% bioavailability. Plasma drug concentration peaks at 
3-4 hours for apixaban and rivaroxaban and 1-2 for edoxaban. Apixaban and 
edoxaban have similarly long half-life (12h and 10-14h respectively), while 
rivaroxaban’s half-life heavily depends on age, with almost double half-life in elderly 
(11-13h) compared to young (5-9h) subjects. Unlike edoxaban, liver metabolism of 
apixaban and rivaroxaban involves the CYP3A4 enzyme with moderate contribution 
to their elimination. Renal and non-renal clearance is equal for edoxaban (50/50%), 
while for apixaban and rivaroxaban it is mostly non-renal (73% and 65% respectively) 
(Heidbuchel et al., 2015, Salmonson et al., 2017). 
 Direct thrombin inhibitors 
Ximelagatran (AstraZeneca, Cambridge UK), the first direct thrombin inhibitor, 
was withdrawn from the market in 2006 after reported hepatotoxicity during clinical 
trials (Figure 1.14) (NCBI b, Keisu and Andersson, 2010). Two years later, in 2008, a 
new DTI called dabigatran etexilate was approved by the European Medicines 
Agency (EMA) for the prevention of thromboembolic disease following hip or knee 
replacement surgery. In 2010, the FDA approved it for the prevention of 
thromboembolism in AF, DVT and PE. Although the data presented to the authorities 
were much criticised for selection bias, dabigatran was investigated in the 
randomized evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial and was 
found to reduce stroke or systemic embolism by 34% compared to warfarin (Albert, 
2014). Dabigatran was examined for treatment of VTE against conventional 
treatment in Efficacy and Safety of Dabigatran Compared with Warfarin for 6 Month 
Treatment of Acute Symptomatic Venous Thromboembolism (RE-COVER I) and 
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 
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6 months Treatment of Acute Symptomatic Venous Thromboembolism (RE-COVER 
II) trials (Schulman et al., 2009, Schulman et al., 2014). 
Dabigatran etexilate is a prodrug, which after oral ingestion is activated through 
esterase-dependent conversion into the active agent, dabigatran (Figure 1.14). The 
bioconversion occurs in the liver, portal vein and small intestine. It causes 
anticoagulation by directly binding to the active site of thrombin (Hankey and 
Eikelboom, 2011). Thrombin has a main active site and two additional exosites, 
which are useful for fibrin and heparin binding respectively. In the presence of 
dabigatran, both the unbound thrombin and the complex of thrombin-fibrin are 
inactivated. Hence, there is no route available for the conversion of fibrinogen into 
fibrin, resulting in the formation of blood clot. In contrast, after heparin administration, 
the fibrin-binding site is not inhibited (Hankey and Eikelboom, 2011). 
 
 
Figure 1.14: Chemical structures of direct thrombin inhibitors (Adapted from 
PubChem database) 
Dabigatran is not influenced by food intake and is very poorly absorbed from the 
gut. Dabigatran’s P-glycoprotein dependent absorption can be disrupted by P-
glycoprotein inducers or inhibitors (Hankey and Eikelboom, 2011). The oral 
bioavailability is low, between 6 to 7%. Plasma concentration peaks at 1.5 to 2 hours 
with a half-life of 12-14 hours, but it increases in patients with renal impairment 
(Mekaj et al., 2015). All NOACs undergo varying degrees of hepatic metabolism, with 
much lower hepatic metabolism for dabigatran (Heidbuchel et al., 2015).  
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The rapid conversion by esterases, particularly liver esterase Carboxylesterase 1 
(CES1) has recently been shown to be influenced by genetics. A recent genome-
wide association study has brought attention to the polymorphism rs2244613 of the 
CES1. One third (32.8%) of RE-LY participants were identified as carriers of the 
minor allele, which was associated with lower exposure to active dabigatran 
metabolite. As a consequence, these patients had lower risk of bleeding due to their 
genetic background (Paré et al., 2013). ABCB1 (ATP binding cassette subfamily B 
member 1) gene encodes p-glycoprotein and its inhibitors have been found to 
increase bioavailability of dabigatran (Stangier and Clemens, 2009). 
 Clinical indications of NOACs and dosing 
The frequency of dosing and dosage with NOACs are governed by the indications 
the drugs are prescribed for as shown in Table 1.6. Dabigatran is preferred for 
patients with moderate renal impairment, and those with increased risk of bleeding 
and concomitant treatment with verapamil or amiodarone(NICE c) . 
 
Indication Drug and dose 
Prophylaxis of venous thromboembolism following 
knee or hip replacement surgery 
A*, R◊, D ⱡ (total knee or hip 
replacement surgery) 
Treatment of deep-vein thrombosis or pulmonary 
embolism 
R (initialϙ and continued◊ 
treatment), Aϙ, E^, D¢ 
Prophylaxis of recurrent deep-vein thrombosis or 
pulmonary embolism A*, R◊, E^, D
¢ 
Prophylaxis of stroke and systemic embolism in 
NVAF and at least one risk factor (such as previous 
stroke or transient ischaemic attack, symptomatic 
heart failure, diabetes mellitus, hypertension, or age 
75 years and over) 
A**, R◊, E^, D¢ 
A: apixaban, R: rivaroxaban, E: edoxaban, * low dose (A=2.5mg, R= 2.5mg bid), ◊ medium dose (A=5mg, 
R=10/20mg od, E= mg), ϙ high dose (A=10mg, R=15mg bid), E^ =30mg; body weight < 61kg and 60mg; body 
weight ≥ 61kg, D ⱡ = 110mg, followed by 220mg od for adults 18-74 years and 75mg followed by 150mg after 
surgery for adults ≥75 years, D¢= 150mg bid (18-74y)/ 110-150mg (75-79y)/ 110mg (≥80y) 
Table 1.6: Clinical indications of NOACs (Information obtained from the British 
National Formulary, 2019) 
Contraindications for rivaroxaban mainly include a history of bleeding, previous 
surgery, cancer and aneurysm. Apixaban is not indicated in the presence of active 
bleeding or risk factors for bleeding. Edoxaban, apart from bleeding, is 
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contraindicated in hepatic disease, brain injury, gastrointestinal problems, cancer, 
aneurysms and uncontrolled hypertension. Dabigatran is not recommended in the 
presence of active bleeding, prosthetic heart valve, cancer, brain or ophthalmic 
surgery, gastrointestinal problems and vascular aneurysm (NICE c)(NICE c). 
  Monitoring of NOACs 
The great advantage of NOACs is that routine monitoring is not necessary for 
establishment of anticoagulation. However, laboratory monitoring is recommended in 
certain cases, as presented in Table 1.7 (Martin et al., 2016, Moll and Martin, 2018, 
Favaloro and Lippi, 2015, Baglin et al., 2013). 
 
1. Unexpected bleeding or severe trauma on a NOAC 
2. New thromboembolic event on a NOAC 
3. Suspicion for NOAC overdose 
4. Suspicion for non-adherence 
5. Extreme obesity or underweight  
6. Status post bariatric surgery or upper intestinal tract resection surgery 
7. Concomitant therapy with a drug that may significantly affect NOAC 
pharmacokinetics 
8. Assessment prior to major surgery in patient with recent NOAC intake or 
significantly impaired renal or liver function 
9. Assessment of reversal of anticoagulation 
10. Athlete on long-term anticoagulation wishing to engage in contact sports 
11. Suspected pregnancy 
Table 1.7: Possible reasons for NOAC level testing in clinical practice  
 
No simple first-line test has proven reliable enough for defining the patient’s 
anticoagulation status for all the oral factor Xa inhibitors. Due to the differences in the 
mechanism of action compared to VKAs, PT/INR test gives misleading results as this 
is a test for the extrinsic coagulation pathway, mainly affected by VKAs. Other assays 
have been approved, are commercially available and evaluate coagulation activity in 
patients on NOACs. Ecarin clotting time (ECT) and in particular APTT are both used 
to monitor dabigatran as good linear relationship exists between clotting time of 
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APTT for many reagents and dabigatran plasma concentration (Lippi et al., 2014, 
Pollack, 2016).  
Anti-factor Xa (anti-Xa) assay is used to detect plasma concentration of factor Xa 
inhibitors (rivaroxaban, apixaban, edoxaban), but had initially been used for the 
determination of the abilities of unfractionated heparin (UFH) and low-molecular 
weight heparin (LMWH) to inhibit factor Xa (Newall, 2013, Samama, 2013). However, 
this assay needs to be specifically calibrated against the individual drug 
administered, which means calibrators, reagents and controls need to be used to 
calibrate and monitor coagulation analysers. This complicates the introduction of 
such assays in clinical practice (Lippi and Favaloro, 2015, Lippi and Favaloro, 2017). 
There is still limited information as to whether plasma levels of NOACs correlate 
with the incidence of bleeding and thrombotic complications. As patients recruited in 
clinical trials were carefully selected, plasma concentrations reported do not 
represent a minority of patients with extreme demographics, complicated clinical 
characteristics and concomitant medications. Clinical trials and post-marketing 
studies have provided evidence of the wide range of NOAC plasma concentrations 
after oral dosing. According to recent studies by Reilly et al (Reilly et al., 2014) and 
Ruff et al (Ruff et al., 2015), trough levels of dabigatran and edoxaban have a strong 
correlation with haemorrhagic and thrombotic complications. Table 1.8 summarises 
the plasma concentration median and ranges of all NOACs at steady-state (Cuker, 
2016). 
 
Drug Dose Peak concentration (ng/mL) 
Trough concentration 
(ng/mL) 
  Median 5th to 95
th 
percentile Median 
5th to 95th 
percentile 
Dabigatran 150 mg BID 184 64–443 90 31–225 
Rivaroxaban 20 mg daily 270 189–419 26 6–87 
Apixaban 5 mg BID 171 91–321 103 41–230 
Edoxaban 60 mg daily 170 120–250 22 10–40 
Table 1.8: Plasma NOACs concentrations at steady-state 
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 Bleeding risk of NOACs 
Although less frequent, intracranial bleeding is the primary concern due to its 
devastating rate of mortality and impact on quality of life. Gastrointestinal bleeding is 
more frequent but less likely to be fatal. Bleeding incidence of NOACs versus 
warfarin are available from the four phase 3 clinical trials that led to their approval for 
the prevention of stroke or systemic embolism in NVAF. Compared to warfarin, 
dabigatran reduced major bleeding risk and had similar gastrointestinal bleeding with 
low-dose dabigatran (110mg bid), while it had similar major bleeding risk but 
increased gastrointestinal bleeding risk with high dose (150mg bid). In older patients, 
major bleeding risk was similar with warfarin after 110mg and higher although not 
significant after 150mg dabigatran. Apixaban reduced major bleeding risk but had 
similar gastrointestinal bleeding risk with warfarin. Edoxaban reduced major bleeding 
risk after both low and high doses. High dose increased gastrointestinal bleeding, in 
contrast with low dose edoxaban. Rivaroxaban had similar major bleeding risk. In 
patients with gastrointestinal bleeding history, rivaroxaban had higher gastrointestinal 
bleeding risk, but similar in patients without history. All NOACs reduced intracranial 
bleeding risk compared with warfarin (Eikelboom and Merli, 2016) 
Despite their limited follow-up period (<1 year) and the potential absence of 
comparable groups, post-marketing surveillance studies have provided real-world 
figures regarding the bleeding risks associated with NOACs versus warfarin (Villines 
and Peacock, 2016). Dabigatran bleeding risks were consistent with the RE-LY study 
findings overall, with increased gastrointestinal bleeding risk being observed 
particularly in women aged 75-84 years and elderly aged 85 or over (Lip et al., 2016). 
Rivaroxaban and apixaban bleeding rates were similar to the ones reported in the 
ROCKET-AF trial (Tamayo et al., 2015, Peacock, 2015). 
Bleeding risk associated with the use of anticoagulants has been attributed to 
elevated drug exposure on the basis that the latter is increased in anticoagulated 
patients with renal impairment. Previous studies have demonstrated that renal 
impairment is common in elderly populations, with a tendency to decline with 
increasing age (Glassock and Rule, 2012, Imai et al., 2008, Baggio et al., 2005). 
Dose adjustment is currently considered with dabigatran, rivaroxaban, apixaban and 
edoxaban, with specific dose recommendations in relation to serum creatinine levels. 
Age of 80 years or over has been included in the three risk factors that justify a lower 
dose of apixaban (unlike the other three NOACs), only when at least two risk factors 
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are present. Unlike the FDA, the EMA suggests using 110 mg dabigatran twice daily 
for individuals aged 80 years and older (Sardar et al., 2014a). 
 Factors affecting treatment with NOACs 
In recent years, four NOACs, which selectively inhibit a single clotting factor 
(factor Xa or factor IIa (thrombin)) have been developed (Connolly et al., 2009, Patel 
et al., 2011, Granger et al., 2011, Giugliano et al., 2013)   as previously mentioned in 
sections 1.3.3.1 and 1.3.3.3. It is generally accepted that, unlike coumarins, NOACs 
do not interact with dietary vitamin K. This is because of the perception that the mode 
of action of these agents, which exert their pharmacological activity by inhibition of a 
specific clotting protein, is different to that of coumarins which inhibit the recycling of 
vitamin K, necessary for the gamma-carboxylation of vitamin K-dependent clotting 
proteins.  
However, since the functionalisation of both factor Xa and thrombin is inextricably 
linked to vitamin K, there is the possibility that the pharmacological activity of agents 
that inhibit these proteins could be influenced by alterations in vitamin K availability. 
Indeed, in an earlier study in rats vitamin K deficiency significantly enhanced the 
anticoagulation activity of the direct thrombin inhibitor, ximelagatran. Briefly, the 
anticoagulant activity of ximelagatran (20 mmol/kg, twice daily for 8 days) was 
significantly greater in rats on vitamin K deficient diet (12.3-fold for PT, 5.1-fold for 
APTT, and 1.6-fold for ECT) compared to those on normal diet. Factor II activity was 
reduced to 58% by ximelagatran in rats on normal diet. However, factor II activity was 
virtually abolished (<1%) by the drug in rats on vitamin K deficient diet (Kamali et al., 
2009). Whether dietary vitamin K influences anticoagulation response to NOACs in 
man remains to be investigated. 
Genetic influence on NOAC exposure has been investigated and a number of 
genetic polymorphisms have been previously identified. Only one genome wide 
association study (GWAS) has been performed with patients from the RE-LY trial for 
dabigatran and identified three single SNPs; rs2244613 and rs8192935 in the liver 
esterase CES1 gene involved in the rapid conversion of dabigatran etexilate to the 
active metabolite and rs4148738 in the ABCB1 gene which codes for P-glycoprotein 
(P-gp) transporter. ENGAGE-TIMI 48 trial showed no influence of common VKORC1 
and CYP2C9 polymorphisms on edoxaban pharmacokinetics. No GWAS data are 
currently available for either rivaroxaban or apixaban (Mega et al., 2015, Vandell et 
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al., 2017, Paré et al., 2013) . Smaller studies have demonstrated that rivaroxaban 
and apixaban are influenced by SNPs at ABCB1 gene (Figure 1.15). 
 
 
Figure 1.15: Metabolism and genetic influence of NOACs  
 
 Drug interactions 
After absorption in the gut, all NOACs undergo significant gastrointestinal re-
secretion by a P-gp transporter, which is also involved in renal clearance (Mekaj et 
al., 2015). Hence, increased plasma levels will result from competitive P-gp inhibition 
by drugs commonly prescribed in AF patients (e.g. amiodarone, verapamil, quinidine 
and dronedarone). Conversely, strong inducers of P-gp reduce NOAC plasma levels, 
leaving patients at significant risk of thromboembolism. Dabigatran’s absorption can 
be disrupted by both P-glycoprotein inducers or inhibitors (Hankey and Eikelboom, 
2011). 
Strong CYP3A4 inhibition or induction may affect plasma concentrations and 
should be evaluated. CYP3A4/3A5 enzymes are involved in the hepatic clearance of 
rivaroxaban (18%), apixaban (25%) and edoxaban (<4%) (Steffel et al., 2018, Mueck 
et al., 2014). Strong CYP3A4/3A5 inhibitors like ketoconazole and ritonavir led to 
70% and 50% mean inhibition of non-renal (metabolic) clearance of rivaroxaban 
respectively, while a 44% and more than 80% mean inhibition of active renal 
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secretion was observed. Apixaban’s non-metabolic clearance is diverse, which 
reduces the potential for drug–drug interaction (Wang et al., 2010). 
In general, NOAC use is not recommended in combination with drugs that are 
strong inhibitors of both CYP3A4/3A5 and P-gp. Combinations with strong inhibitors 
should be used with great caution or avoided where possible (Steffel et al., 2018). 
 Adverse effects of NOACs 
Apart from the increased incidence of bleeds and bruises, NOACs more 
frequently cause non-bleeding gastrointestinal disorders as well as severe rare toxic 
liver disease (Maura et al., 2018).  
Gastrointestinal complications, other than bleeding, can significantly affect the 
patient’s quality of life leading to reduced compliance or even discontinuation (Beyer-
Westendorf et al., 2016, Al-Khalili et al., 2016, Beyer-Westendorf et al., 2015). NOAC 
therapy is associated with the initiation of drugs for functional gastrointestinal 
disorders excluding drugs for acid-related disorders. Non-bleeding gastrointestinal 
disorders have previously been reported to be uncommon (Chan et al., 2016a). 
Nonetheless, dyspepsia (5-10%) and esophagitis are now increasingly recognized 
complications of dabigatran (Zhang et al., 2016, Heidbuchel et al., 2015) and 
rivaroxaban (Cox et al., 2016). Pyrexia, nausea, constipation and vomiting were 
commonly reported non-bleeding adverse events in rivaroxaban-treated patients 
(Duggan, 2012). In addition to these, another study that used Danish registries 
showed an association between NOACs and acute renal failure (Hellfritzsch et al., 
2018). 
Patients with acute liver disease were excluded from the landmark NOAC 
randomised controlled trials. However, short-term elevation of transaminase enzymes 
was reported during these trials (Connolly et al., 2009, Granger et al., 2011, Patel et 
al., 2011). Although according to a meta-analysis of clinical trials, NOACs were not 
associated with an increased risk of drug-induced liver injury (DILI) (Caldeira et al., 
2014), a range of post-marketing studies have showed that NOACs can cause DILI 
(Raschi et al., 2016, Rochwerg et al., 2012, Liakoni et al., 2015, Liakoni et al., 2014, 
Cordeanu et al., 2016, Raschi et al., 2015) with dabigatran new users having the 
lowest risk compared to factor Xa inhibitors. Close monitoring of liver function after 
initiation of NOAC treatment is therefore necessary, especially in the presence of 
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pre-existing liver conditions or concomitant intake of hepatotoxic agents (Alonso et 
al., 2017). 
Generally, hypersensitivity reactions and hair loss are rare. Rivaroxaban causes 
immunological side effects at a rate of 0.1–1% and few cases with hair loss have 
been reported (Christopoulou et al., 2017). Cases of skin disorders have also been 
reported for patients treated with dabigatran and apixaban (Cakmak et al., 2014, 
NICE c). Reversible neurological reactions have been reported for apixaban (Josyln 
et al., 2018). 
Overall, further studies, hospitalisation data and registry research are needed to 
investigate the prevalence and impact of adverse events in NOAC-treated patients 
(Maura et al., 2018). 
 Reversal of NOACs 
Despite the great problems they cause and the narrow therapeutic range, VKAs 
are superior in terms of experience in clinical practice. For most NOACs there is no 
specific antidote currently available for the reversal of their action in case of over-
anticoagulation despite having a less serious bleeding risk than VKAs.  
According to the European Heart Rhythm Association Survey in case of a major 
bleeding from NOACs, 77.4% of centres would use a PCC or activated recombinant 
factor VII (Larsen et al., 2015). FFP is not recommended as a reversal strategy and is 
instead considered a plasma expander.  
The use of activated charcoal short after ingestion as well as haemodialysis were 
two options for dabigatran’s reversal, with the recent addition of idarucizumab 
(Praxbind, Boehringer Ingelheim, Germany) in 2015 as a result of the phase 3 
multicenter, prospective Reversal Effects of Idarucizumab on Active Dabigatran (RE-
VERSE AD) trial (Burness, 2015, Crowther and Crowther, 2015). It is the first NOAC 
antidote approved by the EMA and the FDA with proven effectiveness in rapid and 
safe reversal of the anticoagulant activity of dabigatran in the emergency setting. 
This specific human monoclonal antibody fragment binds dabigatran with an affinity 
that is 350 times higher than thrombin (Pollack et al., 2015). 
For FXa inhibitors, PCC is an anticoagulation reversal strategy. There is lack of 
evidence about the use of FFP in NOAC-related bleeding (Amish et al., 2017). 
Andexanet alfa is a recombinant protein with similar structure and high affinity 
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binding to FXa which has been investigated as a specific antidote for the FXa 
inhibitors. Andexanet alfa has been shown to reverse the anticoagulant activity of 
rivaroxaban and apixaban in older healthy subjects. The Novel Antidote to the 
Anticoagulation Effects of FXA Inhibitors (ANNEXA-4) trial has found a significant 
reduction in the anticoagulant effect of FXa inhibitors and an effective hemostasis in 
79% of the patients with major bleeding treated with andexanet alfa. To date, 
andexanet alfa is awaiting approval both in the U.S. and in Europe (Connolly et al., 
2016, Kaatz et al., 2017, Di Fusco et al., 2018). 
A third antidote, called ciraparantag, is a small molecule. It is currently in 
development with promising evidence showing that it binds direct factor Xa and IIa 
inhibitors. Available data seem to confirm that it can be considered as a universal 
reversal agent due to its ability to inhibit the anticoagulant activity of FXa, FIIa, 
fondaparinux, unfractionated and low-molecular-weight heparins but not VKAs 
(Milling and Kaatz, 2016). 
It can be safely concluded that a specific reversal agent for each NOAC will be 
available soon. However, due to the risk of a rebound effect which may lead to 
thromboembolic events, their use should be restricted to ongoing NOAC-induced 
uncontrolled or life-threatening haemorrhages and in cases of urgent or emergent 
surgery or invasive procedures associated with a high bleeding risk (Di Fusco et al., 
2018). 
 Epidemiology of anticoagulant use 
VKAs, notably warfarin, has been the only available oral anticoagulant drug for the 
primary and secondary prevention of venous and arterial thromboembolic events, 
used by millions of patients worldwide for the past six decades. In 2010, non-vitamin 
K oral anticoagulants were introduced which have since had dramatic effects on 
warfarin prescribing. In general, the use of oral anticoagulants have been shown to 
increase between 2008 and 2014, with the proportion of AF patients receiving oral 
anticoagulants increasing from 52.4% to 60.7%, NOAC use increasing to 25.8% 
since their marketing in 2010, while warfarin use decreased from 52.4% to 34.8% 
(Marzec et al., 2017). In 2014, the most commonly prescribed NOAC for AF was 
rivaroxaban (47.9% of clinic visits), followed by apixaban (26.5%) and dabigatran 
(25.5%) (Barnes et al., 2015). 
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According to the European Heart Rhythm Association Survey conducted in 
February 2015, in the case of AF, NOACs were used equally (48.5%) or more 
frequently (33.3%) than VKAs in 38 responding centres (Larsen et al., 2015).  
 Anticoagulation in paediatrics 
For several years, oral anticoagulation management focused on adult populations 
that differ in ethnicity, genetic background and medical conditions. A different set of 
factors influence anticoagulation therapy in paediatric populations making 
extrapolation from adults unsuccessful at times. This soon led to studies investigating 
differences in anticoagulation management in both neonates and paediatric patients.  
 Physiological differences 
 There is a wide age range in children requiring oral anticoagulant treatment (from 
infants to teenagers) and there is no standardised maintenance dose according to 
patient age. 
Compared to adults, younger children on warfarin have difficulty in swallowing 
tablets. A limitation in the number of times a tablet can be cut (no more than two) has 
been recommended (Bonduel, 2006). Recently, in order to overcome the difficulties 
associated with oral dosing in children and to increase treatment compliance, 
subcutaneous formulations for LMWH have become available, when oral 
administration is impossible (Desai and Farrington, 2000). 
Differences in other physiological functions among children, such as higher 
resting heart rate, lower susceptibility of arrhythmias and thromboembolic episodes, 
emphasise the need for studies evaluating the efficacy and safety of oral 
anticoagulation therapy in children. Poor absorption and enhanced clearance of 
warfarin in children have been reported, as well as poor venous access. Frequent 
infections, therefore increased use of antibiotics, along with higher level of activity 
and increased possibilities of trauma compared to adults, place children in a more 
demanding position for proper control of anticoagulation therapy (Desai and 
Farrington, 2000)]. 
 Choice of anticoagulant 
Although there are three FDA-approved drugs with paediatric use information 
(UFH, warfarin and argatroban), the 40-year experience of warfarin use in children 
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offers clinicians the confidence for its safe use in this patient population (Law C, 
2015). On the other hand, as there is limited experience with the use of NOACs in 
children (Biss and Kamali, 2012), there are currently no recommendations for use of 
these agents in paediatrics. There are a number of ongoing large multicentre studies 
currently looking at efficacy. The safety, pharmacokinetics and pharmacodynamics of 
dabigatran etexilate in adolescents with VTE has previously shown similar PK/PD 
data to that of adults and good tolerability (Halton et al., 2016).  
Well-designed and controlled clinical trials with warfarin have not been conducted 
in any paediatric population. The current guidelines on the use of oral anticoagulants 
in children are based upon information extrapolated from clinical studies in adults 
with slight adjustments guided by studies identifying the differences between adults 
and children (Law C, 2015, Monagle et al., 2012). No specific recommendations or 
guidelines have been published by FDA about paediatric population taking warfarin, 
apart from avoiding any sports activities which may result in injury (FDA, 2011). 
 Factors affecting response to warfarin in children 
 Age 
At birth, the coagulation system is immature but dynamic. Infants are generally 
less susceptible to clots than adults, while being at very high risk of thrombotic and 
bleeding complications following major haemostatic alterations. The imbalance 
between pro and anti-thrombotic states observed in the neonatal coagulation system 
might explain these observations. Both coagulation and haemostatic systems slowly 
develop over time as a neonate grows, therefore there being significant differences 
between neonates, older children and adults. Levels of vitamin K-dependent factors 
II, VII, IX, X and factors XI, XII, pre-kallikrein, high molecular weight kininogen are 
70% less than those of adults, while levels of antithrombin, proteins S and C activity 
are about 20–60% lower in neonates compared with adult levels (Monagle et al., 
2006, Andrew et al., 1987). In addition, hepatic immaturity is observed, which results 
in younger children being more likely to have significantly lower hepatic CYP 
enzymes expressed (Hakkola et al., 1998). At the age of 6 months, the haemostatic 
system shows resemblance to that of an adult (Desai and Farrington, 2000). 
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Age is inversely related to warfarin dose, therefore infants generally receive the 
highest milligram per kilogram warfarin dose, while adolescents the lowest dose in 
order to maintain therapeutic anticoagulation. 
 Diet 
Diet in infancy plays a key role in anticoagulation management in children. 
Newborns frequently suffer from VKDB, especially those exclusively breast-fed 
(Greer, 2001) (Shearer, 2009a). Geer and colleagues showed that plasma 
phylloquinone concentrations of formula-fed infants were much greater compared 
with breast-fed infants or adults (Greer et al., 1991). Breast-fed infants, due to low 
quantity of vitamin K in human milk, are more sensitive to warfarin’s anticoagulant 
effect compared to formula-fed infants. Infant formula preparations with high vitamin 
K content frequently administered to pre-term neonates, lead to higher warfarin dose 
requirements (Bonduel, 2006, Clarke P., 2015) 
It is recommended that an intramuscular dose of phylloquinone be administered to 
all newborns, due to the life-threatening consequences of VKDB (American Academy 
of Pediatrics Committee on Fetus and Newborn, 2003). Due to the very low vitamin K 
status of neonates, oral anticoagulants are avoided to reduce the risk of bleeding 
(Bonduel, 2006). 
 Indication 
Indications for anticoagulation in children include the prevention or treatment of 
venous and/or arterial thrombosis, mechanical prosthetic heart valves, central 
venous access devices (CVAD), endovascular stents and Fontan operation 
(Bonduel, 2006). 
Monagle et al reported that a multicenter international RCT of primary prophylactic 
anticoagulation after Fontan procedure found no significant difference between 5 
mg/kg/day aspirin and warfarin (started within 24 h of heparin lead-in; target INR 2.0- 
3.0) as primary thromboprophylaxis in the first 2 years (Monagle et al., 2011). 
Indication influences warfarin dose requirements in children (Biss and Kamali, 
2012). Following Fontan procedure, children receive a lower dose than those who 
are anticoagulated for other indications, as they present increased sensitivity in 
warfarin (Kaulitz et al., 1997, Streif W, 1999). 
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 Genetics 
The same CYP2C9 and VKORC1 genotypes that have been studied in adults, 
have also been investigated in children populations. Despite studies showing that 
VKORC1 and CYP2C9 genotype accounted for only 4% of variability in warfarin dose 
(3.7% and 0.4% respectively), further larger studies have confirmed a similar 
influence of genotype to that seen in adult dosing (Nowak-Gottl et al., 2010). In a 
cohort of 120 anticoagulated children, 73% of variability in warfarin dose could be 
accounted for by patient height (30%), VKORC1 (27%) and CYP2C9 genotype (13%) 
and indication for warfarin therapy (3% lower dose for Fontan procedure) (Biss et al., 
2012). The finding was replicated in another study which found target INR to be a 
significant determinant instead of indication (Moreau et al., 2012). 
 Warfarin dosing and anticoagulation control 
There is wide interindividual variability in warfarin dose requirement in children. 
Current dosing recommendations are based on age and weight (Nowak-Gottl et al., 
2010, Desai and Farrington, 2000, Biss and Kamali, 2012), however recent studies 
have highlighted the importance of genetic polymorphisms in VKORC1 and CYP2C9  
(Kato et al., 2011) A number of studies have showed that age and genetic variants 
account for between 38% and 82% of warfarin dose variability (Vear et al., 2014, 
Moreau et al., 2012, Nguyen et al., 2013).  
Vitamin K intake, serious underlying illness and use of other medication are 
considered in dose calculations, as well (Law C, 2015). Current recommended 
dosing regimens for children younger than 1 year old are based on body size, mainly 
represented by weight. Also, dose requirement in younger children is higher due to 
physiological and dietary differences influencing warfarin’s effect. Because of these 
changes, more frequent determinations of INR are recommended to adjust the dose 
with increasing age (Desai and Farrington, 2000). 
The starting dose of VKA is calculated based on patient weight and varies 
between 0.33 mg/kg in infant and 0.09 mg/kg in teenage to maintain an INR of 2.0-
3.0 (Streif et al., 1999), except in prosthetic mechanical heart valves and recurrent 
thrombotic episodes where target INR is 2.5-3.5. (Bonduel, 2006). INR checks to 
monitor warfarin are performed once or 4 times monthly according to the age, dose 
change, concomitant medication and patient compliance (Andrew et al., 1994). INR 
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monitoring with point-of-care monitors should be made available where resources 
make this possible (Monagle et al., 2012). 
Most common adverse events encountered with VKA in children are bleeding, 
skin necrosis and osteoporosis (Rezaieyazdi et al., 2009 , Gatti et al., 2003, Streif et 
al., 1999). Vitamin K, FFP or PCC may be administered to reverse bleeding 
(Bonduel, 2006). According to a recent review from Von Vajna and colleagues, a 
number of studies are currently ongoing to evaluate the use of NOACs in paediatrics 
(von Vajna et al., 2016). In vitro phase I studies have been completed assessing oral 
rivaroxaban and dabigatran, while the only apixaban study was terminated early with 
no published results. Pharmacodynamics and pharmacokinetics of rivaroxaban were 
similar among different age groups, however adult dosing may not be appropriate for 
children. Reduced concentrations were found in serum for children less than 40kg of 
weight (Willmann et al., 2014, Attard et al., 2012). Upon completion, further studies 
will inform about appropriate paediatric dosing and response to NOACs. 
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 Aims of my PhD research 
Identification of the factors which influence clinical response to oral 
anticoagulants could lead to improvements in patient management and treatment 
safety. The aim of my research was to investigate the impact of several factors on 
patient anticoagulation response to warfarin in paediatric and adult populations and 
the impact of ageing on the response to two factor Xa inhibitors ex-vivo in adult 
populations.  
More specifically, the projects I undertook aimed to explore: 
 • the performance of a “tailored” vitamin K dosing regimen for the reversal of INR 
in over-anticoagulated patients at risk of bleeding, • the potential influence of CYP2C9 and VKORC1 genotypes on anticoagulation 
stability during warfarin induction and maintenance warfarin therapy, • the effect of CYP2C9 and VKORC1 genotypes on the rate of INR fall following 
warfarin cessation in patients awaiting surgery in order to validate a 
pharmacogenetics-based algorithm, • the association between CYP2C9, VKORC1 and CYP4F2 genotype and plasma 
vitamin K concentration in children treated with warfarin and any implication this 
has on development, • the use of uncarboxylated matrix-Gla protein as a marker of vascular calcification 
to assess vascular health in children on warfarin. • the effect of ageing on the pharmacological activity of the factor Xa inhibitors, 
rivaroxaban and apixaban. 
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 Introduction 
Despite improvements in the management of warfarin therapy, 50% of patients fail 
to stabilise within their target INR range and are thus prone to the drug’s adverse 
effect of bleeding (Watson et al., 2001). Subgroup analyses of several studies show 
a sharp increase in the risk of bleeding when the INR exceeds the therapeutic range 
and increased risk of thrombosis when the INR falls below it (Fihn et al., 1996, No 
author, 1996a, No author, 1996b). The annual frequency of major bleeding events 
associated with excessive anticoagulation with warfarin ranges from 2.0 to 3.5% (No 
author, 1994, Lip et al., 2011), with the absolute risk of thrombosis associated with 
overcorrection being in the same range (Hanslik and Prinseau, 2004). 
The current guidelines for treating over-anticoagulated patients advocate 
restoration of the INR to the target range quickly in order to prevent bleeding whilst 
avoiding over-correction which increases the patient’s risk of thromboembolism. 
Apart from warfarin discontinuation, non-urgent correction of over-anticoagulation is 
achieved through oral vitamin K administration (Makris and Watson, 2001). Although 
oral vitamin K is effective in lowering INR in over-anticoagulated patients (Watson et 
al., 2001, Crowther et al., 2000), the currently used fixed-dose regimens do not 
adequately allow for differences in individual patient INR values. Whilst in excessively 
anticoagulated patients a particular dose may fail to sufficiently lower the INR, it can 
lead to over-correction in those who are only mildly over-anticoagulated (Sconce and 
Kamali, 2006, Denas et al., 2009).  
In an earlier pilot study, we demonstrated that individualized vitamin K dosing, 
based upon index INR, resulted in a greater proportion of over-anticoagulated 
patients having INR 1.8-4.0 at 24h compared to data held in clinic on patients 
receiving a fixed-dose regimen (71% v 39%; p<0.001) (Briz et al., 2010).  The data 
generated from this pilot study helped us to develop a new improved individualized 
vitamin K dosing algorithm, based upon index INR and body surface area (BSA), 
which was estimated to have a greater power of accuracy in computing vitamin K 
dose for lowering INR to within therapeutic target range in over-anticoagulated 
patients than the original dosing algorithm (Briz et al., 2010).   
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 Aim of the study 
The aim of this study was to assess the performance of the improved ‘tailored’ 
vitamin K dosing regimen against a fixed-dose regimen currently used in our local 
hospitals for the reversal of warfarin-induced over-anticoagulation in a randomized 
controlled clinical trial. As part of the trial, I also investigated retrospectively the 
potential impact of patient factors, as well as genetic factors which influence warfarin 
pharmacology and metabolism and vitamin K disposition, on the extent of INR 
reversal. 
 Patients, materials and methods 
 Sample size calculation 
Based on our clinic data for a 12-month period, just over 30% of non-urgent cases 
over-anticoagulated with warfarin achieved an INR within their target range 24 hours 
after oral vitamin K1 (1 or 2 mg p.o.) administration. To detect a 20% increase (i.e. 
from 30 to 50%) in the proportion of over-anticoagulated patients achieving their 
target INR 24 hours after vitamin K administration using the new tailored dosing 
regimen, with 80% power and at the 5% significance level, required 93 patients in 
each of the two study groups.  
 Study subjects 
This single-centre, open-label, randomized controlled study had approval by the 
National Research Ethics Service-Committee North East, Newcastle & North 
Tyneside (ref: 11/NE/0249). The trial was registered with the ISRCTN Registry under 
the name ‘Reversal of over-anticoagulation with vitamin K’ (trial registration no: 
ISRCTN79841657).  
Over-anticoagulated patients presenting to the anticoagulant clinics at the Royal 
Victoria Infirmary and the Freeman Hospital, Newcastle upon Tyne were recruited 
into the study. Patients on warfarin therapy (irrespective of the duration) referred to 
our clinics with supra-therapeutic INR and either asymptomatic or with minor bleeds, 
according to the classification of Fihn et al (Fihn et al., 1996), were eligible to take 
part. As in our earlier pilot study, only patients with a confirmed venous INR ≥6.0 
were eligible, based on evidence that such patients are at significant risk of imminent 
harm, with a recorded risk of 8.8% for abnormal bleeding and 4.4% for a major bleed 
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in the following 14 days compared to no bleeds occurring in a control population 
within target INR range over the same period (Hylek et al., 2000). Patients were 
excluded if they met one or more of the following criteria: younger than 18 years of 
age, life expectancy less than 10 days, presence of major bleeding requiring 
immediate and complete correction of anticoagulation, a history of thromboembolic or 
major haemorrhagic event in the previous 3 months, known sensitivity to vitamin K, 
liver disease, indication for acute normalisation of INR (such as imminent surgery), 
scheduled discontinuation of warfarin therapy, receiving thrombolytic therapy within 
48 hours, a platelet count less than 50x109 cells/L, unable to return to the clinic the 
next day for laboratory/clinical assessment.  
The primary outcome was the proportion of patients reaching to within ± 0.2 units 
of their absolute therapeutic INR range (reported as ‘within target range’) 24 hours 
after receiving oral vitamin K in the ‘tailored dose’ group compared to the ‘control’ 
group. An INR value of >0.2 units below or above the individual target INR range at 
24 hours was considered as over- and under-correction of over-anticoagulation, 
respectively, as these ranges (according to our local practice) are deemed to be 
clinically relevant thus prompting the personnel in charge of patient anticoagulation 
management to consider the possible need for intervention. 
Secondary outcomes included the need for repeated doses of vitamin K1, the 
need for heparin administration and the presence of any thromboembolic and 
haemorrhagic events during the study period. 
 Sample preparation 
On presentation, after confirmation of eligibility and having obtained informed 
consent, 5ml venous blood was taken from each patient and transferred into EDTA 
tubes for later DNA extraction and genotyping for the VKORC1, CYP2C9 and 
CYP4F2 genes. Information on patient age, sex, body weight, height, co-morbidities 
and concurrent therapy was collected. Possible reasons for over-anticoagulation 
were ascertained (e.g. increased alcohol consumption, intercurrent illness, change in 
medication and change in dietary habits). 
Patients were allocated using block randomisation (block size=10) to two groups 
(‘control’ and ‘tailored dose’) to receive oral vitamin K1 (phytomenadione; Konakion®, 
Roche). The control group received vitamin K1, either 1 or 2 mg p.o. based on index 
INR and bleeding risk according to the current guidelines in place in the Northern 
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Region Hospitals for reversal of non-urgent over-anticoagulation (Hanley, 2004, 
Keeling et al., 2011). The vitamin K1 dose for those patients who were randomised to 
the ‘tailored dose’ arm was calculated in the clinic using a simple calculator 
generated within a Microsoft® Excel file which employed the following formula: 
Vitamin K1 dose (mg) = (0.247 x index INR on entry- target INR -0.1320+1.417 x BSA 
(m2))/1.0135 (Briz et al., 2010). This algorithm was developed by regressing the 
target INR to index INR, BSA and vitamin K dose received. Body surface area was 
calculated using the Du Bois formula: BSA = [0.007184 x height (cm)^0.725 x weight 
(kg)^0.425] (Du Bois and Du Bois, 1916). 
A further venous sample for INR determination was taken at 24 (+/- 3) hours.  The 
INR check was performed by personnel blinded to the study treatment, thus 
preserving the study blinding. The individual patient’s warfarin therapy was re-started 
24 hours after vitamin K ingestion, as instructed by the responsible physician/ 
pharmacist, based on the 4S DAWN AC dosing program (Poller et al., 1998), 
providing that the patient was no longer over-anticoagulated.  
The need for additional doses of vitamin K at ≥24h was considered if the patient’s 
INR was >6.0 outside of the study following the local guidelines (Keeling et al., 2016). 
The need for LMWH administration at ≥24h was considered if the patient’s INR was 
sub-therapeutic and he/she was clinically adjudged to be at significant risk of 
thrombosis. The decision for bridging with LMWH in all patients with sub-therapeutic 
INR results was made following an assessment of the patient’s thrombotic risk 
according to the following clinical scenarios: (a) history of previous VTE whilst INR 
was within therapeutic range with subsequent re-assignment to a higher target INR of 
3.5; (b) mechanical heart valve (other than a bileaflet aortic valve) (Keeling et al., 
2016). LMWH administration was also considered if INR value was below the lower 
limit of the therapeutic range by ≥0.3 unit. 
Patients were followed-up at two further clinic visits (day 7 (+/-2 days) & day 14 
(+/-2 days)) to check for anticoagulation control and possible adverse effects of 
thromboembolism or haemorrhage using standard proforma of questions. Further 
observational information on thromboembolism/bleeding events was collected from 
patients’ notes up to 30 days after the administration of the first dose of vitamin K. 
Causality assessment of adverse drug reactions was performed by the clinicians 
monitoring the study subjects.   
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The study protocol was amended later during the trial to make the visits on days 7 
and 14 optional for patients in an attempt to boost recruitment. The amendment also 
involved inclusion of patients with repeated admissions to clinic for excessive 
anticoagulation. We allowed for double inclusion of patients with supra-therapeutic 
INR provided that there was sufficient length of time (minimum 30 days) between 
each episode, which would not bias the conclusions of the study. 
 Genotyping assay  
Leukocyte DNA was extracted from blood samples according to an established in-
house method (Daly et al., 1996). Genotyping for VKORC1 (-1639G>A; rs9923231), 
CYP2C9 (*2 and *3 alleles; rs1799853 and rs1057910) and CYP4F2 (V433M; 
rs2108622) was performed using the StepOneTM Real-Time Polymerase Chain 
Reaction (PCR) System with TaqMan® SNP Genotyping Assays, Applied 
BiosystemsTM. Genotype results for all polymorphisms were validated using control 
samples that had been genotyped as part of a previous study (Biss et al., 2012) 
 Statistical analysis 
Statistical analyses were performed using Minitab 17.0 (Coventry, UK). Data were 
checked for normality. Where data were not normally distributed, logarithmic 
transformation was applied in order to achieve normality. Two sample t-tests were 
used if approximate normality was achieved. Otherwise, Mann-Whitney U-tests were 
used. Chi-squared tests were performed for comparing categorical data across 
groups. Pearson correlation test was used to evaluate relationships between 
variables. Stepwise regression analysis of data was used to evaluate the impact of 
patient characteristics (age, weight, height) and genetic polymorphisms in VKORC1, 
CYP2C9 and CYP4F2 on INR reversal. Results are presented as mean ± SD (range) 
unless otherwise stated. A p value of <0.05 was taken as statistically significant. 
 Results 
Between June 2012 and February 2016, 186 patients (10 repeat cases) were 
recruited into the study. Five patients were later withdrawn; 3 due to administrative 
problems associated with screening, one lost to follow-up and one failed screening. 
Of the remaining 181 cases, 91 (including 2 repeat cases) were allocated to the 
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control group and 90 (including 6 repeat cases) to the tailored dose group. (Figure 
2.1)  
 
Figure 2.1: CONSORT flow diagram of the progress through the phases of a 
parallel randomised trial of two groups 
 
The two groups were well matched with respect to demographic and clinical 
characteristics (Table 2.1). Index INR on presentation for the whole study population 
was 8.0 ± 2.0 (5.3-21.8). Patients included in the study had different target INR 
ranges based on the indication for which they were being treated with warfarin.  
 
 
 
CONSORT 2010 Flow Diagram 
 
Assessed for eligibility (n=186) 
Excluded (n=5) 
♦   Not meeting inclusion criteria (n=1) 
♦   Lost to follow-up before day 1 (n=1) 
♦   Administrative reasons (n=3) 
Analysed for day 1, n=91 
Analysed for day 7, n=77 
Analysed for day 14, n=72 
Lost to follow-up after day 1 (n=14) 
Lost to follow-up after day 7 (n=5) 
 
Allocated to fixed-dose vitamin K regimen, n=91 
 
♦ Received allocated intervention on day 1, n=91 
Lost to follow-up after day 1, n=19 
Lost to follow-up after day 7, n=8 
 
Allocated to tailored-dose vitamin K regimen, n=90 
 
♦ Received allocated intervention on day 1, n=90 
Analysed for day 1, n=90 
Analysed for day 7, n=71 
Analysed for day 14, n=63 
Allocation 
Analysis 
Follow-Up 
Randomized (n=181) 
Enrolment 
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 Total Control Tailored p-value / 95%CI* 
Sample size, n 181 91 90  
Age (years), mean 
± SD (range) 
71 ± 14  
(19-94) 
72 ± 14  
(19-92) 
71 ± 15  
(22-94) 
(-3.26, 5.26) 
Sex, n (%)   
Female 96 (53) 50 (55) 46 (51) 
0.605 
Male 85 (47) 41 (45) 44 (49) 
Weight, mean ± 
SD (range) ⱡ 
75.8 ± 20.7 
(37.0-163.0) 
77.0 ± 19.8 
(43.0-130.9) 
74.6 ± 21.5 
(37.0-163.0) 
(-3.66, 8.46) 
BSA, mean ± SD 
(range) ⱡ 
1.81±0.27 
(1.21-2.81) 
1.82±0.25 
(1.30-2.39) 
1.81±0.29 
(1.21-2.81) 
(-0.07, 0.09) 
Indication for anticoagulation, n (%)  
Atrial fibrillation 81 (44.75) 40 (43.9) 41 (45.6) 
0.878 
Venous 
thromboembolism 29 (16) 17 (18.7) 12 (13.3) 
Heart Valve 
replacement 26 (14.45) 13 (14.3) 13 (14.4) 
Pulmonary 
embolism 18 (9.9) 9 (9.9) 9 (10) 
Other 27 (14.9) 12 (13.2) 15 (16.7) 
Target INR range, n (%) ◊  
2.0-3.0 145 (80.2) 70 (76.9) 75 (83.3) 
0.338 2.5-3.5 18 (9.9) 9 (9.9) 9 (10) 
3.0-4.0 18 (9.9) 12 (13.2) 6 (6.7) 
Frequency of concomitant medications, n ¥  
No interaction  131 145 
0.579 
Minor interaction  19 14 
Moderate 
interaction  35 38 
Major interaction  17 13 
 
* p-value reported for chi-square test and 95% confidence interval for Student’s t-test 
ⱡ  Based on data for 175 patients 
◊ Based on data for 180 patients 
¥ According to the degree of interaction with warfarin and based on the ‘Drug Interactions Checker’ featured on 
Drugs.com (Drug Information Database) (Drugs.com, c1996-2018) 
Table 2.1: Patient Characteristics 
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The possible reasons for excessive anticoagulation (if recorded) were extracted 
from the patients’ clinical records. These included change in diet (41 patients), 
excessive alcohol consumption (7 patients) and change in medication (41 patients). 
Of the latter group of patients, 12 had stopped taking a medication and 29 had 
started a new medication shortly prior to the event. Of the 12 patients, the medication 
was identified as having either major (in 6 patients), moderate (in 4 patients) or minor 
(in 2 patients) interaction with warfarin. Of the 29 patients the medication was 
identified as having either major (in 6 patients), moderate (in 9 patients) or minor (in 2 
patients) interaction with warfarin; in the remaining 12 patients the medication was 
not deemed to interact with warfarin. 
In the control group, 81 patients received 1mg of vitamin K and 9 patients 
received 2mg of vitamin K, while for 1 patient the vitamin K dose administered was 
not recorded. The tailored dose group on average received a higher dose of vitamin 
K than the control group (1.1±0.3, (1.0-2.0) vs 1.8±0.8 (0.4-6.0), 95% CI for 
difference: -0.8783, -0.5217; t-test) (Figure 2.2). Interestingly, one male patient aged 
66 years, weighing 113kg, with index INR of 21.8, target INR of 2-3, but no 
genotypes available, required 6mg of oral vitamin K. Male patients required greater 
doses of vitamin K than their female counterparts (95% CI for difference: 0.299-
0.933; t-test) (Figure 2.3).   
 
 
Figure 2.2: Vitamin K dose distribution (actual and predicted dose) per patient 
group 
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Figure 2.3: Boxplot showing the median and interquartile range of vitamin K 
dose administered according to patient sex in the tailored group 
 
 Primary outcome 
Mean INR at 24 hours was different between the two study groups (95% CI of 
means: (0.1167- 0.3441; t-test)). (Table 2.2) Overall, the tailored dose vitamin K 
regimen performed better than the fixed-dose regimen, in terms of the proportion of 
cases being within, above or below the target INR range at 24h (p=0.002; chi-
squared test). (Table 2.2) 
 
* Mann-Whitney test 
 Log transformed for data analysis 
Table 2.2: INR values on admission, at 24hours and on days 7 and 14 after 
vitamin K administration 
 Control Tailored 95 % CI^ 
 Mean INR ± SD (range)  
Index INR 7.9 ±1.8 (5.3-17.0) 8.3 ± 2.2 (6.0-21.8) (-0.7002,0.2001)* 
24h 3.3 ± 2.0 (1.2-16.3) 2.5 ± 0.9 (1.1-5.4) (0.1167, 0.3441) 
Day 7 3.2 ± 1.3 (1.4-8.0) 3.0 ± 1.4 (1.3-7.0) (-0.0590, 0.2034) 
Day 14 3.4 ± 1.7 (1.1-9.8) 3.1 ± 1.42 (1.3-8.0) (-0.0638, 0.2290) 
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A greater proportion of cases in the tailored dose group returned to within their 
individual target anticoagulation 24h after vitamin K dosing than the control group 
(68.9% v 52.8%, p=0.026; chi-squared test) (Table 2.3). INR value at 24h was above 
target therapeutic range in a greater proportion of cases in the control group 
compared to those in the tailored dose group (34.0% v 12.2%, p<0.001; chi-squared 
test). The proportion of cases with over-corrected INR was not different between the 
tailored dose group (18.9%) and the fixed-dose group (13.2%) (Table 2.3). The 
median (range) INR at 24h for the under- and over-corrected cases did not differ 
between the fixed-dose and tailored dose regimens (for undercorrected cases 1.7 
(1.2-2.6) vs 1.7 (1.1-2.6), for overcorrected cases 4.5 (3.3-16.3) vs 4.1 (3.3-5.4); 
Mann-Whitney U test). 
 
 Control Tailored  
Frequency of INR values n, (%) p-value 
INR-24h  
Below target range 12 (13.2) 17 (18.9) 0.296 
0.002 Within target range 48 (52.8) 62 (68.9) 0.026 
Above target range 31 (34.0) 11 (12.2) <0.001 
Day 7 
Below target range 9 (11.7) 13 (18.3) 
0.480 Within target range 42 (54.5) 38 (53.5) 
Above target range 26 (33.8) 20 (28.2) 
Day 14 
Below target range 6 (8.3) 8 (12.7) 
0.652 Within target range 42 (58.3) 33 (52.4) 
Above target range 24 (33.4) 22 (34.9) 
Table 2.3: Proportion of INR values below, within and above target range at 24 
hours and on days 7 and 14 following vitamin K administration 
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 Secondary outcomes 
For a subset of cases, INR values on day 7 (71 tailored dose and 77 fixed-dose) 
and day 14 (63 tailored dose and 72 fixed-dose) following vitamin K administration 
were available. There was no difference in mean INR between both groups at either 
time-point (54.5% v 53.5% for day 7; 58.3% v 52.4% for day 14) (Table 2.3).  
Four cases in the control group had an INR >6.0 at 24h and subsequently 
received an oral dose of vitamin K, according to the study protocol. Of the 4 cases, 2 
received a second additional dose of vitamin K 24 and 96 hours later. One case in 
the tailored dose group admitted with a urinary tract infection and raised INR of 7.5 
received a second dose of vitamin K at 48h, following a rise in INR from 5.4 at 24 
hours to 6.9 at 48 hours. On day 7, two cases in the control and two in the tailored 
group had an INR>6.0 and thus received a dose of vitamin K. Similarly, on day 14, 
three cases in the control and two in the tailored group received a dose of vitamin K. 
According to the study protocol, the remaining cases with INR <6.0 at 24h were 
deemed not to require additional dose of vitamin K. One case with INR=6.7 at 24h 
was not deemed by the reviewing clinician to be at high risk of bleeding and hence 
did not receive an additional dose of vitamin K. 
Twenty nine cases (12 in the control and 17 in the tailored group) had a sub-
therapeutic INR (where the INR value was below the lower limit of the therapeutic 
range by ≥0.3 unit) at 24 hours. Of these LMWH was administered to only two 
subjects (one in each of the fixed-dose and tailored vitamin K dose group); both were 
on warfarin therapy for antiphospholipid syndrome and were deemed to be at 
increased risk of thrombosis. Twenty cases were administered heparin between 48 
hours and 16 days after vitamin K administration. However, the decision to 
administer heparin to these subjects was not study-related and reflected alteration of 
anticoagulation during admission with the use of therapeutic or prophylactic LMWH 
while warfarin was interrupted (Table 2.4).  
Vitamin K has a short half-life of 1.5 to 3 hours, with main effect on 
anticoagulation appearing within 12-24 hours after its administration (Roche Products 
Limited). Therefore, events reported during the first 24-48 h after vitamin K 
administration, were considered as being related to study intervention (i.e. either 
vitamin K dose was insufficient to return INR to within target range or it was in excess 
of that required leading to over-correction of INR). 
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 Total patients analysed, n Control Tailored 
Warfarin withheld/changed on admission, n 
(%) ¢    
Yes 174 87 87 
No 3 2 1 
Warfarin administration at 24 h, n (%) ۸    
Withheld 29 18 11 
Resumed 131 63 68 
Additional vitamin K administration post 
initial dose   
At 24h 4 4 0 
48 -96h 3 2 1 
On day 7 4 2 2 
On day 14 5 3 2 
Heparin administration    
At 24h 2 1 1 
After 24 h 20 15 5 
 
¢ Based on data for 177 patients 
٨ Based on data for 160 patients 
Table 2.4: Changes in patients’ treatment following study intervention 
 
No major bleeding events according to the ISTH classification (Schulman and 
Kearon, 2005) were reported in the trial. Of the 10 minor bleeding adverse events 
recorded during the trial, 4 belonged to the control group and 6 to the tailored dose 
group (Table 2.5). Three of the bleeding episodes (1 in control group and 2 in 
tailored dose group) were reported within 2 to 7 days after the initial vitamin K dose 
administration. The remaining 7 minor bleeding events took place within 7 to 23 days 
following vitamin K administration (3 in control group and 4 in tailored dose group). 
All these events are in accordance with bleeding symptoms anticipated while on 
anticoagulation and were unrelated to the initial vitamin K dose administration. 
In all, 1 thromboembolic event in the tailored vitamin K dose group was reported 4 
days after the study intervention. The recurrence of thrombosis was associated with 
malignancy, with the patient’s INR being in the therapeutic range and was therefore 
unrelated to vitamin K administration (Table 2.5). 
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1 Unrelated to warfarin 
2 Possibly related to warfarin 
3 Probably related to warfarin 
4 Definitely related to warfarin 
Table 2.5: Bleeding and thromboembolic adverse events according to severity 
and relation to warfarin treatment 
 Associations between genotype, patient characteristics and vitamin K 
dose 
The genotype frequencies of all tested SNPs were checked for their consistency 
with Hardy–Weinberg Equilibrium compared with the CEU population, comprising 
Utah residents (CEPH) with Northern and Western European ancestry) (Whirl-Carrillo 
et al., 2012) (p=0.797 for CYP2C9, p= 0.343 for the VKORC1, p=0.339 for CYP4F2; 
chi-square test). No differences in genotype frequency for the VKORC1 (-1639G>A; 
rs9923231), CYP2C9 (*2 and *3; rs1799853 and rs1057910) and CYP4F2 (V433M; 
rs2108622) genes were observed between the two study groups (Table 2.6).  
Factors such as age, weight, height, BSA, vitamin K dose, index INR, CYP2C9, 
VKORC1 and CYP4F2 genotype were included in the regression model to predict the 
INR at 24 hours. According to stepwise regression analysis neither age, height, nor 
CYP2C9, VKORC1 and CYP4F2 genotype influenced INR at 24h. Index INR and 
vitamin K dose contributed to INR at 24h (R2=24.6%; p<0.001). After including the 
three factors that appeared to be significant in the regression model, summary 
statistics are presented in Table 2.7. Patient weight appeared to be a more 
significant predictor of INR at 24h compared to BSA, with the latter used in the 
 Bleeding events, n Thromboembolic 
events, n 
Time of 
onset 
Control,  
4 
Tailored regimen, 
6 
Control,  
0 
Tailored,  
1 
2 -7 days 
post 
intervention  
Bruising (leg)2 
Nose bleed2 
 
Deep vein 
thrombosis
1 Specks of blood in 
phlegm2 
7-23 days 
post 
intervention 
Haematuria2 Epistaxis, 23,4 
  Spontaneous bruising 
(eyelid)2 Bruising (neck)
2 
Prolonged bleeding 
after cut3 Vaginal spotting
1 
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tailored dosing algorithm to calculate vitamin K dose. In contrast to the fixed-dose the 
tailored vitamin K dose was influenced by both index INR and BSA as expected 
(Figure 2.4).  
 
 
Genotype No of patients analysed, n (%) ٭ Control, n (%) Tailored, n (%) P-value 
CYP2C9    
0.897 
*1/*1 102 (62.2) 51 (62.2) 51 (62.2) 
*1/*2, *1/*3 57 (34.8) 28 (34.1) 29 (35.4) 
*2/*2, *2/*3, *3/*3 5 (3) 3 (3.7) 2 (2.4) 
VKORC1    
0.377 
GG 64 (39.0) 28 (34.2) 36 (43.9) 
GA 75 (45.7) 42 (51.2) 33 (40.25) 
AA 25 (15.2) 12 (14.6) 13 (15.85) 
CYP4F2    
0.330 
CC 83 (50.6) 38 (46.3) 45 (54.9) 
CT 71 (43.3) 40 (48.8) 31 (37.8) 
TT 10 (6.1) 4 (4.9) 6 (7.3) 
٭ Genotypes available for 164 patients 
Table 2.6: Genotype frequencies for the population and the genes studied 
 
 
Term Estimate Standard error T-Value P-Value 
Constant -0.645 0.64 -1.01 0.315 
Vitamin K Dose -1.278 0.198 -6.44 <0.001 
Index INR 0.4765 0.071 6.71 <0.001 
Weight (kg) 0.02109 0.00563 3.75 <0.001 
Table 2.7: Summary statistics and results from multiple regression analysis 
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Figure 2.4: Variability in vitamin K dose according to index INR and BSA 
between the control and tailored vitamin K dose regimen groups 
The vitamin K dose for the control group was estimated using the tailored dose 
equation. According to regression analysis the difference in vitamin K dose (predicted 
- actual dose) was associated with BSA (R2=32.7%; p<0.001) and index INR 
(R2=17.8%; p<0.001). The predicted dose of vitamin K increased with increasing BSA 
and index INR (Figure 2.5). The mean (range) predicted vitamin K dose was higher 
than the actual dose administered [1.7 (0.1 – 3.0) v 1.1 (1.0 – 2.0) mg; difference in 
dose: 0.6 (-1.0 – 2.0) mg]. For patients who had received the 1mg vitamin K dose 
(n=77) the predicted mean (range) vitamin K dose was higher [1.7 (0.1 – 3.0) mg; 
mean difference: 0.7 (-0.9 – 2.0) mg], whilst for those who had received the 2mg 
dose (n=8) the predicted dose was slightly lower than the actual administered dose 
[1.9 (1.0 – 2.7); mean difference: -0.1 (-1.0 – 0.7) mg].  
The study results were used to produce a new and more refined vitamin K dosing 
algorithm. By regressing the target INR to index INR, vitamin K dose and weight, the 
following vitamin K dosing equation was produced:  
vitamin K dose = (0.4765 x index INR – target INR + 0.02109 x weight – 0.645) / 
1.278; where: vitamin K dose is in milligrams and weight in kilograms.  
This formula predicts on average the same vitamin K dose for the group of 
patients with restored INR to within target range at 24 hours (mean dose change 
±SD, 0.06±0.49; range, -1.19 to +1.53 mg). However, for the overcorrected group a 
reduced dose is predicted (mean dose change ±SD, 0.73±0.80; range, -1.04 to +2.18 
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mg), while for the under-corrected group a small increase in predicted dose is 
estimated (mean dose change ±SD, -0.07±0.49; range, -0.91 to +0.95 mg). 
A simplified version of the abovementioned formula was also examined for its 
prediction accuracy. The following formula was employed after appropriate 
transformations:  
vitamin K dose = (index INR / 2.5) – (target INR / 1.3) + (weight / 64) – 0.5 
Compared to the original algorithm resulting from the regression model, the 
simplified algorithm predicted a mean difference of 0.2mg in vitamin K dose, ranging 
between 0.1 and 0.5mg. While a difference of 0.5mg would have an impact in routine 
clinical practice, based on the fact that in most hospitals vitamin K dose is calculated 
in increments of 0.5mg, this difference was only observed in two patients in our 
cohort with extreme weight and index INR value (one patient weighing 113kg with 
index INR=21.8 and the second having index INR=17 but missing weight).  
 
 
Figure 2.5: Relationship between the difference in vitamin K dose (predicted - 
actual dose), BSA and index INR  
 
 Discussion 
Bleeding is one of the most serious complications associated with warfarin 
therapy (Palareti et al., 1996). The risk of bleeding increases with excessive 
anticoagulation which occurs in approximately 0.2-0.3% of outpatients receiving long-
term warfarin therapy per annum (Penning-van Beest et al., 2001).  
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Restoration of the INR towards the target therapeutic range in over-anticoagulated 
patients is the logical approach, with the choice of treatment depending upon the 
severity of patient symptoms and the anticipated risks.  Evidence from randomized 
controlled trials supports the use of oral vitamin K in lowering the INR in 
asymptomatic or mildly bleeding patients (Crowther et al., 2000, Lubetsky et al., 
2003, Ageno et al., 2005, Dezee et al., 2006). However, there is no clear consensus 
about the optimal dose that should be given to patients. The majority of the reported 
studies have used fixed oral doses of vitamin K (ranging from 1.0 to 5.0 mg), based 
upon assigning dose according to a dichotomy of elevated INR values to reverse 
excessive anticoagulation, with a high percentage of patients at 24 hours after 
vitamin K dosing being either under- or over- anticoagulated, leaving them at risk of 
either thromboembolism or haemorrhage, respectively (Sconce and Kamali, 2006, 
Denas et al., 2009). Current guidelines in our locality recommend intervention with 1 
or 2mg vitamin K orally to accelerate INR lowering in patients presenting with an INR 
>8.0 and those with INR of 4.5-7.9 deemed at high risk of bleeding (Hanley, 2004, 
Keeling et al., 2011). 
A tailored approach to vitamin K dosing could ensure a more predictable reversal 
of over-anticoagulation. In an earlier pilot study of over-anticoagulated patients either 
asymptomatic or with minor bleeds (87 episodes in total), we demonstrated that an 
individualized vitamin K dosing regimen whereby vitamin K dose was calculated 
based upon patient INR on presentation performed better in lowering INR compared 
to fixed-dose vitamin K (38% v 21% INR within target range at 24 h) (Briz et al., 
2010). The results of the pilot study enabled us to refine the original tailored dosing 
algorithm. The latter can estimate vitamin K dose according to index INR, body 
surface area and target INR. We have assessed the performance of the new dosing 
algorithm (measured as the proportion of patients returning to within target INR) 
against that of the fixed-dose regimen in a randomised parallel design study.  
The present study results demonstrate that the tailored vitamin K dosing regimen 
is superior to the fixed-dose regimen; compared to the fixed-dose regimen, the 
tailored dose resulted in a greater proportion of patients returning to target INR 
range, whilst a smaller proportion remained above target INR range at 24h.  
The patients in the control group who had received the 1mg vitamin K dose were 
predicted to require a higher dose of vitamin K whilst those who had received the 2 
mg dose require a slightly lower dose. However, there was a wide range in the 
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predicted vitamin K doses for each of the fixed doses [for 1mg dose: 0.1 – 3.0; mean 
difference between predicted and actual dose: 0.7 (-0.9 – 2.0) mg; for 2 mg dose: 
1.0–2.7 mg; mean difference between predicted and actual dose: -0.1 (-1.0 – 0.7) 
mg] which further suggests that the fixed-dose regimen is inappropriate for lowering 
INR for the majority of over-anticoagulated patients.  
Anticoagulation response to warfarin is influenced by environmental, clinical and 
genetic factors (Sconce et al., 2005a, Isbister et al., 2001) which could also influence 
vitamin K dose requirement in over-anticoagulated patients.  We therefore also 
determined, retrospectively, whether patient age, sex, co-morbidity and genetic 
polymorphisms in the expression of the vitamin K epoxide reductase, the main target 
for warfarin (encoded by VKORC1 gene), cytochrome p450 CYP2C9, the enzyme 
responsible for the metabolism of S-warfarin (encoded by CYP2C9 gene) (Sconce et 
al., 2005a, Kamali and Wynne, 2010), and the mono-oxidase enzyme involved in 
vitamin K1 metabolism (encoded by CYP4F2) (McDonald et al., 2009), affect vitamin 
K dose and the extent of INR reversal so that these can be used to further improve 
the vitamin K dosing algorithm as appropriate. Overcorrection of INR was more 
frequent in women than men (58.6% v 41.4%) although the differences were not 
statistically significant, likely due to the small number of patients evaluated. Female 
sex was found to be independently associated with overcorrection of INR, despite 
female subjects on average having received lower doses of vitamin K than their male 
counterparts. Patient factors of age and body size have previously been reported to 
influence vitamin K dose requirement (Hylek et al., 2001, Kelly et al., 2001). Whilst 
we found that patient weight and index INR influenced INR at 24h and hence vitamin 
K dose requirement, patient age had no effect. Similar to our previous pilot study, we 
found that CYP2C9 and VKORC1 polymorphism made no contribution to vitamin K 
dose requirement, and neither did polymorphisms in CYP4F2. However, the present 
study was not sufficiently powered to detect the influence of genetics on vitamin K 
dose requirement. Therefore, it remains possible that the influence of these genes on 
vitamin K dose requirement will become apparent in a purposefully designed study in 
a larger population of patients.  
There were no incidences of major bleeding requiring intervention, or 
thromboembolic events throughout the trial. There were 10 incidences of minor 
bleeding; patients in the tailored vitamin K dose group with minor bleeding 
complications were more likely to be taking drugs that interact with warfarin 
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(clopidogrel, aspirin) or have chronic comorbidities; factors which are known to 
increase the risk of bleeding (Tran and Alderman, 2013). 
Based on the data of this study, the algorithm predicting the vitamin K dose for 
lowering the INR in excessively anticoagulated patients on warfarin has been further 
optimised. The reported simplified version has similar accuracy to the original 
algorithm resulting from the linear regression model, whilst being more practical for 
clinicians who don’t have easy access to an Excel spreadsheet in clinic. However, as 
the estimated vitamin K dose is slightly higher compared with the original algorithm, 
care should be taken to monitor patient INR to prevent over-correction which 
increases the risk of thrombosis. Adoption of the simple tailored vitamin K dosing 
algorithm is easy and has the potential to benefit a wide range of patients presenting 
with excessive anticoagulation with warfarin.  
 Limitations 
There were missing data in four variables, with the proportion of missing data 
being no greater than 11% of the total sample size involved in this study. In addition, 
some patients were lost during the period of follow-up. The proportion of the patients 
lost in follow-up and randomised to the control and tailored group was 15,4% and 
21% respectively at day 7 and 21% and 30% respectively at day 14. 
 Conclusion 
The current RCT showed that ‘tailored’ vitamin K dosing regimen was superior to 
the fixed-dose regimen, leading to a more accurate reversal of excessive 
anticoagulation and a higher percentage of patients returning to within their target 
INR range. However, for the true clinical benefit of the tailored vitamin K dosing 
regimen in over-anticoagulated patients to be realised, further larger study is required 
to establish its clinical utility, as well as its superiority over fixed-dose regimen in 
terms of its cost-effectiveness. Among other benefits, the tailored vitamin K dosing 
regimen could reduce the burden of management of patients with excessive 
anticoagulation through reductions in the number of repeat treatments/follow-ups, 
and the potential gains in patient quality of life and treatment safety in terms of 
reductions in the incidences of bleeding and thrombosis. 
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 Introduction 
Although anticoagulation with warfarin has been used in clinical practice for over 
six decades, warfarin use still creates concern due to the high risk of bleeding as a 
consequence of over-anticoagulation (Linkins et al., 2003). Stability of 
anticoagulation with an INR within the individual therapeutic range is necessary to 
ensure the safety of warfarin therapy. Percentage time within therapeutic range 
(%TTR) is a standard measure of quality of anticoagulation control and has been 
used as common primary outcome in studies evaluating the factors that affect 
anticoagulation control and the risk of bleeding in patients on chronic warfarin 
therapy.  
Genetics contribute to the variable response to warfarin, with the role of common 
CYP2C9 (rs1788853 and rs1057910) and VKORC1 (rs9923231) polymorphisms 
being well established in this regard. A number of studies worldwide have shown that 
carriers of CYP2C9 and VKORC1 polymorphisms have a greater sensitivity to 
warfarin, thus requiring both lower doses and more time to achieve stable dosing 
(Sconce et al., 2005a, Wadelius et al., 2009, Gage et al., 2008 ). During initiation 
therapy, CYP2C9 variant alleles have been associated with higher risk of supra-
therapeutic INR and serious bleeding (Higashi et al., 2002). Tomek et al have 
previously suggested that patients who are carriers of 3 variant CYP2C9 and 
VKORC1 alleles had a significantly higher risk of major haemorrhage during the 
initiation and maintenance phases of warfarin therapy (Tomek et al., 2013). Higashi 
et al also found an association between CYP2C9*2 and *3  and an increased risk of 
over-anticoagulation (INR≥4) and bleeding events in patients on warfarin therapy 
(Higashi et al., 2002). 
Nonetheless, there are a number of studies that have suggested that either, or 
both VKORC1 and CYP2C9 genotypes may not be predictive of over-anticoagulation 
in patients on warfarin. Meckley et al reported no significant difference in the 
proportion of time spent above range in the first month of warfarin therapy for 
patients carrying CYP2C9 and VKORC1 variants compared to wild-type, although 
both genotypes increased the probability of having an INR>5 (Meckley et al., 2008). 
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Limdi et al found that VKORC1 variant genotype did not confer a significant increase 
in risk for major or minor haemorrhage in a mixed-race population, in contrast to 
CYP2C9 variant alleles (Limdi et al., 2008b). Another study from the same authors 
showed that neither of the two genotypes influenced the time to attain target INR or 
time to stabilization among patients of either European or African Americans ancestry 
(Limdi et al., 2008a). CYP2C9 and VKORC1 polymorphisms were not associated 
with either sub-therapeutic or super-therapeutic INR in a Jordanian population (Al-
Eitan et al., 2019). 
 Study aim 
It was hypothesised that patients with variant VKORC1 and CYP2C9 alleles 
spend a lower percentage of time within the target therapeutic range and therefore 
have less stable anticoagulation control. This cohort-design study evaluated the 
influence of common CYP2C9 and VKORC1 genotypes on %TTR during the 
induction and maintenance phases of warfarin therapy in an adult Caucasian 
population.  
 Patients, materials and methods 
 Study subjects 
Patients on warfarin who experienced an over-anticoagulation event (INR≥6.0 and 
either asymptomatic or with minor bleeds (Fihn et al., 1996)) had been recruited as 
part of a previous randomised controlled clinical study (Chapter 2).  
Demographic characteristics and clinical data relevant to their over-
anticoagulation event (indication for anticoagulation with warfarin, individual target 
INR range and bleeding events) were available. Genotypes for CYP2C9 (*2 and *3 
alleles; rs1799853 and rs1057910) and VKORC1 (−1639G>A; rs9923231) 
polymorphisms were also available. 
 Stability data collection 
Anticoagulation stability data for 6 months for both the induction and maintenance 
(before the over-anticoagulation event) phases of warfarin therapy, including INR 
values and dates of checks were extracted from both 4S DAWN computer dosing 
programme version 7.0 (4S Information Systems Ltd TS, Cumbria, UK) and the local 
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medical records system of the Newcastle upon Tyne Hospitals. Patients with less 
than two INR checks during the 6-month maintenance therapy prior to the over-
anticoagulation event and/or during the first 6 months of starting warfarin treatment 
were excluded from analysis. TTR% was calculated in Visual Basic Calculator 
software 2000 (4S DAWN, Milnthorpe, Cumbria, UK) using the linear interpolation 
method of Rosendaal et al (Rosendaal et al., 1993) (Appendix A). 
 Statistical analysis 
Statistical analysis was carried out using Minitab v17 (Minitab, Inc., Coventry, 
UK). Analyses with single CYP2C9 and VKORC1 genotypes and with total variant 
allele count for both genotypes were performed. Patients were initially divided into 
five groups according to the number of variant alleles to allow for all possible 
combinations, however three groups were used for analysis due to low number of 
patients carrying three variant alleles (1 patient with genotype rs9923231 G/A and 
rs1788853/ rs1057910 *2/*3, 3 patients with genotype rs9923231 A/A and rs1788853 
*1/*2) and no patients carrying four variant alleles (homozygote for both rs9923231 
and rs1788853/ rs1057910). %TTR data followed a normal distribution. The 
association between single genotypes and variant allele count with TTR% at both 
maintenance and induction therapy was examined among the genotype groups using 
ANOVA (analysis of variance). The association between %TTR and genotype will 
also be examined in a recessive model for the variant allele of both polymorphisms. 
A p-value of <0.05 was considered as statistically significant. 
 Results 
One hundred sixty four adult patients, who had previously been genotyped for 
CYP2C9 and VKORC1, were available for analysis. However, for forty two patients, it 
was not possible to extract anticoagulation data for either induction or maintenance 
therapy. One hundred twenty two patients were studied with a mean age of 70 ± 14 
years. There were 55 (45.1%) males and 67 (54.9%) females, all of white Caucasian 
origin. The most frequent indications for anticoagulation were AF (40.9%), VTE 
(14.8%), heart valve replacement (16.4%), PE (12.3%) and other indications (15.6%). 
The target INR range was 2.0–3.0 in 95 (77.9%), 2.5–3.5 in 12 (9.8%) and 3.0-4.0 in 
15 (12.3%) patients. Genotype frequencies for CYP2C9 (rs1799853 for *2; 
rs1057910 for *3) and VKORC1 (rs9923231) were in Hardy-Weinberg equilibrium, 
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similar to other larger studies (Mega et al., 2015) (Table 2.6, section 2.4.3). Total 
variant allele count groups are presented in Table 3.1. 
 
Number of variant allele groups VKORC1 CYP2C9 n (%) 
0 G/G *1/*1 35 (28.7) 
1 
G/A *1/*1 29 (23.8) 
G/G *1/*2 *1/*3 
7 (5.7) 
4 (3.3) 
2 
A/A *1/*1 16 (13.1) 
G/G *2/*2 *3/*3 
0 (0.0) 
1 (0.8) 
G/A *1/*2 *1/*3 
18 (14.8) 
8 (6.6) 
3 
G/A *2/*3 1 (0.8) 
A/A *1/*2 3 (2.4) 
Table 3.1: Total variant allele count 
 
 Stability analysis 
Overall, patients had a mean±SD (range) of 9±7 (2-39) INR checks during 
maintenance and 14±7 (3-28) checks during warfarin induction period. Having 
excluded patients with insufficient number of INR checks (<2), %TTR was calculated 
for 54 subjects for induction phase and for 110 for maintenance phase therapy. For 
42 patients, data were available both for induction and for maintenance therapy.  
Neither VKORC1, nor CYP2C9 genotype were associated with TTR% during 
warfarin maintenance or induction phase (all p>0.05; ANOVA, Table 3.2). There was 
no association between %TTR and the total variant allele count for both the induction 
and maintenance phases of therapy (p>0.05; ANOVA, Table 3.2) (Figure 3.1). 
When analysing the %TTR maintenance data using a recessive model, a 
significantly lower %TTR in patients with two variant VKORC1 alleles is observed 
compared with patients who carry only one or no variant VKORC1 alleles (mean ±SD 
%TTR: 46.2±28.3 v 32.1±22.1; 95% CI for difference in means: (1.50, 26.65), t-test) 
(Figure 3.2).  
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Maintenance therapy Induction therapy 
Sample size 
% TTR [mean±SD (range)]  
Sample size 
% TTR [mean±SD (range)] 
CYP2C9 genotype   
*1*1 72 41.2 ± 26.1 (0.0-100.0) 
35 
45.1 ± 26.3 (0.0-94.9) 
*1*2 & *1*3  37 47.9 ± 29.7 (0.0-96.5) 
18 
43.1 ± 22.7 (0.0-84.1) 
*2*2 & *2*3 & *3*3 ^ 1 100.0 
1 
50.0 
p-value 0.151 ^ 0.813 ^ 
VKORC1 genotype   
GG 41 47.3 ± 28.8 (0.0-100.0) 
22 
43.9 ± 22.2 (0.0-94.9) 
AG 52 45.3 ± 28.2 (0.0-100.0) 
25 
44.4 ± 28.0 (0.0-81.8) 
AA 17 32.1 ± 22.1 (0.0-63.3) 
7 
47.3 ± 23.3 (17.7-81.8) 
p-value 0.150 0.950 
Total variant allele 
count   
0 31 45.5 ± 28.5 (0.0-100.0) 
15 
41.6 ± 22.9 (0.0-94.9) 
1 37 43.9 ± 26.1 (0.0-100.0) 
20 
46.9 ± 29.0 (0.0-84.1) 
2 ⱡ 38 42.9 ± 29.0 (0.0-96.5) 
18 
44.4 ± 22.2 (0.0-81.8) 
3 ⱡ 4 44.7 ± 37.9 (15.9-100) 
1 
22.8 
p-value 0.985 ⱡ 0.767 ⱡ 
^ Data were merged with heterozygote genotype group for analysis due to low sample size of the double variant 
CYP2C9 genotype group. 
ⱡ Data were merged with group 2 for analysis due to low sample size of group 3. 
 
Table 3.2: %TTR during maintenance and induction therapy according to 
genotype group 
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Figure 3.1: Boxplots presenting the TTR% versus CYP2C9 and VKORC1 
genotype alone and the total variant allele count (CYP2C9 plus VKORC1) 
during maintenance and induction phase 
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Figure 3.2: Boxplot of %TTR during maintenance therapy between double 
variant VKORC1 carriers and carriers of one or no variant alleles 
 Bleeding episodes 
Haemorrhagic events for two weeks after excessive anticoagulation were 
recorded. Nine bleeding episodes occurred in a total of 7 patients (2 patients with two 
bleeds). For both VKORC1 and CYP2C9, there was no difference in the number of 
bleedings between the wild-type and carriers of variant alleles (3 and 4 respectively). 
Considering the total variant allele count for the bleeding episodes, 4 patients 
(57.1%) had two variant alleles in total, 1 (14.3%) had one VKORC1 variant allele 
and the remaining 2 (28.6%) had no variant allele.  
 Discussion 
Time in therapeutic range is the major determinant of quality of anticoagulation 
with warfarin, with a lower TTR% being associated with a higher incidence of 
recurrent thromboembolism and major bleeding (Veeger et al., 2005, Chan et al., 
2016b). This study examined the association of %TTR between different genotype 
groups and showed that CYP2C9 and VKORC1 genotypes were not associated with 
stability of anticoagulation during either induction or maintenance warfarin therapy. 
Also, there was no deviation from Hardy-Weinberg equilibrium for CYP2C9 and 
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VKORC1 genotypes in our over-anticoagulated population, suggesting no immediate 
causal relationship between genotype and risk of over-anticoagulation. However, 
when analysing VKORC1 polymorphism and %TTR during maintenance therapy in a 
recessive model, patients with two variant VKORC1 alleles appear to have a lower 
mean %TTR during maintenance compared with wild-type or single variant allele 
carriers.  
The influence of genetic polymorphisms in CYP2C9 and VKORC1 genes on the 
risk of over-anticoagulation and bleeding has been previously examined with 
conflicting reports. Currently, there is no clear consensus on the predictive value of 
polymorphisms in these two genes on anticoagulation control. Studies suggest that 
carriers of CYP2C9 and/or VKORC1 polymorphisms have a higher incidence of 
supra-therapeutic INR (>4.0) during initiation and a higher occurrence of bleeding 
events during both initiation and maintenance therapy (Meckley et al., 2008, Aithal et 
al., 1999, Jorgensen et al., 2009).  
There is evidence of reduced bleeding risk and shorter time to maintenance dose 
using genotype-guided warfarin dosing (Kawai et al., 2014, Dahal et al., 2015). 
However, both EU-PACT and COAG trials have shown that even after consideration 
of the two genotypes, 20–30% of trial patients experienced an over-anticoagulation 
response during warfarin induction (Kimmel et al., 2013, Pirmohamed et al., 2013). 
Taube et al found no increase in the likelihood of over-anticoagulation during long-
term therapy caused by the possession of a variant allele (Taube et al., 2000). 
Neither CYP2C9, nor VKORC1 influenced the time to attain target INR or time to 
stabilization among patients of either European or African Americans ancestry (Limdi 
et al., 2008a). Anderson et al found no difference in out-of-range INRs between the 
standard dosing and pharmacogenetic-guided dosing arms of a randomised trial 
(Anderson Jeffrey et al., 2007). Chun et al have previously shown that much of the 
information provided by CYP2C9 and VKORC1 genotypes during warfarin initiation is 
captured by the early INR response, with genotypes having no association with 
stable warfarin dose (Li et al., 2009). 
Current policies on the use of genetic testing support the argument that 
adjustment of warfarin doses prior to maintenance and during initiation therapy 
counteract the influence of the CYP2C9 and VKORC1 genotypes on the stability of 
anticoagulation (Lindh et al., 2005). In 2008, the American College of Medical 
Genetics considered the existing evidence about routine genotyping in warfarin-naive 
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patients insufficient, followed by the 2008 ACCP guidelines that recommended 
against genotyping patients until further promising evidence was made available 
(Flockhart et al., 2008, Ansell J, 2008).  
Meta-analyses suggest that bleeding risk is significantly higher in over-
anticoagulated patients (OR for INR > 4 compared with the INR 2-3 reference group: 
33.23, 95% CI; 9.12-121.07) (Reynolds et al., 2004). It has been recently shown that 
bleeding risk can be influenced by genetics (Kawai et al., 2014, Tomek et al., 2013). 
In agreement with this, 71.4% of our patients with bleeding complications had at least 
one variant allele in either one or both CYP2C9 and VKORC1 genes. However, this 
study was not powered to show an impact of genotype on the incidence of bleeding 
and to confirm this association a larger sample size is required. The meta-analyses 
reported to date have looked at different ethnic populations with different allele 
frequency and with different clinical outcomes, both of which make the results of 
these studies difficult to interpret (Jorgensen and Williamson, 2008).  
Most studies in the literature consider over-anticoagulation as a small deviation 
(>4) of INR above target therapeutic range, which is 2.0-3.0 for most patients (Dezee 
et al., 2006). However, guidelines suggest that it is reasonable to offer correction of 
INR with vitamin K in patients presenting with INR between 5-8 (Keeling et al., 2011), 
which is further supported by the prospective study of Hylek and colleagues, who 
showed that patients with INR>6 face a significant short-term risk of major 
hemorrhage (Hylek et al., 2000). In our study cohort of patients, over-anticoagulated 
patients at high risk of bleeding exceeding the threshold INR for consideration of 
correction with oral vitamin K and an INR value above 6 was considered as over-
anticoagulation.  
 Limitations 
Stability data for both induction and maintenance phases of warfarin therapy were 
available in only a subset of patients (n=42) which is considered as a study limitation. 
Other study limitations include the retrospective nature of stability data collection and 
the low number of patients with high total variant allele count and double variant 
CYP2C9 alleles, due to the small sample size (n=122). Results for certain variant 
alleles had to be combined for further analysis due to their low numbers. This might 
have diluted the potential effect of individual polymorphisms on anticoagulation 
stability. Overall, sample size and therefore statistical power of this study is low, 
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despite the fact that the association between the presence of two VKORC1 alleles 
and %TTR during maintenance was significant at the statistical level even at this 
sample size. TTR can be biased by the number of INR checks and the dates 
performed. The TTR can be very similar between a patient with fairly stable control of 
anticoagulation with only a few INR checks over a period of time and a patient with 
very frequent INR checks over the same period of time due to unstable control of 
anticoagulation, in an attempt to keep the INR within range. 
 
 Conclusion 
In this study, the hypothesis that CYP2C9 and VKORC1 genotypes have a 
significant effect on induction and long-term stability of anticoagulation control in 
patients on chronic warfarin therapy has been disproved. Only when looking at a 
recessive model, the association between the presence of two VKORC1 alleles and 
%TTR during maintenance became significant. The results of this study support 
published reports suggesting the absence of genetic impact on the anticoagulation 
response during warfarin maintenance therapy in adults. However, in contrast there 
are also studies that suggest that common polymorphisms in CYP2C9 and VKORC1 
are associated with over-anticoagulation particularly during initiation therapy, poor 
anticoagulation control and bleeding events. In our cohort, bleeding from over-
anticoagulation occurred more often in patients with at least one variant allele in 
CYP2C9 and/or VKORC1 genotypes, however the number of events was very low 
and require a larger sample size and/or prolonged follow-up. Further large, 
prospective, well designed studies are needed to provide conclusive evidence.  
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 Introduction 
It has been widely demonstrated that genetic factors influence warfarin dose 
requirements. Polymorphisms in CYP2C9 and VKORC1 genes, in particular, are 
demonstrated to significantly influence sensitivity to warfarin and anticoagulation 
response following initiation of therapy (Avery et al., 2011, Pirmohamed et al., 2013). 
The elimination of the pharmacologically more potent enantiomer, S-warfarin, is 
dependent heavily on CYP2C9 genotype, with its half-life ranging between 28 and 
118 hours according to the absence or presence of variant alleles respectively 
(Hamberg et al., 2010). 
Patients on warfarin are normally required to stop treatment for a fixed number of 
days (5 days according to local guidelines) prior to an invasive procedure, in order to 
minimise the risk of peri-operative bleeding (Douketis et al., 2012). However, the 
anticoagulant activity of warfarin subsides at different rates among different patients, 
thus a period of 5 days may not result in restoration of normal coagulation in all 
patients following the interruption of warfarin therapy. Discontinuation of warfarin too 
early may predispose the patient to thrombosis and stopping it too late may result in 
peri-operative bleeding or cancellation of the planned procedure. Previous studies 
have shown that patients with CYP2C9 variant alleles take a longer period of time 
(more than the recommended 5 days) after stopping warfarin treatment for their INR 
to become sub-therapeutic (i.e. INR<1.5) (White et al., 1995, Abohelaika et al., 
2015b).  
In a recent study in adult patients who interrupted warfarin therapy prior to elective 
surgery, the rate of INR decline following warfarin cessation was found to be slower 
in patients with two CYP2C9 variant alleles, additional to increasing patient age, 
weight and number of comorbidities. The rate of INR decline was shown to increase 
with increasing index INR. The aforementioned factors accounted for approximately 
90% of the inter-individual variability in the rate of INR decline following cessation of 
warfarin therapy (Abohelaika et al., 2015a). A genotype-guided protocol to tailor 
warfarin withdrawal according to individual patient’s CYP2C9 genotype could reduce 
cancellation or delays of planned procedures and could also be of benefit when 
transitioning patients from warfarin to a NOAC. 
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 Aim of the study 
Based upon their study data, Abohelaika and colleagues (Abohelaika et al., 
2015a) developed a pharmacogenetics-based algorithm to predict the INR decline 
following warfarin treatment withdrawal in individual patients based upon 
demographic, clinical and genetic information. This study aimed to validate the 
algorithm, using data from an independent cohort of patients who had discontinued 
warfarin therapy.  
 Patients, materials and methods 
 Study cohorts 
The pharmacogenetics-guided algorithm developed by Abohelaika and colleagues 
(Abohelaika et al., 2015a) was derived by the multiple regression analysis of data in 
a cohort of adult patients, who discontinued warfarin for surgery(designated as the 
algorithm cohort) as shown below:  
 
𝐼𝐼𝐼𝐼𝐼𝐼 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 = −0.195 − 0.00428 �𝑎𝑎𝑎𝑎𝑑𝑑 (𝑦𝑦𝑑𝑑𝑎𝑎𝑦𝑦𝑦𝑦)�
− 0.2374 (𝑝𝑝𝑦𝑦𝑑𝑑𝑦𝑦𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑜𝑜𝑜𝑜 𝐶𝐶𝐶𝐶𝐶𝐶2𝐶𝐶9 𝑑𝑑𝑜𝑜𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑣𝑣𝑎𝑎𝑦𝑦𝑑𝑑𝑎𝑎𝑑𝑑𝑣𝑣)+ 0.9143 (𝐼𝐼𝐼𝐼𝐼𝐼 𝑣𝑣𝑎𝑎𝑑𝑑𝑑𝑑𝑑𝑑 5 𝑑𝑑𝑎𝑎𝑦𝑦𝑦𝑦 𝑑𝑑𝑑𝑑𝑜𝑜𝑜𝑜𝑦𝑦𝑑𝑑 𝑦𝑦𝑑𝑑𝑦𝑦𝑎𝑎𝑑𝑑𝑦𝑦𝑦𝑦)
− 0.00246 �𝑤𝑤𝑑𝑑𝑑𝑑𝑎𝑎ℎ𝑣𝑣 (𝑘𝑘𝑎𝑎)� − 0.0306 (𝑑𝑑𝑑𝑑𝑛𝑛𝑑𝑑𝑑𝑑𝑦𝑦 𝑜𝑜𝑜𝑜 𝑑𝑑𝑜𝑜𝑛𝑛𝑜𝑜𝑦𝑦𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑣𝑣𝑑𝑑𝑑𝑑𝑦𝑦) 
 
An independent cohort of Caucasian patients aged 18 years and over (designated 
as the validation cohort), who had completed a course of warfarin for indications of 
either VTE or AF with a target INR of 2.0-3.0, were available for the algorithm 
validation. The patients in the validation cohort had been recruited as part of a 
separate study (Abohelaika et al., 2018). Information on demographics (age, weight, 
height, and sex), clinical data (medical history, indication for anticoagulation, warfarin 
daily dose, alcohol intake and concomitant medication) and INR value on the day of 
warfarin cessation and on alternate days for the following 9 days were available. The 
patients attended the clinic on 3–4 occasions over the 9 days, with some variation to 
avoid missed appointments and scheduling conflicts. They had previously been 
genotyped for CYP2C9 polymorphisms (*2 and *3) using a real-time PCR technique.  
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 Data analysis 
The accuracy of the pharmacogenetics-guided algorithm was tested by assessing 
the correlation between the observed INR decline (calculated by subtracting the INR 
value on day 5 from the index INR value on the day of warfarin cessation) and the 
predicted decline in INR according to the algorithm. The performance of the algorithm 
was evaluated, according to the method of Sheiner and Beal (Sheiner and Beal, 
1981), using the root mean squared prediction error (RMSE) as a measure of 
precision and the mean prediction error (ME) as a measure of bias. The mean 
squared deviation of prediction errors from their mean (mSDEM) is an estimate of the 
variance of the prediction error. 
The days of INR checks following warfarin cessation varied among the validation 
cohort for scheduling purposes. For those with an INR check on day 5 after the last 
dose of warfarin (±10 hours), the INR value was used to calculate the decline which 
was used as the observed value for comparison with the predicted value derived 
from the algorithm. For those without an INR check on day 5, a linear approximation 
model that assumes an exponential INR decline asymptotically over time was used 
as previously described by White and colleagues (White et al., 1995). This 
approximation model assumes that following warfarin discontinuation INR will show 
an exponential decline asymptotically over time to a baseline (warfarin-free) value of 
0.8 (Kornberg et al., 1993). Further transformation of INR into the natural logarithm 
after subtracting the asymptote results in a linear model.  
The natural logarithm of INR after subtracting the asymptote 0.8, which is the 
assumed minimum value of INR, was plotted against the time in hours since warfarin 
cessation. The linear regression equation was then used to calculate the INR value 
on day 5 from the point of warfarin withdrawal, which was considered as the 
observed INR value for comparison (an example of this method is presented in 
Appendix B).  
 Excel (Microsoft Corp., Redmond, WA, USA) was used for data collation and 
Minitab (Coventry, UK) was used for statistical analysis. Where necessary, data were 
transformed to achieve approximate normality. Demographic and clinical data 
common to both cohorts were used for comparison. Unless otherwise stated, data 
are presented as mean (range).  
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 Results 
One hundred and thirty one patients were available in the validation cohort for 
analysis. Seven patients were excluded due to having an index INR of 1.5 or lower. 
Two patients had no index INR value recorded and for two data on at least two 
parameters included in the algorithm were missing. Three patients were excluded 
because their last recorded INR check was performed more than 40 hours before 
day 5, thus any approximation of their INR value at day 5 was deemed potentially 
unreliable. Overall, one hundred and seventeen patients were available for analysis, 
with mean index INR value of 2.5.  
Demographics for both patient cohorts are presented in Table 4.1. Patients in the 
algorithm and validation cohorts were significantly different in age (p<0.001 for males 
and p=0.002 for females; Student’s t-test), mean warfarin weekly dose (p=0.004 for 
males and p=0.036 for females; Student’s t-test) and indication for anticoagulation 
(p<0.001; chi-square test).  
All but one patients reached INR<1.5 at day 5. The one patient with INR=1.6 at 
day 5, which was a predicted value through the linear approximation model in the 
absence of an INR check close to day 5, was a 71-year old female, weighing 94kg, 
with index INR of 2.3, 2 comorbidities and with only one variant CYP2C9 allele. 
Seventy out of 117 patients had an INR check on day 5 (± 10 hours). The INR on 
day 5 was 1.1 (0.9-1.4). The decline in the observed INR value (i.e. INR on day 1 – 
INR on day 5) was 1.4 (0.4-3.5) while the algorithm predicted a decline in INR of 1.6 
(0.9-3.4). There was a very strong and highly significant correlation between the 
observed and predicted INR values (r= 0.969, p<0.001; Pearson test).  
To check the accuracy of the linear approximation model, the INR value on day 5 
was also estimated using the linear regression equation in this subgroup according to 
the method of White and colleagues (White et al., 1995) and the observed INR value 
was compared with the value obtained from the algorithm. Once again, there was a 
very strong and highly significant correlation (r= 0.905, p<0.001; Spearman test) 
between the observed INR and the estimated INR on day 5 using the linear 
regression formula (Figure 4.1), with a maximum difference in INR of 0.2 units which 
is unlikely to be clinically significant.  
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 Algorithm cohort 
Validation 
cohort p-value 
No of patients 152 117  
Sex, n (%) 
Male 
Female 
 
102 (67) 
50 (33) 
 
65 (55.6) 
52 (44.4) 
□ 
0.053 
Age (y), mean (range) 
Male 
Female 
 
74 (43-90) 
72 (49-93) 
* 
63 (29-92) 
64 (21-88) 
♦ 
<0.001 
0.002 
Height (cm), mean±SD 
Male 
Female 
◊ 
174 ± 9 
160 ± 5 
^ 
176 ± 7 
161 ± 8 
♦ 
0.052 
0.224 
Weight (kg), mean±SD 
Male 
Female 
 
88 ± 17 
81 ± 19 
^ 
92 ± 20.3 
81 ± 22.6 
♦ 
0.081 
1.000 
Warfarin weekly dose (mg), 
mean±SD 
Male 
Female 
 
 
28.7 ± 10.3 
27.4 ± 14.0 
¥ 
 
34.9 ± 15.0 
33.4 ± 14.5 
♦ 
 
0.004 
0.036 
Indication for anticoagulation,  
n (%) 
Atrial fibrillation 
Venous thromboembolism 
Pulmonary embolism 
Other 
 
125 (82) 
27 (18) 
0 
0 
 
12 (10.3) 
63 (53.8) 
33 (28.2) 
9 (7.7) 
□ 
 
<0.001 
No of comorbidities, mean (range) 3.3 (1-8) 1.7 (0-6)^ <0.001 
CYP2C9 genotype 
*1/*1 
*1/*2 
*1/*3 
*2/*2 
*2/*3 
*3/*3 
 
92 
35 
15 
4 
6 
0 
¥ 
64 
31 
14 
5 
1 
0 
□ 
 
 
0.553 
Index INR mean±SD (range) - 2.5 ± 0.6 (1.6-4.5)  
 
* Based on 112 patients 
^ Based on 116 patients 
¥ Based on 115 patients 
◊ Based on 140 patients 
♦ Student’s t-test 
□ Chi-squared test 
Table 4.1: Patient demographics for the algorithm and validation cohorts 
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Figure 4.1: Actual INR value on day 5 following warfarin cessation versus INR 
value obtained from linear regression slope (n=70) 
 
In a subgroup of 20 patients out of the abovementioned 70, with mean index INR 
2.4 (1.8-3.6), the INR value was 1.5 or lower at 24 hours and the INR was sub-
therapeutic on day 5 (ranging from 1.0 to 1.2). On average, the observed INR decline 
between day 1 (the day of warfarin withdrawal) and day 5 was 1.3 (0.7-2.5). For this 
subgroup, according to the algorithm the predicted mean INR decline was 1.5 (0.9-
2.8). There was a very strong and highly significant correlation between the observed 
and the predicted INR values (r= 0.988, p<0.001; Pearson test). 
For the remaining 47 out of 117 patients without an INR check on day 5, the INR 
value was individually estimated using the equation derived from the linear 
approximation model, with a mean of 1.1 (0.9-1.6) on day 5 and a decline in INR 
(INR on day 1 – INR on day 5) of 1.3 (0.5-3.3). Based on the algorithm, the predicted 
decline in INR is 1.5 (0.6-3.3). There was a strong and highly significant correlation 
between the observed and predicted INR values (r= 0.932, p<0.001; Spearman test). 
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Overall, there was a strong and highly significant correlation between the 
observed and predicted INR values for all the 117 patients (r=0.949, p<0.001; 
Spearman test, Figure 4.2).  
When removing the effect of genotype from the algorithm, an increase of 0.2 units 
in the INR decline was predicted only for patients with two variant CYP2C9 alleles. In 
the 6 patients with double variant CYP2C9 genotype, the algorithm based on 
demographic and clinical characteristics only, without pharmacogenetic information 
predicted a greater mean (range) INR decline of 0.1 (0-0.2). Removing the presence 
of CYP2C9 variant alleles from the INR decline prediction algorithm resulted in an 
equally strong and highly significant correlation between the observed and predicted 
INR values for all the 117 patients (r=0.958, p<0.001; Spearman test). 
 
 
Figure 4.2: Predicted versus observed INR decline (24 hours – day 5) 
 
In terms of prediction performance of the algorithm, the RMSE was 0.22, which 
means that the algorithm was precise at 0.22 units of INR decline. The ME was 0.15 
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and the mSDEM was 0.028, which confirm the low degree of bias and variance of the 
prediction error.  
 Discussion 
Discontinuation of anticoagulation treatment prior to surgery occurs in 
approximately 1 in 6 patients per year treated with warfarin (Verdecchia et al., 2016). 
An accurate method of predicting INR decline is particularly useful for patients with 
extreme demographics and in frail older patients with many comorbidities and other 
physiological factors that affect normal coagulation, who may present with 
therapeutic INR on the day of surgery, as reported in previous studies (Jaffer et al., 
2003, Mari et al., 2008). Accurate prediction of INR is also relevant for people 
withdrawing from warfarin with the aim of switching to treatment with NOACs, in 
which case there is specific threshold of INR value below which the transitioning to a 
NOAC can be performed (when INR is ≤3 for rivaroxaban, ≤2.5 for edoxaban, and ≤2 
for apixaban and dabigatran) (Heidbuchel et al., 2015). 
In order to minimize the risk of perioperative bleeding, guidelines suggest that 
warfarin therapy is stopped 5 days before an invasive procedure (Douketis et al., 
2012, Ortel, 2012). This recommendation is based upon the estimated warfarin 
clearance and the rate of production of functional coagulation factors II and X after 
the withdrawal of warfarin treatment (Palareti and Legnani, 1996).  
Warfarin elimination is significantly influenced by polymorphisms in the CYP2C9 
gene, which reduce the ability of the CYP2C9 enzyme to metabolise warfarin, as well 
as other demographic characteristics such as age, which influences both liver size 
and liver blood flow (Wynne et al., 1995). A significant proportion of patients remain 
above the INR threshold of 1.5 five days after the cessation of warfarin therapy 
(White et al., 1995, Kovacs et al., 2004, Steib et al., 2010). Earlier, our group 
demonstrated that the variability in INR decline following withdrawal from warfarin 
therapy is significantly influenced by CYP2C9 genetic polymorphism (Abohelaika et 
al., 2018). A genotype-guided approach has the potential to reduce treatment costs 
by reducing the postponement or cancellation of planned invasive procedures in 
patients on warfarin therapy. 
Our research group also recently demonstrated that the variability in the decline in 
INR over time following warfarin withdrawal is influenced by genetic, demographic 
and clinical factors. A pharmacogenetic-guided algorithm was subsequently 
98 
developed which could predict the length of time needed for individual patients to be 
off warfarin in order for their INR to reach <1.5. The algorithm included information on 
patient genetics (presence of CYP2C9 double variant genotype), demographic (age 
and weight) and clinical data (index INR, and number of comorbidities). In search of 
the clinical applicability of this algorithm, I set out to test its accuracy in a second 
independent cohort of patients on stable maintenance therapy withdrawing from a 
short course of warfarin treatment. My results showed that the predicted decline in 
INR on day 5 was very closely correlated with the observed decline in INR value. 
There was a slight over-estimation of the fall in INR (by 0.2 units) in the subgroup of 
70 patients who had an INR check on day 5, and a slight under-estimation of INR in 
the subgroup of 47 patients who did not have an INR check on day 5. However, this 
is regarded to be within the expected variability and would not be clinically relevant, 
but would necessitate another INR check prior to an invasive procedure.  
Where INR data on day 5 were missing for some patients due to scheduling 
arrangements, the linear approximation model (White et al., 1995) was shown to be 
highly accurate in predicting the INR value.  
The results of the present study are in agreement with the well-recognised 
association of CYP2C9 genotype and age with the decline in INR following warfarin 
cessation, however there are also other studies which found no such associations, 
possibly because of missing data (Burmester et al., 2015).  
The findings of this algorithm validation are useful and have practical applicability 
in patient populations who discontinue warfarin for a surgical procedure (algorithm 
cohort) and not directly to the validation cohort, which consisted of patients who 
simply discontinued warfarin after completing a short course of warfarin. The decline 
of INR and the factors influencing it can be studied in a wide range of patients who 
discontinue therapy for a number of reasons and results obtained from other patient 
cohorts could inform clinical practice and benefit patients who discontinue due to a 
surgical procedure.  
The validated algorithm is easy to implement through a simple Excel formula and 
prior genotyping for CYP2C9, which can be available nowadays at a low cost in 
those healthcare systems with access to such technology. Therefore, a 
pharmacogenetic-guided approach could be both a safe and cost-effective way of 
withdrawing patients from warfarin prior to planned invasive procedure.  
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Considering the lack of genotyping facilities in many healthcare systems 
worldwide, this study also looked at the predictive ability and accuracy of the same 
algorithm after removing the requirement for CYP2C9 genotype. Apart from the fact 
that out of the 117 patients, only 6 (5.1%) had two variant CYP2C9 alleles (Table 
4.1) which is consistent with the observed low frequency in the Caucasian population 
(Johnson and Cavallari, 2015), the predicted difference in INR decline has a very 
minor effect on the overall accuracy of the algorithm and would be of little clinical 
importance for the patient population in this study. Further study in patient 
populations discontinuing warfarin therapy, either specifically for a surgical procedure 
or for a different reason, with a greater proportion of patients remaining above the 
INR threshold of 1.5 at day 5 is necessary for the true clinical benefit of this algorithm 
to be appreciated. 
 Limitations 
The two cohorts were significantly different in a number of demographics and 
clinical data, namely age, warfarin dose and indication for warfarin. The validation 
cohort included on average younger patients with a higher weekly dose of warfarin 
and greater variability in indication for anticoagulation, with most patients being 
treated for VTE and PE instead of AF. While the difference in age and number of 
comorbidities could have affected the present study outcome, such variability is 
representative of the wide range of different populations discontinuing warfarin prior 
to an invasive procedure.  
The validation cohort consisted of patients who simply completed a course of 
warfarin, without an upcoming surgical procedure. However, the study of INR decline 
after warfarin cessation in such a population resembles the one in patients due for a 
surgical procedure and therefore, although it is worth clarifying this point, it is unlikely 
to have affected the study outcomes.  
What could have biased these results is the fact that all but one patient in the 
validation cohort reached INR≤1.5 on or before day 5. Therefore, the results of this 
algorithm validation study are limited to patients that will reach INR of 1.5 or lower on 
day 5 after warfarin discontinuation. There is no information about the validity of the 
algorithm in patients that will remain above the INR threshold at day 5, which 
requires further study. 
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 Conclusion 
The algorithm generated from a previous study in patients undergoing elective 
surgery and therefore withdrawing warfarin 5 days prior to the event was validated. 
The results showed that the algorithm is highly accurate in predicting the decline in 
INR following cessation of warfarin therapy in an unrelated cohort of patients. In 
healthcare systems where pharmacogenetic information is not available, the 
algorithm is still valid and can be used for the accurate prediction of INR decline.  
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 Introduction 
The vitamin K antagonist, warfarin, is commonly prescribed as an oral 
anticoagulant for the prophylaxis and treatment of thromboembolic disease. In 
children, it has been estimated that more than 70% of the variability in warfarin dose 
requirement is attributed to by genetic polymorphisms in VKORC1 and CYP2C9, 
height and indication for warfarin.  
Polymorphism in another member of the cytochrome P450 family, CYP4F2, is 
also associated with the variability in warfarin dose requirement. Genome-wide 
association studies have shown that CYP4F2 variant allele (V433M; TT, CT) carriers 
require higher warfarin doses (Takeuchi et al., 2009). The enzyme expressed by the 
TT and CT variant alleles of the CYP4F2 gene has lower biological activity than that 
expressed by the CC wild-type genotype. CYP4F2 has an important physiological 
role (Danese et al., 2012). The enzyme is highly expressed in kidney and liver and 
has an ω-hydroxylase activity towards long-chain (C16-C26) fatty acids, tocopherol 
and vitamin K, all of which share similar structural characteristics. CYP4F2 is thus 
important in the activation of signalling compounds, the initiation and resolution 
phases of inflammation and the regulation of vitamin E (Sontag and Parker, 2002, 
Johnson et al., 2015). High levels of CYP4F2 protein have also been reported to be 
present in several forms of cancer (Johnson et al., 2015).  
Many of the physiological states or functions dependent upon vitamin K 
availability can be affected by exposure to warfarin and further compounded by 
CYP4F2 genotype (Johnson et al., 2015). The vitamin K-mediated γ-carboxylation, 
apart from activating coagulation factors, is essential for the biosynthesis of 
osteocalcin in bones and the functionalisation of MGP which inhibits soft tissue 
calcification (Villa et al., 2016).  
Several studies have shown that vitamin K deficiency can lead to reduced bone 
mineral density (BMD) and increased risk of fractures (Kuwabara et al., 2011). 
Furthermore, low BMD seen in children with cardiac disease is likely to be 
multifactorial; poor nutrition due to cardiac cachexia, malabsorption due to heart 
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failure, liver congestion and reduced bone loading due to poor exercise tolerance 
(Laura Gabriela et al., 2012). 
Low vitamin K availability can be detrimental to bone formation in children. 
Achieving adequate peak bone mass in childhood is considered important in 
preventing the development of osteoporosis later in adulthood (Rezaieyazdi et al., 
2009 ). The prevalence of the "calcification paradox" which refers to concurrent 
osteoporosis and arterial calcification is shown to be particularly high in 
postmenopausal women on chronic warfarin therapy (Persy and D'Haese, 2009). 
Warfarin through its inhibitory effect on the recycling of vitamin K, can lower 
vitamin K availability which might, in the long-term, have detrimental effects on bone 
formation and vascular calcification in children. As vitamin K undergoes CYP4F2-
mediated ω-hydroxylation during its catabolism (Danese et al., 2012), we 
hypothesised that vitamin K systemic availability in children on chronic therapy with 
warfarin is influenced by CYP4F2 genotype. 
 Aim of the study 
This study aimed to assess the effect of dietary vitamin K status, in association 
with CYP2C9, VKORC1 and CYP4F2 genotype, on anticoagulation response and 
long-term stability in children receiving chronic warfarin therapy.  
 Patients, materials and methods 
 Study subjects 
Plasma samples from a cohort of children recruited as part of a previous study 
(defined as whole cohort) (Biss et al., 2012), which had been granted ethical 
approval, were available for this study (defined as sub-cohort). The children were 
aged 18 years or under and had stable control of anticoagulation with no change in 
warfarin dose for at least the previous 3 consecutive INR measurements over a 
minimum period of 4 weeks. Demographic characteristics such as height, weight, age 
and gender, as well as indication for warfarin anticoagulation, target INR range, 
warfarin dose, duration of therapy and genotypes for VKORC1 (-1639G>A; 
rs9923231), CYP2C9 (*2 and *3 alleles; rs1799853 and rs1057910) and CYP4F2 
(V433M; rs2108622) for the sub-cohort were available (Biss et al., 2012) 
 
103 
 Plasma vitamin K determination using HPLC  
Plasma vitamin K concentrations were determined by HPLC according to an 
established high performance liquid chromatography (HPLC) method using post-
column derivatization with zinc metal powder (Wang et al., 2004). The detection limit 
of the assay (signal/noise ratio=3) was 10 pg/ml. The coefficient of variation for 
quality control samples was 8.4% at 620 pg/ml and 15.0% at 372 pg/ml.  
 Sample preparation 
Vitamin K1 was isolated from patient plasma by a two-step process involving 
liquid phase extraction followed by solid-phase extraction (SPE). All solvents were of 
HPLC grade. All samples were analysed in duplicate as follows. 
For the liquid-phase extraction 0.5 ml of plasma sample was transferred to 
suitably marked glass tubes with 50 μl of internal standard solution (MK-6, 120 pg/μl) 
was added. 1ml water was added followed by 2ml ethanol to precipitate proteins in 
the plasma. After vortex mixing for about 15-20 seconds, 6 ml of hexane was added. 
The tubes were capped and vortex mixed for about 30 seconds, and then centrifuged 
at 2500 rpm for 5 minutes to allow separation of the aqueous and organic phases. 
The uppermost organic phase was transferred to a new glass tube, evaporated to 
dryness at 45ºC under a stream of air, and the residue was reconstituted with 1ml 
hexane.  
The solid-phase extraction followed the liquid one. Silica SPE cartridges (Sep-
Pak® Vac 3 cc (200mg), Waters®, USA) were placed in an SPE manifold under 
vacuum and conditioned with 3ml of 3% diethyl ether in hexane followed by 6 ml of 
hexane. The samples extracted from the liquid phase extraction step were loaded 
onto SPE cartridges and washed with a further volume (6ml) of hexane. The retained 
vitamin K and MK6 (internal standard) were then eluted with 6ml 3% diethyl ether in 
hexane into a new tube.  
The eluted samples were evaporated to dryness at 45ºC under a steam of air. 
The residue was reconstituted with 30 μl dichloromethane and 100 μl mobile phase, 
and vortex mixed for a further 10-15 seconds. The reconstituted samples were 
transferred into 1.5 ml tubes, and spun on a benchtop centrifuge for 2-3 minutes at 
maximum speed to precipitate any particulate matter, prior to HPLC analysis. 
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 Preparation of standard curve and quality control  
Pure vitamin K1 was obtained from Sigma-Aldrich, UK. A primary vitamin K1 stock 
solution was prepared in hexane. This solution was then diluted with methanol to 
prepare a secondary working solution, which was used for constructing a vitamin K1 
standard curve (range 0-880 pg/ml). Appropriate volumes of methanolic vitamin K 
solution together with 50 μl of internal standard (MK-6) were added to labelled 1.5 ml 
tubes. After evaporating under a stream of air, the residue was reconstituted and 
injected to the column.  
A pool of 50ml plasma was obtained from the hospital blood bank for quality 
control sample preparation and treated with direct sun light for 24-48 hours to obtain 
vitamin K free plasma. The sun-treated plasma was then injected to HPLC to confirm 
that no vitamin K was present. It was subsequently aliquoted into smaller volumes 
and frozen at -20ºC for later use for the preparation of quality control samples. 
Quality control samples were extracted in duplicate in the same way as previously 
mentioned and tested for with every assay run. 
 HPLC instrumentation and conditions  
A Shimadzu VP HPLC machine was used for measuring plasma vitamin K1 
concentration. The system was fitted with a RF-10AXL fluorescence detector 
(emission wavelength 440 nm and excitation wavelength 243 nm). The analytical 
column was a 3 μm C18 BDS Hypersil, with dimensions of 150 X 3 mm (Thermo, 
Runcorn) to which a post-column zinc reducer was attached. A degasser was fitted to 
ensure the flow rate and the function of the pump is not influenced by air bubbles 
present in solvents. The mobile phase was composed of methanol and 
dichloromethane [90:10 (v/v)], and 5 ml per litre zinc acid solution (2M zinc chloride, 
1M sodium acetate, and 2M acetic acid) and it was run at a flow rate of 0.5 ml/min. 
The run time for each sample was 12 minutes. Vitamin K1 and MK-6 were eluted on 
average at 5.9 and 7.2 minutes, respectively (Figure 5.1). 
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Figure 5.1: Chromatogram of vitamin K1 and MK-6 showing retention times 
 
 Data analysis 
The chromatograms were analysed using Shimadzu LC Solutions 
Chromatographic software. The standard curve was created by plotting vitamin K to 
internal standard peak height ratio versus vitamin K1 concentration. 
 Statistical analysis 
Statistical analysis was performed using Minitab 17 Statistical Software (Coventry, 
UK). Where necessary, data were transformed to achieve normal distribution. 
Between-group comparisons for all demographic, clinical and genetic variables were 
performed using parametric and non-parametric tests based on data distribution. A p-
value <0.05 was considered statistically significant. 
 Results 
One hundred and seven children on warfarin (74 males) with a median age of 11 
years (range: 2-18 years) and a median duration of warfarin therapy of 56 months 
(range: 2-199 months) were available for analysis. Demographics and genotype 
results for the cohort are shown in Table 5.1. There was no significant difference in 
demographic and clinical characteristics between the two groups apart from the 
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target INR range, which depends on the indication for anticoagulation with warfarin 
(Table 5.2).  
All genotypes were tested for consistency with the Hardy-Weinberg equilibrium 
against the CEU population as previously in section 2.4.3 (p=0.537 for CYP2C9, 
p=0.528 for the VKORC1, p=0.371 for CYP4F2; chi-square test). 
 
Variables N (%) 
Indication for warfarin, n (%)  
Fontan procedure 
Other (prosthetic heart valve, coronary aneurism, dilated 
cardiomyopathy, DVT, PE, pulmonary hypertension, stroke) 
61 (57.0) 
 
46 (43.0) 
CYP2C9 genotype, n (%)  
*1/*1 
*1/*2, *1/*3 
*2/*2, *2/*3 
75 (70.1) 
30 (28.0) 
2 (1.9) 
VKORC1 genotype, n (%)  
GG 
AG 
AA 
39 (36.4) 
46 (43.0) 
22 (20.6) 
CYP4F2 genotype, n (%)  
CC 
CT 
TT 
52 (48.6) 
46 (43.0) 
9 (8.4) 
Table 5.1: Patient demographic and genotype 
 
Plasma vitamin K was detected in only 21 children (19.6%), with a mean ± SD 
(range) of 165.7 ± 202.4 (10.1-765.0) pg/ml; in the remaining 86 children (80.4%) 
plasma vitamin K was below the assay limit of detection. For data analysis, the study 
subjects were allocated into two groups; children with plasma vitamin K concentration 
either above or below 10pg/ml. Patient demographic and genetic data for the two 
groups are shown in Table 5.2.  
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Patient group 
Vitamin K 
levels 
<10pg/ml 
Vitamin K levels 
>10pg/ml 95% CI 
Age (years), mean ± SD 
(range) 11 ± 4 (2-18) 12 ± 4 (6-18) 
(-2.988, 
0.988) 
Height (cm), mean ± SD 
(range) 
140.2 ± 25.8 
(82.0-195.5) 
142.7 ± 23.0 
(87.6-178.6) (-14.18, 9.18) 
Weight (kg), mean ± SD 
(range) 
38.6 ± 19.1 
(11.7-100.1) 
44.1 ± 21.5 
(12.3-94.6) (-16.00, 5.00) 
   p-value 
Warfarin daily dose, mean 
± SD (range) 
4.0 ± 2.2 (0.9-
12.5) 3.8 ± 1.7 (0.5-6.7) 0.790
^ 
Duration on warfarin 
therapy (months), mean ± 
SD (range) 
61 ± 53 (2-199) 84 ± 60 (10-195) 0.089^ 
Gender, n (%) 
Male 
Female 
 
57 (66.3) 
29 (33.7) 
 
17 (81) 
4 (19) 
 
0.192 
Indication for warfarin, n 
(%) 
Fontan procedure 
Other 
 
51 (59.3) 
35 (40.7) 
 
10 (47.6) 
11 (52.4) 
 
0.332 
Target INR range, n (%) 
2.0-3.0 
2.5-3.5 
 
77 (89.5) 
9 (10.5) 
 
15 (71.4) 
6 (28.6) 
0.032 
CYP2C9 genotype, n (%) 
*1/*1 
*1/*2, *1/*3 
*2/*2, *2/*3 
 
63 (73.3) 
21 (24.4) 
2 (2.3) 
 
12 (57.1) 
9 (42.9) 
0 (0.0) 
0.148* 
VKORC1 genotype, n (%) 
AA 
AG  
GG 
 
20 (23.2) 
33 (38.4) 
33 (38.4) 
 
2 (9.5) 
13 (61.9) 
6 (28.6) 
 
0.124 
CYP4F2 genotype, n (%) 
CC 
CT 
TT 
 
47 (54.6) 
33 (38.4) 
6 (7.0) 
 
5 (23.8) 
13 (61.9) 
3 (14.3) 
0.038 
^ Kruskal-Wallis test 
* Chi squared test performed between wild-type and variant allele carriers 
Table 5.2: Paediatric patient demographic and genetic data 
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There was a significant difference in the frequency of CYP4F2 genotypes 
between the two groups of children (p=0.038; chi-square test). When considering a 
recessive model for the T allele (CC wild-type expresses enzyme with maximal 
activity), the frequency of CYP4F2 variant allele carriers (TT+CT genotypes) is 
significantly higher in the group of children with plasma vitamin K levels greater than 
10pg/ml (76.2% vs 45.4%, p=0.011; chi square test). After Bonferroni correction for 
multiple testing (Simes, 1986), there is a significant difference between CC and CT 
genotypes between the groups (p=0.016). There was no difference in the mean 
plasma vitamin K concentration among subjects with (n=16) or without (n=5) CYP4F2 
variant alleles in the group of children with detectable plasma vitamin K levels 
(Figure 5.2).  
 
 
Figure 5.2: Boxplot of median, quartiles and outliers of plasma vitamin K 
concentration according to the number of variant CYP4F2 alleles 
 
Although there is a trend towards significance in the frequencies of both CYP2C9 
and VKORC1 genotypes, this is not significant at the statistical level (Table 5.2). As 
expected, there was no significant difference in warfarin dose requirement between 
the two groups given that warfarin dose requirement in both adults and children is 
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mainly governed by CYP2C9 and VKORC1 genotype as well as factors of age, body 
size and intensity of anticoagulation, whilst by comparison CYP4F2 has a smaller 
effect on warfarin dose (Cooper et al., 2008, Biss et al., 2012) 
 Discussion 
Plasma vitamin K concentration is a marker of dietary vitamin K status (Thane et 
al., 2002a, McKeown et al., 2002, Booth et al., 1997). In healthy adults, reference 
fasting values of plasma vitamin K concentration range between 0.1-1.2ng/ml with a 
median of 0.5ng/ml (Sadowski et al., 1989, Shearer, 2009b). In adult hospitalised 
patients, the prevalence of low vitamin K concentration is high (O'Shaughnessy et al., 
2003). In anticoagulated adults, vitamin K concentrations measured prior to warfarin 
treatment were significantly different from those after receiving warfarin treatment 
(median 1.72 vs 0.59 ng/ml) (Kim et al., 2015).  
The mean observed plasma vitamin K concentration in this cohort of 
anticoagulated children (in 86 of whom plasma vitamin K concentration was below 
10pg/ml) is consistent with the finding in fasting adults and towards the lower limit of 
the adult range [mean±SD (range): 0.165±0.202 (0.010-0.765) ng/ml). However, this 
value is lower than those previously reported in healthy children (Kalkwarf et al., 
2004). A previous study in anticoagulated children reported non-fasting plasma 
vitamin K concentration of 670 (20-2810) ng/ml, which is much higher compared to 
our levels as well as much less variable despite a larger sample size (37 versus 21 
children on warfarin with detectable levels) (Hirai et al., 2013). In addition, non-
anticoagulated children receiving parenteral nutrition have been shown to have 10 
times higher circulating vitamin K concentrations compared with non-anticoagulated 
control children, whose levels ranged between 0.5 and 5ng/ml (Pettei et al., 1993). 
Hence, a great variability in reported vitamin K levels in plasma between adults and 
children is observed. Factors such as young age, fasting status and warfarin therapy 
appear to be associated with reduced and parenteral nutrition with increased plasma 
vitamin K concentration.  
It is possible that the observed low and undetectable plasma vitamin K levels in 
the anticoagulated children were caused by either poor nutrition possibly due to ill-
health (as most of the children had undergone cardiac surgery), and/or the use of 
medications which affect vitamin K absorption or disposition. Significantly, though, 
warfarin through its inhibitory effect on the recycling of vitamin K, can also lower 
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vitamin K availability which could have detrimental effects on bone formation and 
vascular calcification. Uncontrolled cohort studies have described reduced bone 
density in children on long-term warfarin treatment (Boris and Harris, 2003, Monagle 
et al., 2002). Children with congenital heart disease receiving warfarin have lower 
BMD than those not receiving warfarin (Bendaly et al., 2015). This however is also 
likely to be due to a number of other factors, including poor nutrition due to cardiac 
cachexia, malabsorption due to heart failure and liver congestion and reduced bone 
loading due to poor exercise tolerance (Laura Gabriela et al., 2012). MGP is a 
vitamin K-dependent inhibitor of soft tissue calcification, and the risk of 
cardiovascular disease is increased with decreasing levels of the functional MGP 
(Shea and Holden, 2012). In relation to this, children on warfarin have been 
demonstrated to be at an increased risk of arterial and vascular calcification. 
Tracheobronchial calcification is another reported complication of anticoagulant 
treatment in children, observed in particular after Fontan procedure (Eckersley et al., 
2014). 
 Limitations 
In this study, vitamin K concentration measurement of a single plasma sample 
was used as a surrogate marker of dietary vitamin K intake. Additional plasma 
samples would have provided a more accurate representation of plasma vitamin K 
status of the study cohort, however the retrospective nature of this study did not allow 
for further plasma sample collection. There was no direct measure of vitamin K 
through a validated questionnaire. Also, as the study subjects were previously 
recruited for a warfarin pharmacogenetics study, there was no information recorded 
about the possible fasting status of the subjects at the time of blood sampling, 
variability in which could have affected the plasma vitamin K levels. 
Although the detection limit of the HPLC assay used to measure plasma vitamin K 
levels (10pg/ml) is lower compared to the reported limits of the same assay in the 
literature, it was not sensitive enough to measure vitamin K levels below 10 pg/ml.  
Another limitation is that paediatric plasma volumes were low. Hence, for a few 
patients only a fraction of the plasma volume required by the protocol was analysed 
and the results were obtained through extrapolation.  
A larger sample size in the group with detectable levels of plasma vitamin K would 
have the potential to allow for a more robust analysis of the association between 
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vitamin K concentration and patient genotype groups. This underpowered study is 
likely to have diluted the effect of CYP2C9 and VKORC1 genotypes, therefore further 
study is necessary to address any existing contribution of these genotypes to plasma 
vitamin K levels.  
 Conclusion 
The findings of this study suggest that CYP4F2 genotype influences vitamin K 
availability in anticoagulated children. Chronic low vitamin K availability in children on 
warfarin may have important implications for physiological functions beyond the 
blood coagulation system. In general, children with low vitamin K levels, compounded 
by CYP4F2 genotype and chronic exposure to warfarin, might be at increased risk of 
developing osteoporosis and cardiovascular disease later in life which need further 
investigation (Barnes et al., 2005). 
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 Introduction 
There are concerns about the long-term effect of warfarin therapy on vascular 
calcification and bone formation in children (Kampouraki et al., 2017). The 
deleterious effects of warfarin on vascular health have been demonstrated in a 
number of case reports, cross-sectional and retrospective observational studies 
showing that warfarin therapy increases the risk of vascular calcification in adults, 
notably elderly patients (Poterucha and Goldhaber, 2016, Palaniswamy et al., 2011). 
Until recently vascular calcification was thought to be irreversible. However, the 
current viewpoint is that vascular calcification is an active process modulated by both 
inhibitors and stimulators of the calcification process and is reversible. In relation to 
this, warfarin cessation has been shown to help reverse warfarin-induced vascular 
calcification in patients with calcific uraemic arteriolopathy (Coates et al., 1998).  
Vascular calcification has previously been studied in children with chronic kidney 
disease (CKD) because coronary calcification is one of the most frequently observed 
cardiovascular adverse outcomes in children with CKD, with 15–30% of children on 
chronic dialysis presenting with coronary calcification (Shroff et al., 2011). To date, 
there is no firm evidence whether long-term warfarin treatment increases the risk of 
vascular calcification in children on oral anticoagulant therapy. 
In humans, the main source of vitamin K is obtained through the diet (as vitamin 
K1; phylloquinone) which is particularly abundant in green leafy vegetables (Booth, 
2012). Vitamin K in its hydroquinone form is an essential cofactor for the 
functionalisation, through post-translational γ-carboxylation of glutamic acid residues 
located at the N-terminal of vitamin-K dependent proteins, such as clotting proteins, 
osteocalcin and MGP (Kamali and Wynne, 2010). 
The vitamin K-dependent clotting proteins are synthesized in the liver, whereas 
osteocalcin and MGP are synthesised in extrahepatic tissues. The transport system 
for vitamin K ensures adequate distribution of vitamin K to extrahepatic tissues, whilst 
maintaining the preferential distribution to the liver when vitamin K availability is 
limited. This explains the observation that vitamin K insufficiency firstly leads to 
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under-carboxylation of the extrahepatic Gla proteins, while the clotting mechanism 
remains intact (Theuwissen et al., 2012). 
MGP is a small vitamin K-dependent protein, which is synthesized by vascular 
smooth muscle cells and chondrocytes and acts as a local inhibitor of vascular 
mineralization (Shea and Holden, 2012). It has a protective role against tissue 
calcification and was the first recognised key inhibitory proteins in vivo (Luo et al., 
1997). MGP undergoes two types of post-translational modification: carboxylation of 
five glutamate residues and phosphorylation of three serine residues, both 
contributing to its function as a calcification inhibitor (Schurgers et al., 2007, Price et 
al., 1983, Price et al., 1994). 
Depending on phosphorylation and/or carboxylation, MGP exists in various states. 
One form of MGP found in plasma is uncarboxylated MGP (uc-MGP). Uc-MGP 
concentrations in plasma and serum are inversely associated with the extent of 
arterial calcification in adults (Cranenburg et al., 2009). The mean plasma uc-MGP 
concentration in healthy adults is found to be twice as much as that in patients with 
end-stage renal disease (4704 ± 1053 nM v 2306 ± 706 nM) (Cranenburg et al., 
2010, Holden et al., 2010). The latter are at increased risk for cardiovascular 
complications (Blacher et al., 2001, Schlieper et al., 2016), with a prevalence of 
vascular calcifications between 60-80% (Cranenburg et al., 2009) and the presence 
of subclinical vitamin K deficiency (McCabe et al., 2013).  It is possible that plasma 
uc-MGP concentration can be a useful biomarker for assessing the relationship 
between exposure to warfarin and vascular calcification in children on chronic 
warfarin therapy.  
 Aim of the study  
In this post-hoc study in anticoagulated children, we aimed to assess the long-
term effect of warfarin therapy on vascular heath in children by measuring plasma uc-
MGP concentrations, as an indicator of arterial calcification. 
 Study subjects and methods 
 Subjects 
Plasma samples from a cohort of anticoagulated children on warfarin recruited as 
part of a previous study (Biss et al., 2012) were available for laboratory analysis. The 
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children were aged 18 years or under and with stable anticoagulation control. 
Anticoagulation stability was considered as no change in warfarin dose for at least 
the previous 3 consecutive INR measurements over a minimum period of 4 weeks. 
Demographic and clinical data such as indication for warfarin anticoagulation, target 
INR range, warfarin dose and duration of therapy were available. 
 Plasma MGP concentration determination 
Plasma uc-MGP concentration was determined using a competitive ELISA 
(Cranenburg et al., 2010). In brief, rabbit polyclonal anti-mouse IgG was bound to the 
microtitre plate and saturated with a monoclonal antibody directed against uc-MGP. 
Samples were supplemented with a biotinylated synthetic peptide tracer before being 
transferred to the plate followed by an overnight incubation at 4 ˚C. After washing, 
plates were supplemented with streptavidine-peroxidase and stained with 
tetramethylbenzidine. The lower limit of detection for the assay was 98 nM. The intra- 
and inter-assay coefficient of variation were 7 and 11%, respectively.   
 Statistical analysis 
Statistical analysis was performed using Minitab 17 Statistical Software. Data 
were transformed to achieve approximate normality. T-test was used to compare 
means between the two groups receiving different anticoagulation intensity. Pearson 
correlation was used to test the associations between plasma uc-MGP concentration, 
warfarin dose and duration of therapy. Results are presented as mean ± SD (range) 
unless otherwise stated. A p value of < 0.05 was considered as being statistically 
significant. 
 Results 
Ninety one children were included in the study. Demographic characteristics such 
as height, weight, age and gender, as well as indication for warfarin anticoagulation, 
warfarin dose and duration of therapy for the study population per INR target group 
are shown in Table 6.1. 
There was a wide range in plasma uc-MGP concentration (161 – 2904nM) with a 
median value of 823nM (Figure 6.1, Table 6.2). Intensity of anticoagulation, 
indicated by the target INR range, was 2.0-3.0 for the majority of the children 
(84.6%), with the remainder (15.4%) having a target INR range between 2.5 to 3.5.   
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INR target group 2.0-3.0 2.5-3.5 p-value / 
95% CI  n (%) 
n (%) 77 (84.6) 14 (15.4)  
Gender  
Male 
Female 
 
52 (85.2) 
25 (83.3) 
 
9 (14.8) 
5 (16.7) 
 
0.813* 
Indication 
Fontan procedure 
Other 
 
48 (98.0) 
29 (69.0) 
 
1 (2.0) 
13 (31.0) 
 
<0.001 
 mean ± SD (range)  
Age (years)  10.7 ± 4.4 (2.0-18.0) 13.2 ± 4.5 (6.0-18.0) (-5.25, 0.25) 
Height (cm) 
139.9 ± 25.0  
(82.0-184.0) 
147.0 ± 27.3  
(87.6-176.5) 
(-23.63, 
9.43) 
Weight (kg)                
39.8 ± 20.0  
(11.7-100.1) 
46.8 ± 20.5  
(12.3-73.3) 
(-19.52, 
5.52) 
Warfarin daily dose 
(mg) 3.9 ± 2.0 (0.9-11.0) 5.0 ± 2.7 (1.9-12.5) (-2.71, 0.51) 
Duration on 
warfarin (months)  
60.1 ± 50.2  
(2.0-195.0) 
88.0 ± 69.4 
(4.0-199.0) 
(-69.3, 13.5) 
*One cell with expected count less than 5 is present 
Table 6.1: Demographic characteristics of the study population by INR target 
group 
There was no difference in mean plasma uc-MGP concentration between children 
with target INR range 2.0-3.0 and those with target INR range 2.5-3.5 [95% CI:         
(-0.150, 0.390), Estimate for difference: 0.120; t-test]. There was no association 
between circulating plasma uc-MGP concentration and either duration of warfarin 
therapy (p= 0.281, r= -0.114; Pearson correlation) or warfarin dose (p= 0.897,          
r= -0.014; Pearson correlation), irrespective of age (Table 6.2). As expected, there 
was a significant positive correlation between age and both duration and dose of 
warfarin (r= 0.521, p< 0.001 and r= 0.496, p< 0.001 respectively; Pearson 
correlation). 
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Figure 6.1: Histogram of plasma uc-MGP concentration per INR target group 
 
  n Mean ± SD (range) 95% CI for difference 
uc
-M
G
P 
(n
M
) a
 
Total 
INR target group 2.0-3.0 
INR target group 2.5-3.5 
91 
77 
14 
823 ± 408 (161 – 2904) 
843 ± 425 (161 – 2904) 
714 ± 284 (422 – 1322) 
 
(-0.150, 0.390) 
 p-value/ r 
Warfarin daily dose (mg) b 91 4.1 ± 2.1 (0.9 – 12.5) 0.897/ -0.014 
Duration of warfarin therapy 
(months) 91 64 ± 54 (2 – 199) 0.281/ -0.114 
a log transformed for data analysis 
b sqrt transformed for data analysis 
Table 6.2: Plasma uc-MGP concentration according to target INR range and 
associations between plasma uc-MGP and warfarin dose and duration of 
therapy 
There was no correlation between uc-MGP and the previously detected plasma 
vitamin K concentration, as described and analysed in Chapter 5 (p=0.306, r=0.264; 
Pearson correlation), nor there was a difference in mean uc-MGP between the two 
groups with detectable and undetectable plasma vitamin K levels [95% CI: (-0.360, 
0.167), Estimate for difference: -0.096; t-test]. 
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 Discussion 
Anticoagulation therapy with warfarin is an important modality for the treatment 
and prevention of thromboembolic disorders in children. There is increasing evidence 
that long-term warfarin administration can have detrimental effects on bone 
mineralisation and vascular health as demonstrated in adult patients (Han and 
O'Neill, 2016, Mayer O Jr et al., 2016). Although such adverse effects of warfarin 
therapy have not been previously assessed in children, tracheobronchial 
calcifications are common in children with congenital heart disease on warfarin 
without firm evidence of a causal relationship (Golding et al., 2013). Cases of 
warfarin-induced calcification have been reported after both mitral valve replacement 
and Fontan surgery (Eckersley et al., 2014, Rifkin and Pritzker, 1984). Cardiac vessel 
calcification is associated with congenital heart disease in both adults and children 
(Topaz, 1986, Halpern et al., 2015, Nance et al., 2015). Underlying heart condition, 
immunosuppressive therapy and warfarin therapy have been identified as potential 
risk factors for calcifications (Nance et al., 2015). 
Lately, quantification of a specific form of extrahepatic MGP, namely uc-MGP, a 
biomarker associated with vascular calcification, has become possible through the 
use of a conformation-specific ELISA (Cranenburg et al., 2010). The present study 
thus used the ELISA technique to examine the possible impact of warfarin therapy on 
arterial calcification in children.  
As this is a post-hoc study and the subjects were part of a previous study, a 
retrospective power calculation was performed to assess what difference could be 
found with this study population. Regarding the association between log(uc-MGP) 
levels and target INR, with groups of 14 and 77 children, there is an 80% chance of 
detecting a difference in means of 0.823 (SD: ±0.385). The actual difference is 0.12. 
For the correlation between uc-MGP and both warfarin dose and duration of therapy, 
with 91 observations there is an 80% chance of detecting a correlation of r= ±0.289. 
Actual correlations were r= -0.014 and r= -0.114.  
Anticoagulation intensity was found to have no effect on circulating plasma uc-
MGP concentrations in children. Also, we found no association between plasma uc-
MGP levels and either duration of warfarin therapy or warfarin daily dose.  
The possible association between warfarin therapy and valvular/vascular 
calcification has mainly been studied in elderly patients with kidney disease and 
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calcification has been detected using a variety of methods apart from circulating uc-
MGP levels [echocardiogram, computed tomography (CT), biopsy, cardiac magnetic 
resonance imaging (MRI)] (Palaniswamy et al., 2011). As there is no prior information 
available on plasma uc-MGP concentrations in anticoagulated children, the results 
cannot be directly compared with the published data in adult cohorts (Koos et al., 
2009, Cranenburg et al., 2010, Cranenburg et al., 2009). However, based on a study 
in anticoagulated adult patients with calcific aortic valve disease (Koos et al., 2009), 
lower uc-MGP concentrations would be expected in anticoagulated children than 
those in non-anticoagulated children. 
Only one previous study by Shroff et al has investigated plasma uc-MGP 
concentrations in children (albeit healthy children) using the same ELISA method as 
that used in our study. In this study the mean±SD uc-MGP concentration in healthy 
children was 527±185μM, ranging from 220 to 1000μM.  Plasma uc-MGP was 
independent of age (Shroff et al., 2008). Similar to adults, the mean plasma uc-MGP 
concentration in healthy children is twice as high compared to children on dialysis 
(232±116μM) (Shroff et al., 2008). Importantly, Shroff et al reported no association 
between plasma uc-MGP concentration and vascular stiffness or other clinical and 
vascular measures of calcification assessed in their study (Shroff et al., 2008). 
However, the plasma uc-MGP concentrations in children reported by these authors 
are much greater compared to plasma uc-MGP concentrations found both in our 
cohort of children and those in adults (Cranenburg et al., 2008). There is concern on 
my part as to whether plasma uc-MGP concentrations reported by Shroff et al has 
been correctly reported (μm units reported by Shroff et al versus nM reported by 
Cranenburg et al (Cranenburg et al., 2010)). Notably, the detection limit of the assay 
is 98nM as reported by Cranenburg et al who first introduced the assay (Cranenburg 
et al., 2010). It is possible that the vast discrepancy in plasma uc-MGP reported 
between the abovementioned and other studies (Cranenburg et al., 2008, Dalmeijer 
et al., 2013, Parker et al., 2010a, Parker et al., 2010b) is a genuine reflection of the 
vast differences in plasma uc-MGP concentrations that exists between 
anticoagulated children and healthy children. 
 Limitations 
Our findings might be mitigated by the fact that the ELISA assay used to measure 
plasma uc-MGP concentration was originally validated using citrated plasma 
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whereas the current study used heparinised plasma. Nevertheless, this discrepancy 
should not affect the overall study findings.  
Another consideration is that only a small number of children with the higher 
target INR range were included in this study (14 children with target INR range of 2.5-
3.5 versus 77 children with target INR of 2.0-3.0). In addition, the target INR range 
between the two groups is overlapping, which was due to the cohort of patients 
having been recruited as part of a previous study and as a result I had no control 
over the recruited patients. 
Finally, as there is no clear consensus on the reported uc-MGP levels in healthy 
children, having studied a separate cohort of healthy children and measured their uc-
MGP levels in plasma at the same time with the same assay would give the 
opportunity for direct comparison between uc-MGP plasma levels in anticoagulated 
and healthy children.  
The observed high occurrence of tracheobronchial calcification in children on 
warfarin could also be due to the poor cardiovascular health of these children. This 
could only be studied in populations of children with cardiovascular conditions that 
necessitate anticoagulation with warfarin versus children with other cardiovascular 
conditions that do not receive warfarin anticoagulation.   
 Conclusion 
In conclusion, in this preliminary study we found no association between 
circulating plasma uc-MGP concentration and either the intensity of anticoagulation, 
warfarin treatment duration, or warfarin daily dose in children. However, to confirm 
our findings and assess the usefulness of circulating uc-MGP as a biomarker for 
vascular calcification in children, further prospective studies in larger population of 
children on chronic warfarin therapy with carefully selected groups of paediatric 
patients having non-overlapping target INR ranges, and which allow for other 
potential confounders of vascular calcification, will be needed. 
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 Introduction 
Direct oral anticoagulants (NOACs), including the factor IIa inhibitor, dabigatran 
and factor Xa inhibitors, rivaroxaban, apixaban and edoxaban, have been approved 
for the treatment of thrombosis, the prevention of thromboembolism in post-operative 
patients, as well as the prevention of thromboembolic strokes in patients with AF; in 
the latter NOACs having been demonstrated to be non-inferior to warfarin in clinical 
effectiveness (Connolly et al., 2009, Patel et al., 2011, Granger et al., 2011, 
Giugliano et al., 2013). Prescription numbers for NOACs have grown rapidly both for 
patients newly diagnosed with AF and for patients taking coumarins, in particular 
those with unstable anticoagulation control (Abo-Salem and Becker, 2014, Xu et al., 
2013, Agnelli et al., 2013, Kirley et al., 2012), such that they now account for 31% of 
treated patients and around 93% of expenditure on anticoagulant therapy 
(Lowenstern et al., 2018).  
Bleeding associated with anticoagulation therapy remains the major concern for 
clinicians and patients. Whilst quantification of the risk of bleeding has been 
inconsistent due to differences in study sample sizes, patient populations and time 
frames, studies with NOACs in general indicate an increased risk of gastrointestinal 
haemorrhage and a lower risk of intracranial bleeding compared to warfarin (Tamayo 
et al., 2015) and with apixaban and edoxaban being superior to rivaroxaban, 
dabigatran and warfarin in terms of bleeding risk, according to studies reviewing RCT 
and real-world data (Hellenbart et al., 2017). 
Subgroup comparisons of trial data between younger (< 75 years) and older (≥ 75 
years) patient groups show higher bleeding rates in the older cohort (Hellenbart et 
al., 2017), with the most elderly also showing to be at highest risk of bleeding 
complications in clinical practice (Kirchhof et al., 2016). It is possible that age per se 
influences anticoagulation response to NOACs. However, it is difficult to evaluate the 
inherent effect of age on the pharmacological activity of NOACs, being unable to 
control in vivo for the presence of the potentially confounding influences of age-
related changes in body mass, decline in renal function, increasing comorbidities and 
concurrent medication (Glassock and Rule, 2012, Deedwania, 2013). 
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 Aim of the study 
This study aimed to determine the effect of age on the pharmacological activity of 
the direct factor Xa inhibitors, rivaroxaban and apixaban, by comparing ex-vivo, the 
effect of each drug on haematological parameters between a group of community 
dwelling fit elderly people and a group of fit young people.  
 Patients, materials and methods 
The study was approved by the Newcastle upon Tyne Ethics Committee and was 
conducted in compliance with the Declaration of Helsinki. 
 Sample size calculation 
As there was no a priori information available on the extent to which age affects 
haematological response to rivaroxaban ex-vivo in humans, we deemed that a 
sample size of 60 subjects (30 elderly and 30 young) would be sufficient to test our 
hypothesis that ageing enhances the pharmacological activity of factor Xa inhibitors. 
 Study subjects 
Following written informed consent, fit elderly subjects were recruited from a local 
day centre and healthy young subjects were recruited from amongst university staff 
members. Subjects with liver dysfunction, or other disease, or receiving any 
medication known to affect haemostasis were excluded. All subjects were generally 
in good health, had normal diets, were living independently and did not consume 
alcohol for the last 24 hours before recruitment. Each subject provided a fasted 
venous blood sample (20ml) collected in citrated tubes. Following double 
centrifugation at 2000× g for 7 min each, the plasma samples were aliquoted and 
stored at -80oC for later analyses.  
 Haematological assessments 
All tests were carried out at the accredited Haematology Laboratory at Freeman 
Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust. Rivaroxaban and 
pure powder were kindly provided by Bayer Schering Pharma (Berlin, Germany). 
Apixaban was commercially available from a local distributor and was initially 
manufactured from Bristol Myers Squib. Both powders were solubilised in dimethyl 
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sulfoxide solution (DMSO, Sigma-Aldrich, Missouri USA) according to the 
manufacturer’s recommendations, at a final concentration of 10µg/ml. 
Assessment of the factors affecting clotting tests was initially performed. The 
temperature at which plasma samples were thawed, the presence or absence of 
centrifugation of the thawed sample as well as the time that the sample remained on 
the heat block were investigated.  
After analysing the impact of these factors, on the day of each experiment plasma 
aliquots were thawed at 37oC on heat block for a maximum of 15 minutes and 
centrifuged at 2000x g for 7 minutes. Plasma samples were incubated with 
rivaroxaban (0, 100, 250, 400, and 500 ng/ml) and apixaban (0, 75 and 150ng/ml) at 
a concentration range similar to that observed in plasma following oral dosing 
(Kubitza et al., 2005a, Kubitza et al., 2005b, Baglin et al., 2012). Control plasma 
samples were incubated in parallel with the clinical samples to gauge the accuracy of 
the measurements.  
The IL TOP ACL 700 CTS instrument (Instrumentation Laboratory Company, 
Bedford, MA, USA) was used for all coagulation assays. Prothrombin time (PT) was 
measured using RecombiPlasTin2G® and APTT using HemosIL® (Instrumentation 
Laboratory Company, Bedford, MA, USA) (Rodgers et al., 2013). Clotting time was 
also assessed using modified prothrombin time (mPT), which is a PT assay modified 
by adding calcium chloride (CaCl2) to the RecombiPlasTin 2G® reagent to expand 
sensitivity and enhance assay dynamics. After reconstituting the thromboplastin 
reagent with distilled water, it was diluted 1:2.25 with 100mmol/L CaCl2 solution, 
prepared with anhydrous powder (VWR, Pennsylvania, USA) (Barrett et al., 2013). 
Clotting factor II (FII), VII (FVII), IX (FIX), and X (FX) activities in plasma were 
measured with standard clotting assays using respective clotting factor deficient 
plasma (Instrumentation Laboratory Company, Bedford, MA, USA). The average 
coefficient of variation for replicate analysis of samples at baseline and with factor Xa 
inhibitor using control plasma were as follows; for PT (4.9 and 2.9%); for mPT (5.7 
and 4.8%); for APTT (6.4 and 4.3%); for fibrinogen (16.4 and 17%); for FII (7 and 
6%); for FVII (17.7 and 15%); for FIX (21.8 and 14%) and for FX (13.6 and 12.3%).   
FX and FIX antigen levels were measured using commercially available ELISA 
kits (Diagnostica Stago, Parsippany, NJ, USA). (Appendix C and D) 
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 Thrombin Generation Assay  
Thrombin generation assay is used to evaluate the endogenous capacity of the 
overall haemostatic potential and is therefore a measure of coagulability of blood. 
More specifically, it is useful in measuring the speed in which a clot is formed by 
assessing thrombin generation and decay. Despite its limitations including the lack of 
standardisation to date, studies have demonstrated the wide range of applications of 
this assay in clinical practise, as well as its potential superiority over routine 
coagulation assays (Duarte et al., 2017, Mullier et al., 2012, Tripodi, 2016).  
A number of parameters of thrombin generation assay were analysed. Lag time is 
the time until thrombin generation commencement; peak height shows the maximum 
thrombin concentration; time to peak (ttpeak) is the time it takes to reach the 
maximum amount of thrombin; endogenous thrombin potential (ETP) indicated the 
total amount of thrombin generated; and velocity index which is the speed of 
thrombin generation/clot formation. (Figure 7.1) 
 
 
Figure 7.1: Thrombin generation assay parameters in plasma (red) and plasma 
spiked with a factor Xa inhibitor (blue) 
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Thrombin generation assay was performed using the Calibrated Automated 
Thrombogram with Fluoroskan® Ascent Fluorometer (Thermo Fisher Scientific, 
Waltham, MA) and the thrombinoscope software (Thrombinoscope BV 5.0). The 
assay was performed by pipetting 20μl platelet-poor plasma (PPPH) reagent 
(20pmole/L TF) and 10μl factor Xa inhibitor solution in DMSO (final concentration in 
plasma was 187.5 ng/ml for rivaroxaban and 100 ng/ml for apixaban), or 10μl DMSO 
(for baseline measurement) into individual wells of a 96-well microtiter plate with 70μl 
plasma. After 10 minutes of pre-incubation at 37°C, the reaction was started by the 
addition of 20μl FluCa-kit. The fluorescence was measured for 120 minutes at 37°C 
(excitation, 390 nm; emission, 460 nm) (detailed protocol in Appendix E). 
The concentration selected for incubation of subject plasma with both rivaroxaban 
and apixaban was similar to the mean plasma concentrations after oral dosing 
(Kubitza et al., 2005a, Kubitza et al., 2005b, Baglin et al., 2012). For rivaroxaban, the 
concentration selected was 187.5ng/ml and for apixaban, the concentration of 
100ng/ml was chosen. 
 Statistical Analysis 
Data were checked for normal distribution. Logarithmic transformation was 
applied to data not normally distributed to approach normality. Parametric (Student’s 
t-test) and non-parametric (Mann-Whitney U) tests were used to compare data; a p-
value of <0.05 was considered to be statistically significant. Microsoft Excel 
(Microsoft Corp., Redmond, WA, USA) and Statistical Package for Social Sciences 
(SPSS version 22) were used for data analyses and reporting. Data are presented as 
mean±SD unless otherwise stated. 
 Results 
 Rivaroxaban 
 Study subjects 
Two groups of subjects were recruited; 36 fit elderly subjects (16 males) and 30 
healthy young subjects (10 males). The median (IQR) age and weight of the elderly 
and young subjects were [83 (75-87) v 30 (26-38) years; p<0.001] and 77 (69-89) v 
72 (64-85) kg, respectively. 
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 Factors affecting routine clotting tests 
Based on previous findings with control plasma (Abohelaika, 2017), PT as 
opposed to mPT, APTT and fibrinogen showed no significant variability between 
different days of analysis. A number of factors were deemed potentially important for 
the observed variability.  
Plasma samples were prepared for analysis using routine clotting tests APTT and 
fibrinogen as well as mPT. Baseline samples consisted of pure plasma obtained from 
healthy volunteers, while plasma was also spiked with rivaroxaban (400ng.ml) to 
create a different set of samples. Results both at baseline and with 400ng/ml 
rivaroxaban are shown in Table 7.1.  
In order to gauge the impact of temperature during plasma thawing (room 
temperature versus 370C on heat block), centrifugation after thawing and the time 
plasma samples stay on the heat block before use, a number of tests were 
performed in the same pool of control plasma donated from healthy volunteers. 
Clotting time at baseline (0ng/ml rivaroxaban in plasma) and at 400ng/ml 
concentration of rivaroxaban was assessed using mPT, APTT and fibrinogen assays. 
The conditions of sample preparation (thawing at 370C on heat block for 15 minutes 
followed by centrifugation) remained the same for all the samples to reduce the 
variability in the above-mentioned clotting tests and eliminate the chance of type I or 
II errors. 
The thawing temperature had a significant effect on plasma fibrinogen levels and 
mPT, although it had a lesser effect on APTT. At 250C compared to 370C, plasma 
fibrinogen levels were reduced both at baseline and 400ng/ml rivaroxaban, mPT 
increased mainly at 400ng/ml rivaroxaban concentration and APTT slightly increased 
at both rivaroxaban concentrations. The impact of centrifugation was significant only 
for mPT, mainly at 250C, but had no impact on APTT and fibrinogen. The time delay 
of plasma on heat block did not affect clotting time at baseline. Only mPT value 
decreased as time delay increased at 400ng/ml. 
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Tests 
Baseline: 0 ng/ml 
No centrifugation Centrifugation 
370C 250C 370C 250C 
Time 0 minutes 
Fibrinogen 3 2.45 2.89 2.35 
APTT 28.6 30.6 28.3 30.6 
mPT 21.8 22.9 22.7 24.9 
      
Time 15 minutes 
Fibrinogen 2.93 2.42 2.96 2.39 
APTT 28.5 30.2 28.5 30.8 
mPT 21.5 23.6 22.8 24.1 
      
Time 30 minutes 
Fibrinogen 3.06 2.42 3 2.38 
APTT 29.2 30 29.3 30.4 
mPT 22.7 22.8 23.9 24.6 
 Rivaroxaban: 400 ng/ml 
 No centrifugation Centrifugation 
 370C 250C 370C 250C 
Time 0 minutes 
Fibrinogen 2.2 1.82 2.21 1.78 
APTT 51.4 54.4 51.9 54.4 
mPT 63.5 68.3 71.3 76.7 
      
Time 15 minutes 
Fibrinogen 2.19 1.83 2.22 1.79 
APTT 50.3 53.2 52.8 54 
mPT 63 67.9 65.2 74.3 
      
Time 30 minutes 
Fibrinogen 2.23 1.82 2.21 1.77 
APTT 51 52.9 51.7 53.9 
mPT 66.5 62 65.9 70.4 
Table 7.1: Impact of temperature, centrifugation and time delay between 
preparation and time of run on clotting tests (data presented as mean) 
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 Haematological measurements 
Rivaroxaban concentration-dependently prolonged PT and mPT (Figure 7.2a, b). 
Rivaroxaban caused a significantly greater prolongation of PT (p<0.05) and mPT 
(p<0.001) in elderly subjects compared to young subjects across the rivaroxaban 
concentration range studied. The mean difference in PT between the two groups 
ranged from 1.6s at 100 ng/ml to 6.1s at 500 ng/ml plasma rivaroxaban 
concentrations. The mean difference in mPT between the two groups ranged from 
23.5s at 100 ng/ml to 71.1s at 500 ng/ml plasma rivaroxaban concentrations. 
 
 
 
 
Figure 7.2: Mean (SEM) PT (a) and mPT (b) prolongation by rivaroxaban in 
young and elderly subjects 
 
The mean baseline FX activity in elderly subjects was similar to that in the young 
subjects (Figure 7.3a). In both elderly and young subjects, FX activity decreased in 
the presence of rivaroxaban in a concentration-dependent manner. Rivaroxaban 
caused a significantly greater inhibition of FX activity in the elderly compared to the 
young subjects (Figure 7.3b). There was a close correlation between FX antigen and 
factor activity levels (r=0.632, p<0.001; Figure 7.4). According to the ELISA assay 
functional FX antigen levels were lower in the elderly compared to the young group of 
subjects (median±SD: FX:Ag= 70.4±16.3% v 83.3±13.4%, p=0.001, t-test). 
Calculation of the activity/antigen ratio showed relative suppression of factor X 
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protein expression in the elderly, but functionality was similar between the two groups 
(FX:C / FX:Ag =1.25 v 1.03 for young and elderly, respectively).  
At baseline, mean FII activity was significantly lower in the elderly compared to 
young subjects (p=0.002) (Figure 7.3c). Although FII activity was significantly lower 
in the elderly group compared to the young group across the entire rivaroxaban 
concentration range studied, there were no significant differences in the extent of FII 
activity inhibition between the two groups (Figure 7.3d). In both elderly and young 
subjects, FIX activity decreased in the presence of rivaroxaban in a concentration-
dependent manner. Mean FIX activity at baseline and in the presence of rivaroxaban 
was significantly greater in the elderly compared to the young subjects (110.2±22.8% 
v 90.7±18.5%; p=0.001 at baseline, 38.2±10.3% v 29.8±7.5%; p=0.007 at 500ng/ml) 
(Figure 7.3e). FIX was inhibited to a similar extent in both groups. 
There were no significant differences between the two groups in FVII activity both 
at baseline and in the presence of rivaroxaban (88.1±28.8% v 97.0±30.9% at 
baseline and 45.4±15.8% v 49.6±17.9% at 500ng/ml for young v elderly subjects 
respectively) (Figure 7.3f). Baseline plasma fibrinogen concentration was 
significantly greater in the elderly compared to the young group (4.34±1.08 v 
3.79±0.65 g/L, p=0.02). However, fibrinogen concentrations were similar between the 
young and the elderly groups in the presence of rivaroxaban (2.92±0.71 v 2.88±0.42 
g/L at 150ng/ml for elderly v young subjects) (Figure 7.3g). 
APTT was prolonged in a concentration-dependent manner in both groups; 
however, the prolongation was greater in the elderly compared to young subjects 
across the rivaroxaban concentration range studied (p<0.01 for all comparisons) 
(Figure 7.3h). 
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* p<0.05, **p≤0.01 (t-test) 
Figure 7.3: Mean (SEM) clotting factor activity (a-g) inhibition and APTT 
prolongation (h) by rivaroxaban in young and elderly subjects 
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Figure 7.4: Scatterplot of factor X antigen and activity levels at baseline for 
rivaroxaban cohort by subject group 
 
 Thrombin generation assay 
At baseline, the elderly subjects had a longer initiation phase of thrombin 
generation, as demonstrated by the longer lag time (p=0.01) and ttpeak (p=0.001), 
and significantly higher ETP (p=0.004), peak thrombin concentration (p<0.001) and 
velocity index (p<0.001) compared to the young subjects (Table 7.2).  
In both young and elderly subjects rivaroxaban (187.5ng/ml) significantly affected 
the key parameters of the thrombin generation assay (Table 7.2). Rivaroxaban 
caused a greater prolongation of lag time as demonstrated by the greater percentage 
difference from baseline in the elderly compared to the young subjects (p=0.03). 
Rivaroxaban also suppressed the propagation phase of thrombin generation to a 
greater extent in elderly subjects compared to the young, as shown by a greater 
decrease from baseline in both peak (p<0.001) and ETP (p=0.002).  
An example thrombogram from a young and an elderly subject is presented in 
Figure 7.5. The change from baseline for both ttpeak and velocity index were 
comparable between the two groups (Figure 7.6). 
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 Baseline Rivaroxaban 
 Young Elderly Young Elderly 
Lag time (min) 2.9 (0.1) 3.3 (0.1) 9.6 (0.2) 11.6 (0.6) 
Peak (nM) 322.9 (8.2) 263.9 (7.9) 67.0 (4.2) 41.3 (1.8) 
ttpeak (min) 5.5 (0.1) 6.4 (0.2) 25.6 (0.7) 29.1 (0.9) 
ETP (nM*min) 2396.9 (57.0) 1978.4 (63.9) 1682.2 (51.6) 1279.7 (38.3) 
Velocity index 
(nM/min) 127.7 (5.4) 87.7 (4.8) 4.7 (0.6) 2.6 (0.2) 
Table 7.2: Thrombin generation assay parameters, at baseline and with the 
presence of rivaroxaban. Data are presented as mean ± SEM 
 
 
Figure 7.5: Representative thrombogram of a young and an elderly subject  
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* p<0.05, ** p≤0.01 (t-test), ϙ p≤0.01 (Mann-Whitney U test) 
Figure 7.6: Change from baseline in thrombin generation assay parameters for 
rivaroxaban cohort 
  
133 
 Apixaban 
 Study subjects 
Following the completion of the rivaroxaban experiments there was sufficient 
plasma remaining from only 17 subjects (7 males) in the elderly cohort to carry out 
experiments with fewer apixaban concentrations. The median (IQR) age and weight 
of the elderly and young subjects included for the apixaban study were [83 (79-90) v 
30 (26-38) years; p<0.001] and 72 (64-85) v 74 (67-82) kg, respectively. 
 Haematological measurements 
Due to the limited volume of plasma available from the elderly cohort, 
haematological tests were performed at 150ng/ml (n=17) and at the 75ng/ml (n=8) 
apixaban final concentration. Apixaban concentration-dependently prolonged PT and 
mPT (Figure 7.7a). Apixaban caused a significantly greater prolongation of PT 
(p<0.001) in elderly subjects compared to young subjects at the highest 
concentration studied (150ng/ml).  
 
 
 
* p<0.05 (t-test), ** p≤0.01 (t-test), ϙϙ p≤0.01 (Mann-Whitney U test) 
Figure 7.7: Mean (SEM) PT (a) and mPT (b) prolongation by apixaban in young 
and elderly subjects 
 
At baseline, mPT was greater in elderly compared to young subjects (p=0.004). 
Apixaban caused a greater prolongation of mPT (p<0.001) in elderly subjects 
compared to young subjects at 150ng/ml. At 150 ng/ml plasma apixaban 
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concentration, the mean difference from baseline between the two groups in PT was 
3.6s, which was not statistically significant and in mPT was 33.4s, which was 
statistically significant (Figure 7.7b). 
The mean baseline FX activity in elderly subjects was similar to that in the young 
subjects (Figures 7.8a). In both elderly and young subjects, FX activity decreased in 
the presence of apixaban in a concentration-dependent manner. Apixaban caused a 
significantly greater inhibition of FX activity (at 150ng/ml) in the elderly compared to 
the young subjects (Figure 7.8b).  
At baseline, mean FII activity was significantly lower in the elderly compared to 
young subjects (p=0.001) (Figure 7.8c). Although FII activity was significantly lower 
in the elderly group compared to the young group across the apixaban concentration 
range studied, there were no significant differences in the extent of FII activity 
inhibition between the two groups) (Figure 7.8d).  
FIX activity was similar both at baseline and in the presence of rivaroxaban 
between the young and elderly groups (Figure 7.8e). There were no significant 
differences between the two groups in FVII activity both at baseline and in the 
presence of apixaban (96.0±30.8% v 110.3±63.1% at baseline and 45.4±15.8% v 
30.9±17.9% at 500ng/ml for elderly v young subjects respectively) (Figure 7.8f). 
Baseline plasma fibrinogen concentration was significantly greater in the elderly 
compared to the young group (4.18±0.78 v 3.88±0.54 g/L, p=0.001). However, 
fibrinogen concentrations were similar between the young and the elderly groups in 
the presence of apixaban (3.45±0.98 v 3.19±0.52 g/L at 150ng/ml for elderly v young 
subjects) (Figure 7.8g). 
APTT was prolonged in a concentration-dependent manner in both groups. 
Although at baseline, APTT was similar between the two groups, the prolongation 
was greater in elderly compared to young subjects at 150ng/ml apixaban 
concentration (p=0.018) (Figure 7.8h). 
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ϙ p<0.05 (Mann-Whitney U test), ϙϙ p≤0.01 (Mann-Whitney U test) 
Figure 7.8: Mean (SEM) clotting factor activity (a-g) inhibition and APTT 
prolongation (h) by rivaroxaban in young and elderly subjects 
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 Thrombin generation assay 
At baseline, the elderly subjects had a longer initiation phase of thrombin 
generation, as demonstrated by the longer lag time (p=0.002) and ttpeak (p=0.003), 
and significantly higher ETP (p=0.026), peak thrombin concentration (p=0.014) and 
velocity index (p=0.014) compared to the young subjects (Table 7.3).  
 
  Lag time 
(min) 
Peak 
(nM) 
ttpeak 
(min) 
ETP 
(nM*min) 
Velocity 
index 
(nM/min) 
Baseline 
Young 3.1 (0.11) 
301.3 
(9.30) 
5.7 
(0.15) 
2210.8 
(70.51) 
117.6 
(6.39) 
Elderly 4.1 (0.25) 
260.7 
(12.21) 
7.0 
(0.34) 
1898.3 
(79.23) 
91.9 
(7.43) 
Apixaban 
Young 8.1 (0.62) 
70.2 
(5.81) 
22.1 
(1.14) 
1649.9 
(69.26) 
6.5  
(1.28) 
Elderly 10.5 (0.83) 
45.3 
(4.05) 
23.5 
(1.44) 
1183.8 
(67.27) 
3.9  
(0.68) 
Table 7.3: Thrombin generation assay parameters, at baseline and with the 
presence of apixaban. Data are presented as mean ± SEM 
 
In both young and elderly subjects, apixaban (100ng/ml) significantly affected the 
key parameters of the thrombin generation assay (Table 7.3). Apixaban suppressed 
the propagation phase of thrombin generation to a greater extent in elderly subjects 
compared to the young, as shown by a greater decrease from baseline in both peak 
(p=0.011), ttpeak (p=0.012) and ETP (p=0.001). The change from baseline for both 
lag time and velocity index were comparable between the two groups (Figure 7.9).  
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** p≤0.01 (t-test), ϙϙ p≤0.01 (Mann-Whitney U test) 
Figure 7.9: Mean (SEM) FIX activity for apixaban cohort 
 
 Discussion 
Elderly people were not well represented in the major clinical trials evaluating the 
safety and efficacy of NOACs and this is of concern for clinicians prescribing them. In 
the ROCKET-AF trial, for example, the median age of the patients on rivaroxaban 
therapy was 73 years and only a quarter of the patients were 78 years of age or older 
(Patel et al., 2011). In the ARISTOTLE trial, the median age of patients on apixaban 
was 70 years or over, less than a third of patients were 75 years of age or older and 
only 13% were aged 80 years or over (Granger et al., 2011, Halvorsen et al., 2014). 
In the AMPLIFY trial, the mean age of patients on apixaban was 57.2 years (Agnelli 
et al., 2013). Post-marketing surveillance studies have reported bleeding rates 
associated with rivaroxaban to be similar to those reported in the ROCKET-AF trial 
(2.86 per 100 person-years (95% CI: 2.61-3.13) and 3.6 per 100 person-years (HR 
1.04 (95% CI: 0.90-1.20) respectively) (Tamayo et al., 2015, Eikelboom and Merli, 
2016, Villines and Peacock, 2016, Peacock, 2015, Adeboyeje et al., 2017). However, 
a real-world observational study reported a higher bleeding event rate of 17.2% for 
rivaroxaban compared to 7% for dabigatran, and 8.7% for apixaban (Al-Khalili et al., 
2016). The incidence rate of hospitalization for NOAC-related bleeding has been 
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reported as 3.44 per 100 person-years (95% CI: 2.35-4.86) with 87% of the 
admissions being aged ≥75 years, reflecting both the age profile of those prescribed 
these drugs and their increased risk of bleeding due to age, renal insufficiency, 
comorbidities and concomitant medication. Of these patients, 19% were receiving the 
maximum therapeutic daily doses in spite of dose reduction recommendations 
(Garbayo et al., 2018). 
Current guidelines suggest dose adjustment for NOACs in relation to serum 
creatinine levels on the basis that renal impairment increases systemic drug 
exposure, with impaired renal function accounting for approximately a 44 to 64% 
increase in rivaroxaban systemic exposure and 56% higher exposure to apixaban 
(Byon et al., 2017), and adhering to these guidelines could reduce bleeding 
episodes. A meta-analysis of randomised trials has indicated that, in patients with 
renal insufficiency, the recommended doses of NOACs are non-inferior and relatively 
safe compared to warfarin (Sardar et al., 2014b), which indicates that the increase in 
bleeding risk suggested by drug adverse event reporting and case reports may be 
contributed to by other factors, such as old age (Harper et al., 2012). Unlike the 
guidance for rivaroxaban use, apixaban guidelines suggest that age of 80 years or 
over is one of the three risk factors that would lead to receiving lower dose of 
apixaban (2.5mg compared to 5mg twice daily) (Halvorsen et al., 2014). 
Evaluation of the true effect of age on anticoagulation response to NOACs in vivo 
is challenging in older people because of the difficulty in separating any such effect 
from co-factors which influence drug exposure, including declining renal function, 
change in body mass, concomitant medication and illness. To overcome this, I 
compared the pharmacological activity of rivaroxaban in groups of fit elderly and 
young subjects, ex-vivo. We purposefully selected the elderly subjects, on the basis 
of them having similar ages (72% in the rivaroxaban cohort and 82.3% in the 
apixaban cohort were aged 78 years and over) to those of the elderly population with 
AF who are prescribed anticoagulation therapy. None of the study subjects used any 
drugs which affect haemostasis or interact with the mode of action of factor Xa 
inhibitors. Rivaroxaban and apixaban concentrations chosen for this study were in 
the range of the plasma concentrations reported following therapeutic dosing 
(Kubitza et al., 2005a, Kubitza et al., 2005b, Baglin et al., 2012). The clotting time 
assay, PT and the global coagulation test, thrombin generation assay were 
performed and clotting protein activity was measured. PT measures the time taken to 
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initiate the clot formation after the stimulation of the extrinsic coagulation pathway. In 
contrast, thrombin generation assay measures not only the time to initiate thrombin 
generation but also the rate and amount of thrombin formed after stimulation with TF.  
My results, which demonstrate elderly subjects to be more sensitive to the 
pharmacological activity of both rivaroxaban and apixaban than younger subjects, 
may indicate one mechanism for the observed trend to a higher risk of NOAC-
associated major bleeding with age in the previous clinical trials (Schulman, 2014). 
There is evidence that the coagulation system becomes more active with increasing 
age, while fibrinolysis is impaired. Physiological changes taking place with increasing 
age can thus affect the production of activated clotting proteins (Palta et al., 2014, 
Franchini, 2006, Attena et al., 2015, Engbers et al., 2010, Abbate et al., 1993). Both 
factor Xa inhibitors produced a greater prolongation of prothrombin time (both PT and 
mPT) in the elderly than in the young subjects. The baseline FXa activity was similar 
between the two groups in both cohorts. The older subjects had a greater inhibition of 
FXa activity by rivaroxaban compared to the younger subjects, which was replicated 
in the apixaban cohort at the highest concentration (150ng/ml). Baseline FIX activity 
was significantly greater in the older subjects compared to the younger ones, which 
is consistent with the previously reported effect of ageing on FIX activity (Boland et 
al., 1995, Mari et al., 2008). Higher FIX levels are suggested to be associated with 
increased risk of venous thromboembolism (van Hylckama Vlieg et al., 2000) which 
increases with advancing age. FX and FIX antigen levels for all the study subjects 
were within the reported assay normal ranges. At baseline, the elderly subjects had 
significantly lower FII activity levels, but the extent of FII activity inhibition from 
baseline was similar between the two groups for both cohorts. Rivaroxaban 
prolonged time-based parameters of thrombin generation (lag time and ttpeak) and 
suppressed the rate and amount of thrombin generation (velocity index, peak and 
ETP) to a significantly greater extent in older subjects compared to young ones. 
Apixaban prolonged the ttpeak instead of lag time, while all other findings were 
similar to those for rivaroxaban.  
Fibrinogen, apart from its key role in haemostasis, also has a role in acute-phase 
inflammation and plasma fibrinogen levels are shown to increase in response to 
interleukin-6, with both being strongly correlated with ageing (Ershler, 1993). The 
elderly subjects had significantly higher baseline fibrinogen levels compared to the 
young subjects in both cohorts, consistent with previous observations (Mari et al., 
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2008). In the presence of rivaroxaban and apixaban, fibrinogen levels were found to 
be similar between the two groups. Factor VII plasma levels are also shown to 
progressively increase with age (Mari et al., 2008). Thrombotic disorders have been 
shown to be more frequent in subjects with higher plasma FVII levels but this has not 
been replicated in other studies (Tripodi, 2003). Interestingly, our study results 
showed that factor VII activity was similar between the two groups both at baseline 
and in the presence of both rivaroxaban and apixaban.   
The results of this study support the hypothesis that elderly subjects are more 
sensitive to the pharmacological activity of both factor Xa inhibitors studied and that, 
in addition to factors which increase drug exposure, including impaired renal function, 
low body weight, concurrent medication and illness, age per se could be an important 
contributor to the reported incidence of bleeding associated with NOAC therapy in 
older patients.  
Accurate, validated and clinically approved assays for use with NOACs are 
expected to be available in the near future and it is anticipated that they will be of 
considerable benefit for patients requiring invasive procedures and for the over-
anticoagulated bleeding patients. More routine use of these assays before bleeding 
occurs might also be of benefit to some elderly patients who, because of their 
increased sensitivity to both rivaroxaban and apixaban, and potentially other NOACs 
yet to be investigated, may require lower doses of the drug to achieve therapeutic 
anticoagulation. As clinical experience with NOACs is too short to provide models of 
use which can take into account the influences of renal function, comorbidities, 
medication, weight and age to minimise the complication of bleeding and optimise 
the benefits of therapy, monitoring has the potential to make an important 
contribution to improving the clinical effectiveness of these already valuable drugs. 
Prospective studies in patients taking NOACs are needed in order to establish 
whether the therapeutic outcomes of using fixed doses supported by randomised trial 
results could be improved upon by NOAC monitoring and dose adjustment, to reduce 
stroke and bleeding events. Our results indicate that these studies should include the 
investigation of the effect of age as well as the established confounders of renal 
function, interacting drugs and body mass. 
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 Limitations 
There was insufficient plasma to carry out a full set of experiments with apixaban 
as had originally been planned. A small sample size may well be responsible for 
some of the statistically non-significant data observed with apixaban at 75 ng/ml.  
There were some differences between the baseline values for rivaroxaban and 
apixaban, possibly due to a combination of day-to-day assay variability, reagent 
batch variability and the impact of multiple freeze-thaw cycles. 
 Conclusion 
Elderly subjects were more sensitive to rivaroxaban compared to young subjects 
with the same levels of drug exposure ex-vivo. Both rivaroxaban and apixaban 
produced a greater prolongation of both PT and modified PT in the elderly compared 
to young subjects, while factor II and X activity levels were significantly lower in 
elderly than young subjects in both cohorts. Both factor Xa inhibitors prolonged time-
based parameters of thrombin generation and suppressed the rate and amount of 
thrombin generation to a significantly greater extent in the elderly compared to young 
subjects. The impending validated assays for use with NOACs will be of considerable 
benefit for bleeding patients and those requiring urgent invasive procedures. Their 
more routine use might also benefit some elderly patients who, because of their age-
related increase in sensitivity to the factor Xa inhibitors studied, may require lower 
doses of the drug for safe and therapeutic anticoagulation. 
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Current guidelines advocate using fixed-doses of oral vitamin K to reverse 
excessive anticoagulation in warfarinised patients either asymptomatic or with minor 
bleeds. Over-anticoagulated patients present with a wide range of INR values and 
response to fixed doses of vitamin K varies. Consequently, a significant proportion 
remain outside their target INR after vitamin K administration making them prone to 
either haemorrhage or thromboembolism. In an RCT performed at the Newcastle 
upon Tyne NHS Foundation Trust, I compared the performance of a novel tailored 
vitamin K dosing regimen to that of a fixed-dose regimen with the primary measure 
being the proportion of over-anticoagulated patients returning to their target INR 24h 
later. A fixed-dose regimen, whereby patients with an index INR >6.0 (asymptomatic 
or with minor bleeding) received orally either 1 or 2mg of vitamin K, was compared to 
a tailored dose regimen based upon an individualised dosing algorithm. The 
algorithm uses patient INR at presentation, target INR and BSA to calculate the 
vitamin K dose required. 
I found that the tailored dose regimen was superior and more accurate to the fixed 
dose regimen in terms of the proportion of patients returning to within target INR 
above target INR range. Further refinement of the algorithm showed weight to be a 
more significant predictor of INR at 24h compared to BSA. This algorithm has already 
been adopted by the local Trust and used in routine practice for the reversal of non-
urgent excessive anticoagulation in patients either asymptomatic or with minor 
bleeds.  
A further, simplified version of this refined algorithm was also tested against its 
differences in the predicted vitamin K dose compared with the original refined 
algorithm. I found that the differences in computed vitamin K dose are minor and 
such differences unlikely to heavily affect the application of the more practical 
algorithm in clinical practice. This simple algorithm provides a powerful tool to 
clinicians who may even memorise the formula and who don’t always have the 
opportunity to use an Excel spreadsheet for the calculation of the appropriate, 
individualised oral vitamin K dose in excessively anticoagulated patients presenting 
in clinic with high INR and requiring non-urgent reversal of anticoagulation. 
Communication of the success of local practices to clinicians through committees 
and scientific conferences could lead to further refinement of the algorithm using a 
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larger more diverse sample size and eventually adoption of the individualised 
algorithm to other Trusts nationally. Further research and adjustment of the algorithm 
to other countries healthcare systems is also possible. 
Stability of anticoagulation with an INR within the individual therapeutic range is a 
necessary commodity to ensure the safety of warfarin therapy. One measure of 
quality of anticoagulation control is %TTR. In my cohort study, I examined the 
association of %TTR between different genotype groups in a subset of patients who 
previously participated in the RCT and showed that CYP2C9 and VKORC1 
genotypes were not associated with stability of anticoagulation during either induction 
or maintenance warfarin therapy. However, when a different type of analysis was 
employed, VKORC1 appeared to be associated with %TTR only during maintenance 
therapy. Consequently, whilst patient genotype may be valuable information in 
predicting warfarin dose and thus preventing excessive anticoagulation and bleeding 
during initiation of therapy, combined genetic information from common SNPs at 
CYP2C9 and VKORC1 may not be useful in predicting anticoagulation stability. 
Further study for the role of VKORC1 is necessary to replicate my results. 
It is common for patients on warfarin to discontinue their anticoagulation treatment 
a fixed number of days prior to surgery. However, studies report that there are still 
patients who present with therapeutic INR on the day of surgery, making the 
prediction of INR decline particularly useful for frail older patients with many 
comorbidities and those with extreme demographics. In a previous study, a 
pharmacogenetic-guided algorithm was developed including information on patient 
genetics, demographic and clinical data, which could predict the length of time 
needed for individual patients to withdraw warfarin in order for their INR to reach 
<1.5. I used data from an unrelated patient cohort on stable maintenance therapy 
who completed a short course of warfarin treatment for a reason unrelated to 
surgery, but providing the same opportunity to study INR decline following warfarin 
cessation. My results showed that the predicted decline in INR on day 5 was very 
closely correlated with the observed decline in INR value. In addition, the observed 
slight over-estimation and under-estimation of the fall in INR (by 0.2 units) in two 
patient subgroups was within the expected variability and would not be clinically 
relevant, but would mandate another INR check prior to an invasive procedure. With 
the cost of genotyping dropping every year, genotyping devices are quickly 
incorporated into clinical practice. However, even without the availability of 
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genotyping facilities, a healthcare system would still benefit from adopting the 
algorithm without pharmacogenetic information. I have showed that the predictive 
accuracy of the algorithm is only slightly undermined in patients with double variant 
CYP2C9 genotype. The algorithm that includes only demographic and clinical 
characteristics could be a good alternative where genotyping is not easy or available. 
The algorithm I have validated could be further tested in a wider population as part of 
an RCT. If my study results are replicated, they could pave the way for the clinical 
utility of either the existing or a refined version of the algorithm on a wider scale.  
Warfarin, a vitamin K antagonist, inhibits the recycling of vitamin K and can also 
lower vitamin K availability in the body. This has the potential to affect all vitamin k 
dependent proteins, such as osteocalcin in the bones and matrix-Gla protein which is 
a natural calcification inhibitor. In my second cohort study in an anticoagulated 
paediatrics population, I looked at the association between CYP4F2 genotype and 
vitamin K availability. Plasma vitamin K concentration was measured by HPLC with 
plasma vitamin K being detected in only around 20% children. In the remaining 
children plasma vitamin K was below the assay limit of detection. When comparing 
the frequency of CYP4F2 variant allele carriers, there was a significant difference 
between the two groups of children, suggesting that CYP4F2 genotype influences 
vitamin K availability in children on warfarin. Several studies have shown that vitamin 
K deficiency can lead to reduced BMD and increased risk of fractures. Consequently, 
chronic low vitamin K availability in anticoagulated children may have important 
implications for physiological functions beyond the blood coagulation system and 
might be at increased risk of developing osteoporosis and cardiovascular disease 
later in life which need further investigation. Further assessment of BMD using DEXA 
(dual-energy x-ray absorptiometry) scan as well as detection of calcification using 
imaging techniques such as CT scans, intravascular ultrasound, MRI or angiography 
(Wang et al., 2018) in anticoagulated and non-anticoagulated (control) children would 
help identify any links to vitamin K deficiency. 
In adult populations, there are studies reporting that warfarin therapy is indeed 
associated with increased risk of vascular calcification. As there is no such 
information available in children, I examined the total uncarboxylated form of MGP 
(uc-MGP) which has been shown to be a sensitive biological marker of vascular 
calcification and explored the link between warfarin treatment duration and intensity 
of anticoagulation and vascular calcification in the abovementioned cohort of 
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children. In this preliminary study, I did not find an association between warfarin 
therapy and circulating uncarboxylated MGP which would suggest immediate 
concern about warfarin-induced arterial calcification in children. The absence of a 
control group of healthy children did not allow for direct comparisons of the uc-MGP 
values, taking into consideration the large variability in levels reported in the 
literature. Further studies in larger cohorts of children are required to assess the 
long-term effects of warfarin therapy on vascular health. Study design can be crucial 
in revealing any possibly existing associations between warfarin therapy and 
vascular calcification measures; studying in parallel a group of healthy children, a 
group of children on chronic warfarin therapy and a group of children with 
cardiovascular disease that does not necessitate warfarin therapy may provide an 
insight into the potential causal relationship between warfarin and vascular 
calcifications. On the other hand, it will provide convincing evidence as to whether 
calcification is a common complication in children with cardiovascular diseases, 
irrespective of warfarin therapy. In addition, as already mentioned, direct measures of 
the extent of calcification using imaging techniques could be used to detect any 
associations with both the duration and intensity of anticoagulation with warfarin in 
children. These measures could be used for the verification of existing surrogate 
markers of calcification, such as uc-MGP or identification of novel, more practical 
ones that could be used for further research. 
In an attempt to identify anticoagulant treatment alternatives to warfarin, a number 
of landmark studies have proven the safety and clinical effectiveness of NOACs. All 
four currently available NOACs; dabigatran, rivaroxaban, apixaban and edoxaban are 
at least as effective as warfarin and were associated with a significantly lower risk of 
major bleeding. Elderly people were not well represented in the major clinical trials 
which causes concern for clinicians prescribing them. According to a meta-analysis of 
randomised trials, the recommended doses of NOACs in patients with renal 
insufficiency are non-inferior and relatively safe compared to warfarin, which 
indicates that the increase in bleeding risk may be contributed to by other factors, 
such as old age. However, evaluation of the true effect of age on anticoagulation 
response to NOACs in vivo is challenging in older people due to the presence of 
other co-factors that influence drug exposure, including body mass changes, 
declining renal function, concomitant medication and illness. To overcome this, I 
compared the pharmacological activity of rivaroxaban ex-vivo in groups of fit elderly 
and young subjects.  
146 
Rivaroxaban and apixaban concentrations chosen for this study were in the range 
of the plasma concentrations reported following therapeutic dosing. Both factor Xa 
inhibitors produced a greater prolongation of both PT and modified PT in the elderly 
compared to young subjects. Factor II and X activity levels were significantly lower in 
elderly than young subjects in both cohorts. Both drugs prolonged time-based 
parameters of thrombin generation and suppressed the rate and amount of thrombin 
generation to a significantly greater extent in the elderly compared to young subjects. 
My study results demonstrate that elderly subjects to be more sensitive to the 
pharmacological activity of both rivaroxaban and apixaban than younger subjects. 
This provides evidence that in addition to factors that increase drug exposure, age 
per se could be an important contributor to the reported incidence of bleeding 
associated with NOAC therapy in older patients.  
According to the results of all clotting factors studied, a trend towards great 
differences in clotting factors of the intrinsic pathway can be observed in older 
subjects compared to the young. The only factor studied from the extrinsic pathway 
did not show any differences in clotting factor activity. This may provide evidence of a 
specific impairment of the intrinsic pathway of the coagulation mechanism with age, 
which is also supported by the literature while comparing individual clotting factors. A 
second explanation is the presence of higher albumin levels in the plasma of elderly 
people compared with young subjects. Both factor Xa inhibitors studied have a high 
rate of protein-binding (primarily in albumin; 93.5% for rivaroxaban and 87% for 
apixaban). Therefore, it is possible that the augmented pharmacological activity of 
factor Xa inhibitors is a reflection of protein binding and increased recovery. This 
warrants further evaluation.  
Following further replication of these results, clinicians should consider this when 
prescribing NOACs to elderly and frail patients, who are generally more susceptible 
to bleeding complications according to real-world data. A dose modification may be 
required for this population irrespective of renal function or the presence of 
concomitant illnesses and medication. Treatment monitoring could also assist with 
dose adjustments, with the latest development and clinical application of anti-Xa and 
direct thrombin inhibitor assays for detection of factor Xa inhibitors and dabigatran 
plasma concentrations respectively.  
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APPENDICES 
 
Appendix A. 4S DAWN software calculator for TTR calculation 
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Appendix B. Example calculation of INR at day 5 using the linear 
approximation model 
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Appendix C. FIX antigen ELISA analysis protocol  
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Appendix D. FX antigen ELISA analysis protocol  
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Appendix E. Thrombin generation assay protocol  
 
A modified assay of Perzborn, Morishima, and Douxfils was used (Morishima and 
Kamisato, 2015, Perzborn and Harwart, 2009, Douxfils et al., 2012). Fluoroskan® 
Ascent Fluorometer instrument (Thermo Fisher Scientific, Waltham, MA) and the 
thrombinoscope software (Thrombinoscope BV) were used. The fluorescence was 
measured at excitation of 390 nm and emission of 460 nm, which the machine is 
already programmed for and there is no need to adjust it.    
1. Switch on the large, corner waterbath at 37oC 
2. Reconstitute Normal Control with 1ml H2O (leave for 30 mins) 
3. Switch on PC and Fluoroskan Ascent  
4. Place Fluo buffer (2 for a full plate) and a universal of distilled water in 37 oC 
waterbath 
5. Defrost samples in heat block at 37oC and then centrifuge at 3500rpm for 7 minutes 
6. Open Thrombinoscope Software and login. 
7. Select “Measure” 
8. Click yes to take plate drawer back in. 
9. Check every time calibrator activity in settings and change if necessary 
10. Programme plate layout  (this can be done at any time before analysis) 
a. Each sample needs 9 wells (3 Thrombin calibrator + DMSO, 3 Thrombin 
generator + DMSO and 3 Thrombin generator + Rivaroxaban) 
b. Select yellow button for calibrator wells then select A1, A2 and A3 
c. Select red button for thrombin generation wells, then select A4 – A6 
d. Click Add Group and Rename the group with lowercase letters 
e. Add another group with A1-3 (Thrombin calibrator), plus A7-9 (thrombin 
generator) and name it with capital letters +R (which means the group that 
contains generator with rivaroxaban and calibrator) 
f. Continue as per plate design, with controls in the very last positions (wells A/B/C 
10-12). Controls have the same configuration as patients therefore 9 
wells/control. 
g. Ensure temperature is 37ºC, check time and intervals 
h. Ensure the running time is set at 120 minutes 
11. Reconstitute PPPH (20pM tissue factor and 4 µM phospholipids) and Thrombin 
Calibrator reagents with 1ml H2O. Swirl and leave for 2mins. 
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12. Pipette 10µl of factor Xa inhibitor (i.e. rivaroxaban or apixaban) 1.5 ng/µl working 
stock solution (187.5ng/ml final rivaroxaban concentration in plasma or 100ng/ml 
final apixaban concentration in plasma) in wells 7-9, or 10µl blank DMSO in 
appropriate wells (1-6) 
13. Pipette 20µl thrombin calibrator using reverse pipetting into appropriate wells (1-
3) 
14. Pipette 20µl PPPH reagent using reverse pipetting into appropriate wells (4-9). 
15. Pipette 70µl subject plasma into appropriate wells (1-9). 
16. Click Plate out, place plate with A1 in top left corner, click Plate in. 
17. Click START – 10 minute incubation starts 
18. Fluo Substrate is precious, take care when handling. It is stored in the second 
drawer at Paul’s bench in a separate box. Prepare the FluCa by adding 40µl Fluo 
Substrate to each warmed vial of Fluo buffer. Vortex until clear. 
19. If running a full plate, combine both vials in a glass jar. 
20. Follow on screen instructions to prime the dispenser using the warmed universal of 
H2O and empty universal. 
• Watch plunger for bubbles and check H2O is dispensed in a straight line. 
• Fill the system with FluCa as directed on screen. Ensure no bubbles in plunger 
and FluCa dispensing in a straight line. 
• Place dispenser tip in the hole “M” ensuring aspirating tube remains in the 
FluCa throughout the dispensing step. 
• Place the dispenser tip in a universal of H2O to avoid blockage. 
• Close lid and let it run. 
21. After measurement, place the aspirating tube in a universal of at least 5ml H2O 
• Place the dispenser in an empty universal 
• Go to “instrument” and select “prime dispenser”, enter 5000µl 
• After priming, go to “instrument” and select “empty dispenser”, making sure that 
both the dispenser and aspirating tubes are in the empty universal. 
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